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The work described in this dissertation attempts to advance the science of 
developing semisolid microbicide products through (a) application-oriented 
design of drug delivery vehicles and (b) selection of HIV-specific active 
ingredients that yield advantage over the current antiretroviral strategies, 
particularly in regards to the mechanism of action through inhibition of HIV entry.  
Two approaches that exploit the underlying composition-structure-
property-performance relationship in polymeric systems to improve semisolid 
gels for the prevention of sexual transmission of HIV were explored. Firstly, an 
algorithm that allows de novo engineering of a delivery vehicle was developed, 
optimizing the composition and consequently the properties of the material to 
meet a predefined set of performance criteria for vaginal drug delivery. Secondly, 
a pH-responsive mucus-like material with the ability to attenuate the transport of 
virus and immune cells was engineered. Inhibition of viral transport was observed 
at pH above 4.8, with minimal signs of toxicity to vaginal tissue.  
Second part of this dissertation describes the assessment of two potent 
antiretroviral agents that inhibit HIV entry. The ingenuity of these agents lies in 
(a) the dual mechanism of HIV inhibition associated with the small molecule 
pyrimidinedione analogs, and (b) the design of a gp120 targeted macromolecular 
therapeutic that is synthetic in nature and shows activity comparable to that of 
  iv  
the protein-based lectins. Hydroxyethyl cellulose gels formulated with 0.25 w% 
pyrimidinedione analog showed activity at ~ 14 ug/mL in an in vitro antiviral 
assay. In the design of gp120 targeted synthetic lectins, benzoboroxole showed 
weak affinity for nonreducing sugars; however, it demonstrated antiviral activity at 
nanomolar concentrations when incorporated into high molecular weight 
polymers. Activity increased with increasing degree of functionalization and 
molecular weight of the polymer. Supplementing the polymer backbone with 
sulfonic acid increased its aqueous solubility in addition to a synergistic increase 
in antiviral activity.  
These strategies support the paradigm shift from use of generic semisolid 
drug delivery systems to a performance-based design of polymeric materials for 
vaginal drug delivery. Furthermore, formulating semisolid systems to deliver 
antiretroviral agents, such as the pyrimidinediones or the synthetic lectins, may 
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 PREFACE 
Work in this dissertation attempts to address two major challenges in the 
field of microbicides: (a) develop rational design of semisolid delivery vehicles for 
preventing the sexual transmission of HIV-1 and (b) synthesize and/or formulate 
new antiretroviral agents that inhibit HIV-1 entry. The work presented in this 
dissertation provides multiple strategies in regards to developing methods and 
materials towards improved design of semisolid vaginal microbicide gels, 
Chapter 2 and 3, pertain to the drug delivery vehicle, whereas Chapter 4 and 5 
focus on the active ingredient.  
Semisolid gels constitute a major class of dosage forms developed for 
vaginal delivery. Although there are over 50 vaginal products in the market, the 
knowledge regarding the criteria for selecting a gel for a predetermined 
application is still lacking. Most vaginal gels in the past have been designed to 
either mimic physical properties of commercially available gels, or alternately 
mimic the composition of gels that have been developed for other applications, 
such as contraceptive delivery, vaginal moisturizers or ocular delivery. The major 
problem with the traditional approach is that it confines the choice of gelling 
agents and composition of the gel. The effectiveness of a topical vaginal delivery 
system is, to a large extent, determined by the ability of the vehicle to deploy in 
the vaginal lumen immediately after application as well as it’s retention at the 
  xiii  
target site, both of which depend on the mechanical properties of the delivery 
vehicle. Therefore, it is conceivable that inadequate understanding of the impact 
that mechanical properties of a gel may have on drug release, coating and 
retention, could limit our ability to develop vaginal gels for microbicide delivery.  
Chapter 2 summarizes the work on the development of a semi-empirical 
approach that would enable optimization of a vaginal gel specifically tailored for 
use as a microbicide, prior to in vivo clinical evaluations. In doing so, an in vitro 
preclinical algorithm that elucidates the relationship between composition, 
mechanical properties and performance was designed. Until now, there have 
been no thorough explorations of the composition-performance relationship of 
vaginal gels and the work presented in this thesis is pioneering with respect to 
developing methods that empirically relate the composition of commonly used gel 
excipients to their performance by using deterministic flow calculations. 
The second approach developed as a part of this study focuses on the 
design of a semisolid polymer system that impedes movement of HIV-1 by 
physically entrapping the virions in the polymer network. Barrier technologies, 
such as condoms, have been used for over 400 years as means to physically 
trap and contain the seminal fluid, thereby preventing pregnancy and 
transmission of STIs. Coitally dependent use of condoms in addition to the 
necessity of male consent outweighs the effectiveness of male condoms at 
preventing both conception and STIs. As a result, the usage of male condoms 
exhibits alarmingly low rates (~ 19%), especially in low-income drug abusing 
populations. In spite of the limited usage of male-condoms, they remain the most 
  xiv  
popular method of contraception across the globe. Thus, in attempt to cater the 
growing need for women-controlled barrier modalities, several technologies such 
as the cervical caps, diaphragms and female condoms have been developed and 
approved for use. Although the female condom demonstrated efficacy in 
reducing HIV-1 transmission, its limited availability, low acceptability, non-covert 
usage and cost hindered the overall success of the device. Thus, other effective 
and acceptable, noncoitally dependent women-controlled methods need to be 
developed to prevent heterosexual HIV-1 transmission.  
Chapter 3 presents the work on a bioresponsive crosslinked polymer 
system designed to trap and inhibit the migration of virions from semen to the 
genital tissue. The ingenuity of this system lays in the fact that it embodies the 
inherit advantages of a physical barrier technology whilst, unlike the existing 
barrier modalities, obviating application right before intercourse. The challenge 
with this work lies in designing the mechanical properties of the material that 
would allow complete vaginal tissue coating and, at the same time, serve as a 
barrier to viral transport. To tackle this mechanical tradeoff, the approach 
adopted in this work is the use of in-situ bioresponsive gelation. This particular 
approach allows the weakly crosslinked viscoelastic fluid to flow and coat the 
vaginal tissue on application. Soon after exposure to the semen that may carry 
infectious virions, the polymer network becomes densely crosslinked to form an 
impermeable solid-like barrier, capable of inhibiting viral transport. This system 
relies on a covalently-crosslinked polymer network between phenylboronic acid 
and salicylhydroxamic acid. 
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Focusing on the second challenge—as the spread of HIV-1 continues and 
the emergence of tolerant mutants to existing regimens escalates, the need for 
new drug candidates has become increasingly important. Pyrimidinediones 
represent a unique class of compounds that inhibit HIV-1 entry by targeting a 
conformational epitope that forms prior to fusion of the viral envelope with the 
cellular membrane. In addition, pyrimidinedione analogs also act as non-
nucleoside reverse transcriptase inhibitor, exhibiting activity at nanomolar 
concentrations against clinical strains of HIV-1 and HIV-2.   
Chapter 4 describes the work on preformulation of pyrimidinedione 
analogs and developing a semisolid gel dosage for the delivery of the lead drug 
molecule. It is a well known fact that, given the increasing number of hydrophobic 
and poorly permeable drugs being evaluated as microbicide candidates, it is 
critical to develop a drug delivery system that is not only cost-effective, 
biocompatible and stable, but also capable of delivering the drug to vaginal tissue 
at a concentration high enough to prevent viral replication. Thus, as a part of the 
present study, in order to examine the applicability of the gel as a microbicide, 
chemical stability of the drug candidate and physical stability of the gel, in vitro 
and ex vivo release, safety and antiviral activity was assayed.   
In attempt to address the growing need for lumen active antiretroviral 
agents that target initial steps in the viral entry, work on polymeric synthetic 
lectins that target the gp120 and inhibit HIV-1 entry was initiated. Lectin based 
entry inhibitors present a promising class of antiretroviral agents that inactivate 
HIV-1 in the vaginal lumen even before they reach the susceptible CD4+ cells. 
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Moreover, lumen active agents offer several advantages over antiretroviral 
agents that require delivery to the cervicovaginal tissue, which include lower 
systemic levels of drugs, lower probability of developing resistant mutants and 
alleviated issues, with respect to permeability and biodistribution of the active 
ingredient. The viral envelope protein plays a critical role in HIV-1 entry into cells. 
The surface unit, gp120 initiates the binding between HIV-1 and the susceptible 
cells containing CD4 receptors. Carbohydrate-binding proteins capable of binding 
to the multiple glycans on the N-linked glycosylated regions of gp120 represent a 
promising class of entry inhibitors. Of these, cyanovirin-N, which binds 
specifically to α(1,2)mannose glycans, has shown consistent suppression of HIV-
1 and HIV-2 replication irrespective of the virus, the cell type, or the coreceptor 
tropism of the viral strain. However, production, formulation and stability of 
protein-based lectins may economically impede their use by women in resource-
deprived pandemic regions, such as sub-Saharan Africa.  
Finally, Chapter 5 discusses the work on developing multivalent polymer 
based synthetic lectins that show activity comparable to the protein based lectins, 
without the associated issues with protein-based therapeutics, such as cost of 
isolation, purification, chemical and structural stability.  
This dissertation personifies the four wonderful years of my graduate 
experience in the Microbicide delivery lab. I would like to express my deepest 
gratitude to Dr Patrick F. Kiser for his exemplary mentorship and unceasing 
motivation. My growth as a scientist and a person has been greatly influenced by 
what I have learnt from Dr Kiser. My gratitude also goes to the former and current 
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members of the Microbicide Delivery Lab, who were always there to offer their 
friendship and help when I needed it the most. I would like to thank all the 
coauthors on my manuscripts for their scientific contributions and valuable 
collaboration. I am incredibly grateful to my family, especially my dad, S. 
Mahalingam, my mom, M. Lakshmi, my sister and brother-in-law, S. Abhirami 
and T. Shanmuhanathan, and my nephew Shaan, for their unconditional support, 
patience and belief in me. Finally, I would like to thank my fiancé, Harsha Banda, 
for, without his support, this would not have been nearly as enjoyable of a 
journey. 




BACKGROUND AND INTRODUCTION 
1.1 HIV Pandemic 
AIDS is an opportunistic infection caused by HIV, leading to progressive 
failure of the immune system. With over 33 million individuals infected with HIV 
living globally, AIDS continues to be the most destructive pandemics known to 
date. The recent advent of highly active antiretroviral therapy (HAART) and rising 
awareness on the transmission methods has successfully curbed the spread of 
the AIDS pandemic in some parts of the world.1 However, countries in the Sub-
Saharan Africa remain the most heavily affected regions by the AIDS pandemic, 
accounting for 67% of the total HIV infected individuals and 72% of the total 
deaths due to HIV in the year of 2009.1  
1.2 Impact of HIV on Women’s Health 
Over the last two decades, women have represented the fastest growing 
demographic of the HIV/AIDS pandemic, especially in the developing nations 
(Figure 1.1).2 In some parts of Africa, where heterosexual transmission is the 
dominant mode of infection, women aged 15-24 are three times more likely to 




Furthermore, women in the childbearing age who are at high risk of HIV 
infection raise concerns related to mother to child transmission, which, in turn, 
increases the infant population infected with HIV and responsibility towards 
escalation in orphan population due to the HIV-related death toll.2, 4 Both clinical 
and observational data suggest that the biological and socio-economical 
vulnerability makes women at higher risk for HIV.5, 6 In addition, woman’s 
susceptibility also stems from the fact that current methods of preventing HIV 
infection—abstinence, condoms, and monogamy—are ineffective and often 
 
Figure 1.1   Illustration of the HIV prevalence rate among adult men and women 
in Africa. The high incidence rate in Sub-Saharan Africa underscores the 
disproportionate burden of the pandemic on women health, evident in the 
developing countries. Reprinted from www.unicef.org. 
MEN AGED 15-24 WOMEN AGED 15-24





outside a woman’s control.7 Limitations of the existing prevention approaches 
and the fast spread of the infection rates signify the urgent need for prevention 
strategies, particularly those that women can control.8 
Whilst the urgent need for continuing efforts on developing a preventive 
vaccine is unarguable, providing a women-controlled modality that prevents 
heterosexual transmission of HIV, such as a vaginally delivered microbicide, will 
likely prove to be crucial in containing the pandemic.9-11 Vaginal microbicides are 
prophylactic strategies developed to be applied topically, to protect women 
against male to female sexual transmission of HIV.10-15 Microbicides may function 
as a physical barrier12 or deliver antiviral agents as a single agent or in 
combination.16-18 The success of 1.0 wt% tenofovir (TFV) gel in the CAPRISA 
004 microbicide trial is an historic milestone in the field of microbicides which 
reinforces the hope for preventive strategies in the fight against HIV.15 
1.3 Vaginal Physiology  
1.3.1 Anatomical considerations of the female genital tract 
The vagina is a thin-walled, collapsed fibromuscular tube extending from 
the cervix to the vulva.19, 20 The length of the vaginal canal and consequently the 
surface area varies considerably across populations.21 Average length of the 
vaginal lumen has been estimated to range from 6.0 to 9.0 cm.22 As shown in 
Figure 1.2, the genital mucosa can be subdivided into three major sections—the 




Although considered a mucosal tissue, the vaginal tissue is void of goblet 
cells. Mucin found in the vaginal tract is by virtue of the gravity-induced seeping 
of mucus secreted by goblet cells present in the endocervix.22 Structurally, the 
ectocervix and the vaginal mucosa consist of multilayered nonkeratinized 
stratified squamous epithelium, whereas the endocervical canal is constructed of 
single layered columnar epithelium.23 The squamous epithelium thickness varies 
                                            
 
1Adapted with kind permission from Macmillan Publishers Ltd: Nature Review Immunology, 




Figure 1.2    Schematic illustration of the female genital tract.1 Viral infection was 
believed to occur readily through the endocervix; however, recent evidence 
suggests that infection may also occur through the squamous epithelium, in 
particular since the large surface area of these tissues may increase the 
susceptibility of infection in the vaginal lumen. Mucus provides a reasonable 
barrier to pathogen transport; however, neutralization of mucus by semen 
decreases its barrier function. 
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across population and more so with age.21, 24-26 In women that have undergone 
menopause, the squamous epithelium becomes atrophic, consisting of fewer 
layers.24, 27 
1.3.2 Natural defense mechanisms in the female genital tract 
In addition to the protective multilayered squamous epithelium covering 
most of the female genital tract, innate immunity provides defense against 
invading pathogens.26, 28 Mucin—a high molecular weight glycoprotein 
embellished with immunoglobulin, antimicrobial peptides and enzymes—may 
trap and curb the growth of pathogenic organisms.29-33 Furthermore, the 
endogenous lactobacillus flora present in the vaginal lumen secretes hydrogen 
peroxide and maintains a nonconducive acidic environment to pathogen 
outgrowth.34, 35 Ideally, the combination of these factors should provide sufficient 
defense against the invading pathogens and prevent occurrence of new 
infections.33, 36 However, certain pathogens, including HIV, have evolved to 
bypass these natural defense mechanisms and pave way to gain entry into the 
human immune system.29, 33, 37 
1.4 Heterosexual Transmission of HIV 
Even though sexual contact transmits HIV in less than one in every 200-
2000 events, it accounts for ~80% of the total HIV infections to date.38 The risk of 
acquiring HIV from a single sexual contact may vary with the infectiousness of 
the HIV and susceptibility of the sexual partner towards HIV. The low probability 
of HIV transmission through sexual contact is counterbalanced by the high viral 
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load in the semen and the frequency of the event, making sexual transmission 
the largest contributor and the most concerning causative route of new 
infections.37 Recognizing the factors that play a critical role in the sexual 
transmission of HIV may provide a valuable insight into developing effective 
prophylactic strategies against acquisition of HIV.13, 37 Whilst the exact sequence 
of events occurring between introduction of semen-borne virus and 
establishment of productive infection is unclear,37, 39 several mechanisms have 
been implicated in this initial process. 
1.4.1 Sites in the female genital tract for HIV invasion  
The relative susceptibility and contribution of the vagina, endocervix and 
ectocervix towards HIV infection is yet to be elucidated; reports suggest that 
dissemination of infection can occur at all three sites.33, 38 The vaginal mucosa 
consists of the epithelium on the apical side and the lamina propia on the basal 
side.  In the sexual transmission of HIV, the virions rely on the genital mucosa as 
the port of entry,39 whereby the pathogen must diffuse across the epithelial 
barrier for a productive infection to occur,33, 40 in particular since the vaginal 
epithelium is void of target cells or the traditional HIV receptors. On the contrary, 
the tissue underneath the epithelium contains a rich pool of multiple target cells 
for the virus to infect.37  
The single layered endocervix epithelium is susceptible to microabrasions 
and is a vulnerable target for HIV invasion.33 Until recently, the prevalent belief 
was that transmission of HIV primary occurred via breach in the vaginal 
epithelial.38 Recent evidence corroborates that as, despite the robust mechanical 
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barrier provided by the multilayered squamous epithelium that covers the vagina 
and ectocervix, virions may undergo transcytosis and migrate efficiently across 
intact epithelium.12, 33, 37, 39-42 Subsequently, the virions may be uptaken by the 
underlying rich network of macrophages, dendritic cells and memory 
lymphocytes in the squamous epithelium, eventually infecting intraepithelial 
Langerhan cells and CD4+ T lymphocytes.29, 33, 43 Given that the total surface 
area contributed by the vagina and the ectocervical canal is 15 times greater 
than that of the endocervix, it is conceivable that the transcellular migration of 
HIV across intact epithelium could play a critical role in the dissemination of the 
infection.37 Suggested mechanisms of effective migration of HIV across the 
epithelium are shown in Figure 1.3, including (a) microabrasions and lesions in 
the stratified vaginal epithelium and/or the monolayer (columnar) cervical 
epithelium due to sexual trauma or other genital infections;33, 34, 43, 44 (b) infection 
of the epithelial cells;12 (c) transcellular migration of virus;40, 42, 45 or (d) uptake by 
immune cells, such as the macrophages residing in the vaginal canal.34, 38 
1.4.2 Gaining cellular entry and dissemination of infection 
Of the various mechanisms described above, ex vivo studies indicate that 
simultaneous infection of immune cells in the lamina propria (CD+ T-cell, 
macrophages) and active transport through antigen-processing cells to lymph 
nodes may propagate both local as well as systemic dissemination of productive 
infection.41, 45-47 HIV binds to host cells via a cascade of binding events between 
the viral envelope and cell-surface moieties, such as the negatively charged 





































































































































































































































































































































































































































































































































































































































These binding events result in a structural change that facilitates 
secondary interactions with the chemokine coreceptors—CXCR4 and CCR5.47, 48 
Following the viral binding, the viral envelope protein gp120 and the 
transmembrane protein gp41 initiate envelope fusion and viral entry.37, 49 The 
genomic RNA, enzymes (reverse transcriptase (RT), protease and integrase), 
and regulatory proteins (TAT and Rev) are transported into the host-cell. 
Replication of virus in the host cell is subsequently initiated by reverse 
transcription of the genomic RNA to produce proviral DNA that integrates into the 
host genome and subsequently results in establishment of HIV infection.50 
1.4.3 Contributions of seminal plasma 
The presence of semen-borne infectious virions in the vaginal lumen 
mediates the first step in the onset of the HIV infection.47, 51 By virtue of the 
higher buffering capacity and volume of seminal fluid, the protective acidic 
environment maintained by lactic-acid producing micro flora is neutralized, thus 
creating a hospitable milieu for viral entry, binding and outgrowth.52-54 The 
pathogens that exploit semen as the carrier, similar to the spermatozoa, benefit 
from the protective role of a large number of factors in the seminal fluid.51, 54 For 
example, amines, such as spermine and spermidine, guard the virions from the 
threat of acid inactivation.51 In addition, seminal fluid also triggers a cascade of 
signaling pathways that recruit chemokines, proinflammatory cytokines and 
neutrophils in the cervical epithelium.29, 51 This, in turn, results in accumulation of 
susceptible target cells right at the site of viral inoculums. Thus, the adapted 
mechanisms of HIV transmission evade the inhibitory effect of the vaginal pH and 
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the innate ecosystem, while exploiting the protective role of semen and 
interspersed CD4+ T cells, dendritic cells and macrophages—all of which are 
initial cellular target of HIV.33, 51 
1.5 Challenges with Vaginal Route of Microbicide 
Delivery  
The complex geometry of the vaginal canal poses several difficulties for 
vaginal delivery of microbicides using semisolid dosage forms.20, 33, 55 Firstly, the 
collapsed vaginal lumen and surfaces between the vaginal rugae present 
anatomical challenges towards homogenous application and distribution of a 
semisolid vaginal product. Secondly, seeping of the gel under gravity may result 
in considerable leakage of the product, resulting in suboptimum delivery and 
product acceptability.21 Thirdly, the shearing forces experienced during 
intercourse can disrupt the gel layer.23 Finally, dilution of formulation with vaginal 
fluid and semen prior to and during intercourse can compromise retention of the 
gel.56 Thus, an array of issues related to gel deployment and retention can 
compromise efficacy and acceptability of vaginal gels.57 In addition to the above 
mentioned anatomical challenges, the female genital tract intensifies the barrier 
to successful drug delivery and biological activity of microbicide candidates 
through several mechanisms, including changing epithelial barrier,58 constant cell 
turnover, presence of biological fluids at the surface of the tissue varying from 
vaginal fluid, cervical mucus to seminal fluid25 after the intercourse, activity of 
enzymes such as protease, hydrolases and lyases,52, 57 as well as oxidative and 
acidic stress from hydrogen peroxide produced by the vaginal flora.52, 59 
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1.6 Microbicides – Past, Present and Future 
Almost three decades ago, Zena Stein was the first scientist to propose 
the concept of a topical ‘virucide or microbicide’, analogous to the topical 
‘spermicides’ to block HIV transmission.36 Since then, several microbicide 
candidates have been pursued in clinical studies.9, 13, 60-64 However, none of the 
developed microbicides, with the exception of the most recent Tenofovir gel, 
yielded safe and effective inhibition of HIV.65, 66 With the expanding knowledge 
delineating the mechanisms and biological factors involved in the male-female 
sexual transmission of HIV and the lessons learnt from the unsuccessful clinical 
trials, there is increasing hope and optimism entrusted into the next generation 
microbicide candidates.10 The likelihood of the first tier of microbicide products to 
embody all the characteristics of an ideal product is seemingly low. Thus, it is 
imperative that the immediate global priority remains the development of a safe, 
effective and affordable microbicide, which provides protection if used 
consistently and can appeal to those who need it most.67  
1.6.1 Microbicides in the past 
The first generation microbicide relied on nonspecific inhibition of HIV. The 
primary mechanism of action included disruption of viral membrane using 
nonionic surfactants (Nonxynol-9, C31G, Sodium lauryl sulfate), electrostatic 
interactions between high molecular weight anionic polymers and negatively 
charged viral envelope to block receptor binding (PRO2000, Carraguard, 
Cellulose sulfate, Dextrin sulfate) and systems that enhanced the innate vaginal 
defense through maintenance of vaginal acidity (Buffergel, AcidForm).10, 13, 68 The 
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first generation microbicide candidates, starting with the failure of nonoxynol-9, 
have shown disappointing results in terms of interrupting transmission68-70 and/or 
safety, thereby increasing user’s susceptibility to HIV transmission.70, 71 their 
failure most likely resulted from a combination of factors, including suboptimal 
efficacy especially in the presence of biological fluids, coital use of products 
leading to poor user compliance and potential toxicity.72 
1.6.2 Microbicides pipeline in the changing landscape 
In the past, development of a safe and effective microbicide may have 
been delayed by limited identification of targets and models of HIV 
transmission.43, 67 As a result, candidates in the earlier generation were poorly 
designed and minimally surveyed for safety and efficacy prior to clinical failure.15, 
70, 73-75 Driven by the overwhelming emphasis and global prioritization of the need 
for HIV prophylactics, such as microbicides, there has been a tremendous growth 
in our scientific understanding of the events and pathways involved in HIV 
dissemination.40, 41, 47, 76 This phenomenon is becoming increasingly evident with 
the recent emergence of new generation of antiviral agents, designed to target 
specific transmission events or enzymatic machinery engaged in the HIV 
lifecycle.15, 18, 45, 77 With the advances in the mechanistic understanding of the 
HIV infection, microbicide candidates are being put through rigorous and robust 
safety and efficacy profiling.11, 75, 78-80 
Antiviral agents that target several steps in HIV transmission, such as the 
viral fusion (Fuzeon that binds to gp41),81 attachment driven by nonspecific 
interactions between gp120 and receptors on the cell surface (Cyanovirin that 
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binds to gp120),82, 83 binding to the coreceptors on the cell surface (Maraviroc is 
a CCR5 inhibitor),84 reverse transcription,85 integration (Elvitegravir, MK-2048) 
and protease (saquinavir, ritonavir, indinavir) have been identified.78 Of these, the 
two most popular categories of drugs being actively pursued for microbicide 
development are the entry and reverse transcriptase inhibitors.1, 15, 73, 86, 87 
In the past decade, reverse transcriptase inhibitors (RTI) have set a 
milestone in the advancement of antiretroviral regimens.77 Currently, the 
microbicide preclinical pipeline represents an assortment of candidates, which 
include 35 fusion and entry inhibitors, 11 reverse transcriptase inhibitors, 1 
immunomodulator, 4 with unknown and 23 with multiple mechanisms of action.85 
In spite the diversity amongst the candidates currently in the preclinical stage, 
majority of those already in clinical trials include only RTI, such as tenofovir, 
dapivirine and UC781.88 The two main issues that remain unaddressed by the 
current microbicide pipeline pertain to (a) unified approach of developing RTI-
based microbicides instead of progressing candidates that target other less 
explored steps in the HIV cycle, and (b) preferential emergence of drug-resistant 
isolates of HIV, in which case RTI-based monotherapies may show suboptimal or 
no effect against resistant mutants, proving to be less effective in subsequent 
clinical management of infection.13, 18, 77, 89, 90 
1.6.3 Lessons learnt from the past and approaches towards 
developing microbicides in the future 
Based on the inadequacies learnt from the clinical trials on the first 
generation microbicide candidates, current research efforts have focused on 
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developing longer-duration systems that allow application of the product hours 
prior to intercourse and employ highly active and HIV-specific antiretroviral 
agents.13, 73, 91 Significant resources have been invested in developing improved 
models for preclinical safety and efficacy testing of microbicide candidates.15, 81  
Compared to efficacy and safety evaluations, issues related to formulation 
are often regarded as being of secondary importance.75 Although formulation 
may not seem directly relevant and as critical in the earliest stages of the 
microbicide development process, formulation science plays a vital role in 
governing the overall effectiveness and user acceptability of the final product.92  
An example of this trend is evident in the negligent design of microbicide drug 
delivery vehicles (DDVs). Majority of the semisolid DDVs employed for vaginal 
microbicide delivery thus far, have been formulated by mimicking compositions of 
other commercially available vaginal care products, such as lubricants, 
moisturizers and contraceptives. As a result, all of the first generation microbicide 
candidates had short retention times and were coitally dependent; much like 
other over-the-counter (OTC) vaginal care products. However, meeting the 
distinct requirements of a women-controlled microbicide product, which include 
longer retention time, noncoitally dependent application and therefore ability to 
withstand dilution with biological fluids, inevitably requires engineering 
approaches that are specifically targeted for that purpose.55 
Although RTIs present a promising class of antiviral agents, concerns in 
regards to emergence of drug-resistant strains of HIV underscores the need for 
combination therapies, in particular, including agents that may target other steps 
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in the HIV life cycle.90, 92, 93 Furthermore, based on the outcomes from treatments 
with the HAART regimen, there is a prevailing consensus in the field of HIV 
therapeutics that an effective microbicide formulation would most likely employ 
multiple ARV agents to delay and mitigate the development of resistant HIV 
mutant strains.73 Of the various classes of compounds under development, entry 
inhibitors that impede HIV from entering target cells represent an attractive class 
of molecules. They are of particular interest, given that, inactivating the virus right 
at the port of entry17, 86 by using high molecular weight agents attenuates issues 
related to systemic exposure, development of drug-resistant mutants 
systemically, and tissue level biodistribution. 
Based on the knowledge acquired from the clinical evaluation of 
microbicides and the current understanding of the HIV transmission events, as a 
part of the present study, a systemic methodology was developed, with the aim 
to facilitate vaginal product design and development of lumen active-systems that 
may aid future design of microbicides. Four areas of research were covered: (a) 
rational approach to design and optimize DDV for microbicide delivery; (b) 
developing a mucin-like physical barrier technology that inhibits viral transport 
from semen to target tissue; (c) formulation of a small-molecule antiretroviral 
agent with dual mechanism of action against HIV; and (d) evaluation of a novel 
class of synthetic lectin-based polymeric entry inhibitor. 
1.7 Semisolid Gels - Overview and Classifications 
Dosage forms can be subdivided either based on the route of delivery or 
the physical state of the system. Among the three most common physical 
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states—solid, semisolid and liquid—we have been especially interested in 
semisolid drug delivery systems (DDS). Semisolid DDS constitute a significant 
proportion of the products developed for topical drug delivery, as they allow (a) 
direct delivery of the drug to the accessible mucous membranes, (b) delivery of a 
wide variety of drug molecules, and (c) rapid formulation.94-97 
In a semisolid gel, the solvent is trapped in the three dimensional polymer 
network formed by either physical or chemical crosslinks.98, 99 The polymer forms 
an extended network capable of resisting flow and small deformations.98 Given 
the long-standing history and thorough understanding of the solid and liquid 
states of material, characterization of these physical states is fairly well defined. 
In contrast, the structural complexity and uncertainty in regards to time scale 
associated with semisolid state of materials leaves room for ambiguity and 
further work.98-100 Whilst there is no perfect definition of a ‘gel’, the persistent 
misuse of the terminology to represent materials with high viscosity has 
complicated the situation further.98, 99 Despite significant work by several 
prominent authors, such as Flory, the true meaning of a ‘gel’ remains elusive.101 
The commonly accepted definition of a ‘gel’ is a crosslinked macroscopic 
material in a dilute dilution that exhibits no flow.98, 101 However, observations 
made based on the above definition as a comprehensive representation of ‘gel’ 
may lead to distorted conclusions, as variables, such as the time scale of 
observation, amount of material and method used to determine flow play a 
crucial role.98 Therefore, characterization of a semisolid gel requires a predefined 
time scale of measurement as well as consistent experimental methods and 
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conditions.98, 100 The present study focuses on the exploration of semisolid gels 
for the prevention of sexual transmission of HIV through vaginal delivery of 
antiretroviral agents or by serving as a physical barrier. In attempt to examine the 
composition-structure-property relationships that affect the end performance of 
the semisolid microbicide gels, it is imperative to first identity these relationships 
and explore how these relationships, can be exploited to develop effective DDSs. 
The rest of this chapter focuses on understanding the relationship between 
composition, structure, property and performance (CSPP) of semisolid gels, as 
examining this complex relationship in polymeric systems might provide a 
framework to rationally design semisolid gels for drug delivery. It has to be noted 
that the scope of this section is rather specific, as it focuses only on the factors 
directly relevant to this dissertation, and therefore, should not be mistaken for an 
exhaustive review on factors that may play into the CSPP relationship of gels.  
In the absence of crosslinking, substantially diluted polymer solutions 
display Newtonian flow behavior.102 However, as concentration of the polymer 
increases, network crosslink points in the linear polymer chain may be introduced 
through crosslinks (physical or chemical) and chain entanglements, resulting in 
formation of a large macroscopic polymer networks that exhibit viscoelastic or 
even pure elastic behavior.99, 101-103 The most common classification of gels is 
based on the nature of bonds that form the 3D network as transient networks 
formed by reversible crosslinks and permanent networks formed by irreversible 
crosslinks (Table 1.1).101 Transient networks give rise to viscoelastic behavior, 




 Gels may also be classified based on the ionic charge (anionic, cationic, 
neutral or ampholytic), source of the monomer or polymer (natural or synthetic), 
method of preparation (homopolymer, copolymer or multipolymer) and physical 
structure (amorphous, semicrystalline or H-bonded complexes).104, 105 
1.7.1 Composition of polymeric gels and its relationship to 
gel structure and properties 
Figure 1.4 shows a concept map outlining the relationships between 
composition of a semisolid gel and the structure and properties of the resulting 
polymer network. Variables associated with the composition of a polymeric gel 
Table 1.1   Comparative evaluation of the characteristics of reversible and 
irreversible network forming crosslinks. 
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include chemical and physical nature of the building blocks (charge, 
hydrophilicity), interactions between the building blocks (covalent, ionic etc.) and 
concentration (w/w, mole functionalization).101, 106, 107   
Hydrophilicity of the building blocks is determined by the presence of 
molecular groups that are capable of forming hydrogen bonds with water: -OH, -
COOH,-CONH2, -SO3H, etc.101, 107  Introduction of ionizable pendant groups in 
the polymer chain causes localization of charges and osmotic effects, whereby—
at low salt concentration—repulsion between these identically charged domains 
may potentially force extended conformation of polymer chains in solution, 
resulting in altered flow properties.103, 104, 107, 108 In the presence of high 
concentrations of salt, counter-ions from the salt shield the fixed charges on the 
polymer chain, thereby creating high osmotic pressure within the polymer 
network, which, in turn, causes polyelectrolyte gels to swell. 
Polyacrylic acid (PAA) gels are a classic example of this phenomenon.109 
In an aqueous dispersion of PAA at pH < pKa (of the terminal carboxylic acid), 
the polymer chains stage a condensed globular structure whereas at pH > pKa, 
the ionized carboxylate groups repel each other and compel an rigid elongated 
polymer chain conformation, which results in reduced gel viscosity.109 The 
polymer chain length is critical in defining the state and properties of the 
system.107, 110 As the number of carbons in the polymer chain increases from 10 
to 1000, the physical state transitions from liquid to waxy, and finally to solid, due 


















































































Examples of the effect of secondary valence interactions between 
polymers strands on mechanical properties are H-bonding in Nylon and cellulose 
that form flexible fibers, van der Waal’s interactions in polyethylene that form 
waxy materials, as well as electrostatic and dipole interactions in polyvinyl 
chlorides that form tough plastic materials.101 Although the above discussion 
takes into account only the forces with major contribution, it is likely that several 
forces act simultaneously.110 Polar substituents arrange symmetrically on the C-
atom, increasing the polymer chain length.106 Incorporation of bulky groups or 
increasing the number of stacked polar groups may decrease chain flexibility.101 
1.7.2 Structure of polymeric gels and its relationship to gel 
properties  
Polymer structure in a gel is comprised of three major structural 
components—the polymer chain, crosslinks and the solvent (Figure 1.5).103, 105 
Solvent entrapped in a polymer network could either be aqueous or an organic 
solvent.  
Crosslinks tie the polymer chains together to form a macroscopic matter 
called a ‘gel’ of high molecular weight.111 Since, crosslinks are what structurally 
differentiates network polymers from linear polymer, most gel material properties 
can be delineated by examining network-forming crosslinks.103 The concept map 
depicted in Figure 1.6 outlines the relationships between the network structure of 




Linear polymer chains typically dissolve when placed in a solvent due to 
the favorable entropy of mixing and enthalpic interactions with solvent 
molecules.103, 104 On the other hand, crosslinked polymers imbibe solvent within 
the polymer network, and as a result swell.102, 104  The minimum volume of 
solvent trapped in a polymer network is limited by the polymer-solvent 
interactions described by the Hildebrand’s solubility parameter (δ) (Equation 
1.1),112, 113 which is the geometric mean of the cohesive energy density (c). ΔHvap 
is the heat of vaporization and Vm is the molar volume. Difference in the solubility 
parameter of the polymer and the solvent (Δδ) when is less than or equal to one, 
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Values of Δδ > 1 indicates that the system would not mix. The maximum 
volume of a swollen gel is controlled by the elasticity of the polymer network.103, 
105 As described by Flory and Rehner (Equation 1.2),113, 114 swelling reaches 
equilibrium (ΔGT = 0) when decrease in the solution free energy (ΔGmixing) due to 





where n is the moles of solvent and polymer,
 
Ԃ is the corresponding volume 
fractions, χ is the Flory polymer-solvent interaction parameter, k is the gas 
constant, T stands for the temperature, αs is the expansion factor and ve is the 
number of elastically active chains. 
As shown in Table 1.1, crosslinked polymer networks can be formed 
through physical entanglement of polymer chains, association via cohesive 
forces and/or covalent interactions.103-105 The resulting networks can further be 
subdivided into two major functional classes—reversible and irreversible polymer 
networks (Table 1.1).104 As shown in Figure 1.7, noncovalent physical 
interactions or a selected number of reversible covalent interactions (disulphide, 
polyol-borate) can form polymer networks consisting of reversible crosslinks.  
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Figure 1.7   Illustration of plausible network forming interactions in a reversibly 
crosslinked polymer gel. Physical interactions (Top panel) and reversible 
covalent crosslinks formed by (a) Diels-Alder cycloaddition reaction, (b) disulfide 



































Entangled polymer networks formed by topological interactions between 
polymer chains form ‘pseudo gels’. As given by Equation 1.3, the plateau 
modulus (GN) of an entangled polymer network depends on the critical molecular 
weight for entanglement (Me), polymer concentration (W2), and density (ρ) .Unlike 
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Physical polymer networks comprise of a continuous disordered 
arrangement of crosslinks formed through cohesion forces, which include H-
bonding, van der Waals, electrostatic interactions as well as forces that arise 
from hydrophobic interactions.104 Bonds formed through short-range noncovalent 
interactions are usually weak (bond energy ~ 5 kcal/mol) when compared to a 
covalent bond (bond energy ~ 90–100 kcal/mole) and require close proximity of 
the interacting groups (0.4 nm or less). Therefore, to attain network strengths 
comparable those obtained from covalent interactions, a large number of 
associations must occur simultaneously. In addition, formation of physical 
crosslinks shows profound dependence on the thermodynamic factors, such as 
temperature, pH, ionic strength and others.104  
Chemical polymer networks formed through covalent interactions, which 
are most often irreversible in nature, are often considered permanent 
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networks.104, 111 Unlike linear polymer chains, the macroscopic networks formed 
by covalent interactions between polymer chains do not dissolve on dilution 
unless the covalent crosslinks or the polymer chains are cleaved.104, 111 
Alternatively, a small fraction of covalent interactions that are reversible in nature 
form transient networks. 
Polymer networks formed predominantly by chain entanglements are 
constructed on bonds with low bond energies and exhibit properties similar to a 
viscous fluid.102 Whereas, networks formed by irreversible covalent interactions 
form extended macroscopic networks with infinite lifetime and high bond 
energies, exhibiting properties similar to an elastic solid.100 Intermediate to these 
two network categories are those formed by noncovalent physical interactions. 
Networks formed by physical interactions or reversible covalent crosslinks have 
small but finite bond energy and crosslink lifetime. Consequently, these networks 
exhibit viscoelastic properties.99  
Materials that completely abide to the Hooke’s law of deformation given by 
σ = Gγ, where stress (σ) equals product of the elastic modulus (G) and 
deformation (γ), are termed ideal elastic solids. In contrast, materials that obey 
the Newton’s law of deformation given by σ = η(dγ/dt), where η is viscosity and 
dγ/dt is velocity gradient, are considered viscous fluids. It was not until the 19th 
century, that scientist found materials such as silk threads, that did not fully obey 
either the Hooke’s law of elasticity or the Newton’s law of viscosity. Deborah was 
the first to suggest that, “seemingly solid materials could behave like liquids”, 
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where τ is a characteristic lifetime of the crosslink and t is the time of the 
deformation. De = 0 for a viscous liquid; De = ∞ for a elastic solid and 0 < De < ∞ 
represents a viscoelastic material. Structural evaluations of polymer networks 
reveal that ideal network structures are rarely observed.101, 104 Network defects 
may occur due to presence of unreacted groups, intermolecular loops or chain 
entanglements.104 Additionally, non uniform distribution of crosslinks or phase 
separation during crosslinking may introduce inhomogeniety in networks.101 
Material deformation can be studied using rheology by measuring the 
change in the deformation with time under externally applied force or under 
steady state flow or through application of small perturbations (shown in Table 
1.2). Networks comprised of reversible crosslinks demonstrate time-dependent 
changes in crosslink association and dissociation states, yielding dynamic-
mechanical and viscoelastic properties. When subjected to an external force of 
deformation, randomly coiled polymer chains rapidly consume the energy to 
facilitate relaxation of molecules through bond rotation, causing permanent 
deformation in the form of viscous flow of the polymer.110 In contrast, in the 
presence of permanent covalent crosslinks flow and relaxation of stress is either 
delayed or in some cases prevented due to lower entropy of the polymer chains 
and a higher retractive force.115  
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Table 1.2   Mechanical and rheological characterization of semisolid gels. 
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Transient networks formed through reversible covalent crosslinks, display 
viscoelastic properties at varying timescales that can be monitored and studied 
using techniques such as dynamic rheology.98 
1.7.3 Polymer network properties and its effect on the 
performance of semisolid gels  
Figure 1.8 shows a concept map outlining the relationships between 
properties of a polymer network and its performance as a semisolid gel for 
microbicide applications. Some of the most important characteristics of an anti-
HIV microbicide semisolid gel include (a) deployment, (b) activity that, depending 
on the method of action, may be through drug delivery or physical entrapment, 
(c) bioadhesion, (d) ability to withstand dilution with biofluids, and (e) safety. 
Each of these performance criteria are discussed below.   
In engineering a semisolid gel, it is imperative to control its mechanical 
properties for ease of application, coating and retention of the system.98, 116, 117 
Application and coating necessitates low network viscosity that can easily flow 
over tissue.117, 118 However, low viscosity materials suffer from an inherent 
difficulty in being retained in the vaginal lumen, and may not have the capacity to 
inhibit viral transport to tissue, especially if applied hours prior to intercourse. 
Therefore, being mindful of this property-performance tradeoff—both low and 
higher viscosity—is critical.117, 118  
Alternately, stimuli-responsive gels (pH, temperature etc.) have been 
employed as means to create formulations that can be applied as a liquid ensued 






















































































A semisolid gel may prevent sexual transmission of HIV by either acting 
as a chemical barrier by delivering inhibitory concentrations of antiretroviral 
agents to the tissue14, 122 or by acting as a physical barrier and prevent the viral 
transport from semen to the susceptible genital tissue.66, 120 In both cases, 
understanding and modulating the diffusion of either drug molecules or virions 
through the polymer network is imperative. 
Permeability of drug molecules and particles through polymer networks 
depends on the structure of the polymer that, in turn, depends on the polymer 
hydrophilicity and crystallinity, extent of hydration, chemical and physical nature 
of the releasing agent and crosslinking density.123 Permeation of the releasing 
agent in the polymer matrix may occur via diffusion through solvent-filled pores or 
partitioning of dissolved drug through the different layers of the polymer matrix.104 
In pore-mediated diffusion, the molecular size of the diffusing molecule has an 
important effect on the diffusion coefficient, whereas in partition-mediated 
diffusion, size of the particle plays a lesser role. 
The diffusion process is explained by three prominent theories—free 
volume theory, hydrodynamic theory and the obstruction theory of diffusion. 
Often, a combination of mechanisms collectively govern diffusion rate of 
molecules through polymer networks.104 The free volume theory of diffusion 
developed by Yasuda and modified by Peppas and Cohen-Turnbull, proposes 
that the molecules diffusing through a polymer network are required to find a 
sufficiently large free volume of solvent, in addition to an opening between the 
polymer chains that is large enough to allow the passage of molecules (Equation 
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1.5). The size of diffusing molecule becomes very critical in regards to the 
openings between the polymer chains, the chain mobility and the presence of 
functional groups on the polymer chain that may bind to the solute and impede its 
transport. In the free volume theory, diffusion coefficient in the gel (Dgel) is given 
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where Do is diffusion coefficient of solute in an infinitely dilute solution, Po is the 
probability of finding a opening large enough for diffusion of solute, B is the 
constant of proportionality, a* is the cross-sectional area of the solute, Vf,,w is the 
free volume occupied in water and Ф is the volume fraction of polymer in the gel.  
Stoke-Einstein’s theory assumes that the diffusing molecules moving at a 
constant velocity in a continuum of solvent are resisted by the 
frictional/hydrodynamic drag imposed by the bulk solvent, given by the 
relationship shown in Equation 1.6.125 
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where kB is the Boltzmann constant, T is the absolute temperature, f is the 
coefficient of frictional drag, η is the viscosity of medium and r is the radius of the 
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spherical particle. Ogston’s obstruction theory (Equation 1.7) assumes that the 
diffusive transport of molecules through the tortuous polymer chains increases 
the path length and thereby obstructs diffusitivity.125  
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where rs, rf and r are the radius of the solute, length of the polymer fiber and 
average opening between polymer chains, respectively. Based on the above 
three theories, diffusion coefficient can be expected to decrease with increase in 
solute size, tortousity of the polymer chains and crystallizability of the polymer 
network.104, 105 
Whilst above discussed theories aid a mechanistic understanding of the 
diffusion process, simple power law expression shown in Equation 1.8 may 
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where mt/m∞ is the fraction released at time t; k is the factor dependent on the 




Higuchi developed relationships that describe the rate of drug release from a 
semisolid matrix. Equation 1.9124 is applicable when the drug in the polymer 
matrix is completely dissolved. M (amount of drug released per unit area) is 
directly proportional to Co (concentration of drug in the matrix) and √t (time).  
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In contrast, Equation 1.10126 is suitable for a system where the amount of 
drug present in the polymeric vehicle exceeds its solubility and, therefore, the 
drug is dispersed in the gel. 
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Table 1.3   Types of transport mechanisms described by the Power law for 
fractional drug release.124 







0.5 < n < 1.0 Non-Fickian diffusion f(tn-1) 
1.0 Case-II transport Time dependent 





where D is the diffusion coefficient of drug in the matrix; Q is the total amount of 
drug in the matrix and Cs stands for the solubility of drug in the semisolid vehicle.  
As bioadhesion is an important beneficial characteristic required of most 
topical drug delivery systems, designing polymeric systems that exhibit 
bioadhesion may yield longer retention of the semisolid gel at the site of delivery 
and decreased leakage.106, 116 Mechanism of bioadhesion can occur through 
mechanical bond formation facilitated by penetration of the gel into the tissue 
cracks and crevices. 
In addition, acylating and alkylating agents in the polymeric gel can react 
with amines and hydroxyl groups on the serine or tyrosine, forming a covalent 
bond or interactions, such as H-bonding, van der Waal attractions, giving rise to 
strong bioadhesion.106, 127 Factors that may affect bioadhesion include functional 
groups capable of interacting with the epithelium, turnover rate and hydration.106 
Furthermore, steric effect of substituents, charge density and molecular weight of 
the polymer affect chain flexibility, which is critical in defining the permissible 
conformations of the polymer to adhere to the tissue.106, 110 
When developing materials for vaginal delivery, one essential aspect that 
needs to be considered is the dilution of the semisolid gel with biofluids, such as 
seminal fluid and cervical mucus, as well as the effect of sugars, ions and 
proteins inherently present in the vaginal canal. In particular, polymeric networks 
formed through noncovalent interactions may show marked variations in network 
properties, depending on environmental factors (pH, ionic strength etc). It is vital 
that the gels bear the ability to withstand dilution and retain their viscoelastic 
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network properties, as loss in viscosity on dilution could result in leakage, lower 
user compliance, compromised barrier properties and rapid drug release. 
It is well known that incorporation of negatively charged groups in the 
polymer matrix results in nonspecific interactions between the polymer and 
positively charged cell or pathogen surface. These interactions have implications 
on both the antiviral activity of the end formulation as well as the gel toxicity to 
the genital tissue and the vaginal flora.  
Polymer composition and the solvent in the polymer matrix affect the gel 
osmolarity that, in turn, may cause toxicity due to hyper- or hypo-osmolarity. The 
common issue inherent in synthetic polymeric systems is toxicity associated with 
unreacted monomers, residual organic solvent and toxic initiators that may leach 
out during application. Therefore, careful selection of monomers and a thorough 
understanding of the toxicity of the various building blocks of the polymer are 
very important. 
.       




DESIGN OF A SEMISOLID VAGINAL MICROBICIDE 
GEL BY RELATING COMPOSITION TO 
PROPERTIES AND PERFORMANCE2 
2.1 Introduction 
To date, most vaginal semisolid gels have been designed empirically, with 
mechanical properties mimicking those of other commercial semisolid products. 
For drug delivery products, this approach may have originated, in part, due to 
inadequate recognition of the roles of delivery vehicles in the overall 
effectivenesses and acceptabilities of the products.55, 127-129 Given the nature of 
the historical approach, we have limited appreciation for the extent to which 
these existing vaginal products achieve their designated functions. We therefore 
posit that there is a need for methodologies to help formulation scientists to 
objectively and intelligently select gel compositions for target applications. 
                                            
 
2Adapted from Design of a Semisolid Vaginal Microbicide Gel by Relating Composition to 
Properties and Performance, Pharmaceutical Research, Volume 27, 2010, 2478-91, Alamelu 
Mahalingam, Eric Smith, Judit Fabian, Festo R. Damian, Jennifer J. Peters, Meredith R. Clark, 
David R. Friend, David F. Katz, Patrick F. Kiser.  
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Performance criteria will nonetheless vary based on the use of the vaginal 
product and the drug(s) it contains. Therefore, it is inevitable that pharmaceutical 
scientists will need to vary the properties of gel formulations to satisfy desired 
performance criteria.  For this reason, it is important to understand the underlying 
composition-property-performance relationships (CPPR) of the gels, so that their 
compositions can be rationally varied to achieve given sets of properties and 
performance standards.  
Vaginal gels are a primary dosage form for microbicides, which are 
topically applied products for the delivery of antiviral agents, intended to provide 
protection against the sexual transmission of HIV and other sexually transmitted 
pathogens.10, 67, 92 The performance of a vaginal microbicide gel is both biological 
(i.e., drug delivery) and behavioral (i.e., user acceptability). Performance can be 
measured with respect to a number of functions, including the gel’s ability to 
spread along the vaginal canal and coat the vaginal epithelium. This function 
governs delivery of active ingredient(s) to the target tissue; it also can lead to 
leakage outside the vagina, which adversely influences the acceptability of the 
product.55, 67, 130 Gel performance in relation to the above criteria is strongly 
influenced by the administered volume, an often neglected parameter in gel 
design. Careful selection of the gel volume is crucial, since it has a causal 
relationship to the dynamics of gel coating131 and the potential for leakage.  That 
is, an ideal microbicide gel must provide desired coating with minimal leakage for 
a given volume of administration. To address this tradeoff between coating and 
leakage, an objective, quantitative method relating gel composition to both those 
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performance attributes is needed.  An initial set of biomechanical flow models 
has been created, that relate gel rheological properties, gel volume, vaginal 
forces acting on a gel, and vaginal geometry to measures of gel spreading along 
the vaginal canal.56, 118, 132 These fluid flow models enable us to predict the 
coating and leakage of a gel for a given volume and set of properties. However 
such information, alone, is of limited value to pharmaceutical scientists: the 
performance of a gel, and the properties that give rise to it, are multivariate; they 
depend on the composition-property relationships of the polymers and excipients 
within the formulation. Given the complexity of the relationships amongst 
composition, properties and performance, it is not surprising that most vaginal gel 
compositions were selected empirically with little effort devoted to quantitatively 
relate composition to properties and performance.133 
To address this critical gap in the field of vaginal drug delivery from gels, a 
set of tools was developed to quantitatively explore composition-property-
performance relationships in semisolid gels. A multivariate objective function 
constructed from gel properties, computations of flow behavior of the gel, and 
performance criteria for that flow behavior, is described herein. Analogous 
multivariate optimization approaches have previously been used in many fields, 
including computational biology, bioinformatics, drug discovery and molecular 
optimization for ligand binding.92, 134, 135  As shown in Figure 2.1, Mixture Design 
of Experiments (MDOE) methodology136-138 was used to establish a semi-
empirical relationship between composition-property and property-performance 
relationships; this approach enabled us to obtain a local optimum within a given 
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composition space. Considerable work has been done on the development of 
hydrogels composed of PAA, cellulose and hyaluronic acid for ocular, buccal, 
vaginal and intestinal delivery.97 Among these, cellulose and PAA based 
polymers have received increasing interest for cervical and vaginal drug 
delivery.97 The major attributes of these polymeric carriers that make them 
attractive candidates for vaginal drug delivery are the GRAS status,130 low cost 
and bioadhesion.97 On the basis of the extensive literature available on the use of 
these polymers for vaginal drug delivery, we chose Carbopol 974P and 
hydroxyethylcellulose (HEC) as the two polymeric carriers to be evaluated;55, 92, 
97, 130, 131 however the general methodology we present can be used in any 
semisolid design space. The antiretroviral drugs used in development of the 
models were the HIV-1 reverse transcriptase inhibitors UC78175, 97, 139 and 
TFV.140-142 
2.2 Materials and Methods 
2.2.1 Materials 
Micronized UC781 and TFV were obtained from the CONRAD Program 
(Arlington, VA, USA). Carbopol 974P NF was purchased from Lubrizol (Wickliffe, 
OH, USA). HEC 250 HX PHARM was purchased from Hercules (Wilmington, DE, 
USA). Glycerin NF was purchased from J.T.Baker (Phillipsburg, NJ, USA). 































































































































































































































































































The following commercial gels, Replens® (lot # RD01015), K-Y Jelly® (lot # 
0385C), Advantage-S™ (lot # A05101), Conceptrol® (lot # 8MM6346), and 
RepHresh® (lot # F09142) were purchased from a local pharmacy store. Methyl 
cellulose placebo gel (lot # 100306) and Carraguard (lot # 23175) were obtained 
from the Population Council (New York, NY, USA).  The HEC clinical placebo gel 
(GMID #70018699), 6% Cellulose Sulfate microbicide gel (lot # C1564A001), 
TFV 1% microbicide gel from the CAPRISA trial (GMID #70018698) and UC781 
microbicide gel (lot # 1061) were obtained from the CONRAD Program 
(Arlington, VA). 
2.2.2 Experimental design 
This work was part of our development of semisolid vaginal microbicide 
gels for the delivery of two highly potent antiretroviral drugs – TFV143 and 
UC781141, and these drugs were included in all formulations. To elucidate the 
relationship between composition-property and property-performance, a 
statistical tool - Mixture Design of Experiments (MDOE) was used.  The fractions 
of the two polymers, X1 (Carbopol 974P) and X2 (HEC) were selected as two 
independent variables, which were varied simultaneously. Selection of model 
compositions and the optimization were performed using Design Expert® 7.1 
(Stat-Ease, Inc., Minneapolis, MN) software.  
In order to determine maximum concentrations of gelling agents, viscosity 
measurements was obtained on a series of gels with varying concentrations of 
Carbopol 974P and HEC. For initial comparison of these gels based on viscosity, 
a shear rate of 50 s-1 representing an intermediate physiologically relevant (1-100 
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s-1) value was chosen.139 Upper limits on the concentrations of the gelling agents 
were chosen such that each polymer at its highest concentration would create a 
gel with viscosity comparable to that for commercially available gels at 50 s-1. 
Based on these preliminary investigations, 2.5 wt% and 3.0 wt% were chosen as 
the maximum concentrations to be tested for Carbopol 974P and HEC, 
respectively (Table 2.1). Fixed gel components consisted of 5 wt% glycerin, 0.1 
wt% UC781, 1.0 wt% TFV, 0.15 wt% methylparaben and 0.05 wt% 
propylparaben (preservatives), totaling 6.3 wt% of the gel. DI water was used to 
make up the weight of the gel to 100 wt%.  
Design space for an ‘n’ component mixture is represented by a surface in 
‘n-1’ dimensions. Thus, an equilateral triangle in two-dimensional space 
represents the mixture design space for a three-component system. In this work, 
not all factors varied over the same range; the design space was represented by 
a fraction of the equilateral triangle, as shown in Figure 2.2. A design matrix 
comprising of 19 model compositions was constructed (Table 2.2). This included: 
three vertices of the triangular space (X1, X2, X3) to determine the effect of the 
pure components; three binary blends (X1X2, X2X3, X3X1) to determine the effect 
of combinations of gelling agents; and one centroid point (X1X2X3) and 
represents a center point with each ingredient at one third the maximum 
concentration. The order in which the gels were made and tested was 
randomized to counteract any differences due to aging or time-related effect 




Components Minimum (wt%) Maximum (wt%)
X1 : Carbopol 0.0 2.5
X2 : HEC 0.0 3.0
X3 : Water 78.2 83.7






Figure 2.2   12 point mixture design for a three component mixture. The 
constraints on the model are Carbopol 974P (0 ≤ X1 ≤ 2.5 wt%); HEC (0 ≤ X2 ≤ 
3.0 wt%) and Water (78.2 ≤ X3 ≤ 83.7 wt%). Red points in the design space 
indicate the 19 model compositions. The numbers next to the point indicate 
number of repeats of each composition. 

























Table 2.2   Composition matrix with 19 model compositions. The constraints on 
the model are Carbopol  (0 ≤ X1 ≤ 2.5 wt%); HEC (0 ≤ X2 ≤ 3.0 wt%) and Water 
(78.2 ≤ X3 ≤ 83.7 wt%) 
 
 
Design space for an ‘n’ component mixture is represented by a surface in 
‘n-1’ dimensions. Thus, an equilateral triangle in two-dimensional space 
represents the mixture design space for a three-component system. In this work, 
not all factors varied over the same range; the design space was represented by 
a fraction of the equilateral triangle, as shown in Figure 2.2. A design matrix 
comprising of 19 model compositions was constructed (Table 2.2). This included: 
Gel ID Point type X1 (wt%) X2 (wt%) X3 (wt%)
1 Vertex 2.50 0.00 81.20
2 Vertex 2.50 3.00 78.20
3 Blend check 1.25 0.75 81.70
4 Axial midpoint 1.25 3.00 79.45
5 Centroid 1.25 1.50 80.95
6 Blend check 0.63 2.25 80.83
7 Vertex 0.00 0.00 83.70
8 Vertex 2.50 3.00 78.20
9 Axial midpoint 1.25 0.00 82.45
10 Blend check 1.25 0.75 81.70
11 Vertex 0.00 0.00 83.70
12 Axial midpoint 0.00 1.50 82.20
13 Vertex 0.00 3.00 80.70
14 Vertex 0.00 0.00 83.70
15 Vertex 0.00 3.00 80.70
16 Vertex 2.50 3.00 78.20
17 Axial midpoint 2.50 1.50 79.70
18 Vertex 2.50 0.00 81.20
19 Blend check 1.25 2.25 80.20
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three vertices of the triangular space (X1, X2, X3) to determine the effect of the 
pure components; three binary blends (X1X2, X2X3, X3X1) to determine the effect 
of combinations of gelling agents; and one centroid point (X1X2X3) and 
represents a center point with each ingredient at one third the maximum 
concentration. The order in which the gels were made and tested was 
randomized to counteract any differences due to aging or time-related effects 
(Table 2.2). 
2.2.3 Model selection  
The cubic model was chosen to model the responses because it provides 
a reasonable approximation of actual response surface for a three component 
mixture design. The Scheffé polynomial was used to eliminate redundant 
coefficients introduced by the constraints imposed by the mixture design.57 In 
addition, to obtain a good response surface, extra points were augmented in the 
model to evaluate goodness of fit and pure error. Equation 2.1 gives the 
polynomial for the nonlinear cubic model.144 
 
1 2 2 3
( )
q q q q
i i j i j i j i j kiji ij ijki i j j i j j j k ki j
y X X X X X X X X X X                  (2.1) 
 
 
Here y is the response; Xi, Xj, Xk represent the three components of the mixture; 
βi, βj, βk represent the linear coefficients; βij, βjk, βik represent the nonlinear 
blending model coefficients; and βijk, δij represent the model coefficient for higher 
order nonlinear blending. 
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2.2.4 Preparation of the Carbopol 974P and HEC gels 
UC781 (0.1 wt%) was dispersed in glycerin (3.5 wt%) to form a 
homogenous paste which was then added to 1 wt% TFV solution in water. 
Required amounts of Carbopol 974P were added to the above solution, and 
stirred with a paddle mixer at 350 rpm for 45 m to ensure complete hydration of 
the polymer. Stainless steel paddles (passivated 316L) and USP grade water 
should be used to avoid introduction of trace amounts of metal into the gel during 
preparation. Methylparaben (0.15 wt%) and propylparben (0.05 wt%) were 
weighed and mixed with preheated glycerin (1.5 wt%) at 65°C until all solids 
dissolved. Required amount of HEC was added to the glycerin paste after cooling 
to room temperature. The glycerin paste was then added to the Carbopol 974P 
dispersion with constant stirring. The pH of the gel was adjusted to 5.2 ± 0.2 with 
10 wt% NaOH. Finally, the overall weight of the gel was adjusted to 100g with 18 
mΩ DI water.  
2.2.5 pH and osmolality measurements 
The pH of the gels was recorded at room temperature using a 423 
microprobe electrode (Mettler Toledo Instruments, Germany) prior to rheological 
measurements. Osmolality of gels was measured using a Vapro 5220 
osmometer (Wescor Inc., UT, USA), with the goal of constraining 
hyperosmolality. Ten µL of gel was loaded on solvent free disc and placed in the 
precalibrated osmometer for osmolality measurements. Averages of five 
measurements were taken. The pH of the gels were 5.2 ± 0.2, and all osmolality 
values were < 1000 mOsm/kg. 
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2.2.6 Dilution of gels with vaginal fluid simulant (VFS) 
To study the effect of dilution of gels with vaginal fluid, we performed a 
complete rheological characterization on gels mechanically mixed with VFS at a 
biologically relevant ratio (1:4 dilution; VFS: gel).145 The VFS was prepared as 
previously reported.57 One g of the VFS was mechanically mixed with 4 g of gel. 
Diluted gels were allowed to equilibrate for 24 h before measurements. 
2.2.7 Determination of rheological properties 
Viscosities of gel formulations (undiluted, diluted) were measured using a 
stress controlled AR 550 rheometer (TA Instruments, DE, USA) equipped with a 
20 mm 4° steel cone geometry. One hundred and fifty µL of the gel was loaded 
using a positive displacement pipette and allowed to equilibrate for 2 m on the 
Peltier plate at 37°C, after which a steady state shear was applied. Shear rates 
experienced in vivo range from < 0.1 s-1 during passive seeping between 
epithelial surfaces to the order of ~ 100 s-1 during coitus.146 Thus, viscosity was 
determined over the range of 10-4-1000 s-1 to simulate physiological conditions.57 
2.2.8 Stress growth and relaxation measurements 
The yield and residual stresses in a gel influence its initial flow and also its 
sustained retention within the vaginal canal. We performed stress growth and 
relaxation studies to measure residual stresses, on both undiluted and diluted 
gels. For most gels, we used a Brookfield model 5HBDV-III Ultra rheometer 
equipped with a CPE40 cone at a shear rate of 10 s-1.  Gels (7, 11 and 14) had 
low viscosities and failed to produce measurable torque on this instrument; 
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therefore, a Brookfield model LVDV-III rheometer equipped with a CP40 cone at 
a shear rate of 300 s-1 was used for those gels.  
2.2.9 Fitting rheological data to constitutive models 
Data obtained from the steady state rheological studies and the stress 
growth and relaxation studies were fitted to the Power law and Herschel-Bulkley 
models (Table 2.3).  The latter was used when a nonzero residual stress was 
measured, and the residual stress value was used to approximate the yield 
stress.  Logarithmic values of shear stress or viscosity as a function of shear rate 
(over the range of 10-4 to 100 s-1) were averaged over the replicate experiments, 
and fitted to the models using a Matlab function to minimize the residuals.  
2.2.10 Squeezing flow model 
Estimates of the vaginal area coated by the gel (A) were made, using a 
biomechanical fluid flow model of the coating process.56, 57 This model utilizes the 
concept of constant-force squeezing of fluid between two plates, simulating the 
elastic forces from the posterior and anterior walls of the vagina. Inputs to the 
squeezing flow model were the rheological parameters from the constitutive 
model, initial height of the bolus (0.2 cm), volume of the gel, vaginal dimensions, 
and forces exerted by the vaginal muscles on the gel (1-10 N).118 The output 
from the flow model is the area coated as a function of time.  We focused upon 
that area at 120 s after the onset of gel flow, which serves as a measure of the 




Power Law τ - shear stress
m - consistency index
γ - shear rate
n - shear thinning index
Herschel-Bulkley τ0 - yield stress
nm 
0
nm   
 
2.2.11 Confirmation of the squeezing flow model  
The results of the squeezing flow model were confirmed through 
calculation of area coated and in vivo MRI measurements of gel coating on four 
commercial over-the-counter products – K-Y Jelly®, Replens®, Conceptrol® and 
Advantage-S™.118, 147 
2.2.12 Development of the objective function 
An objective function was designed to serve as a DOE response factor, 
which was constructed as a piecewise continuous function of A: it has different 
analytical forms for A ≤ Amax and for A > Amax, which give equal results at A = 
Amax. The domain of the function is defined from zero to unity such that when its 
value, termed the score (S), equals 1, the gel fully meets the performance 
requirements (Figure 2.3).  
If we assume that the amount of drug delivered by a gel is derived from 
drug diffusion within the gel, and that the process is quasi-state, then drug flux is 
inversely proportional to gel thickness, (h).   
Table 2.3   Constitutive equations to model the non-Newtonian rheological 









Since, J D x
         (2.2) 
 
 
1J h         (2.3) 
 
 
where, J - diffusion flux, Ф - concentration and x - length or thickness. Volume of 
the gel (V) can be expressed as,  
 
V Ah          (2.4) 
 
 
For constant value of V, h is inversely proportional to A.   
 















1h A       (2.5) 
 
 
Since, the amount of drug delivered (Q) depends on the flux and the 
surface area, Q is proportional to A2.   
 
Q JA       (2.6) 
 
 
 Since, J A         (2.7) 
 
 
2Q A         (2.8) 
 
 
We chose a simple form of the objective function based upon this result, 






    
 for max0 A A      (2.9) 
 
 
This expression is evaluated at a fixed time, 120 s, and does not, of 
course, include the time course of the increase in area coated with time. As such, 
it represents an upper bound on drug delivery over this time interval. When the 
area coated exceeds Amax, the gel is predicted to leak from the vagina. Thus its 
merit would decrease in relation to the amount of predicted leakage.  Letting VL 
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be the volume of gel that has leaked, Equation 2.10 relates VL to A* which is the 
value of A at which the score becomes zero. A simple linear function was used to 
model the decline of the score from unity to zero, as area coated increases 
above Amax.  Our expression inputs a maximum value of VL at which the value of 





AA    













        for maxA A    (2.11) 
 
 
Separate computations were performed for undiluted (Sundiluted) and diluted 
(Sdiluted) gels. These scores served as responses to create response surface 
modeling (RSM).  In this algorithm, there are four key inputs: V, Amax and VL and 
the mathematical form of the objective function. V was chosen to be 3.5 mL for 
the initial set of studies because this value is a common dose volume of 
microbicide gels. Maximum volume of the gel leaked after application was taken 
as VL = 1.5 mL, at which the score declined to zero (Figure 2.3). This volume was 
based upon inputs from clinical investigators evaluating acceptability of gels in 
microbicide trials.  Choosing the value Amax, which is a specified target area for 
optimal coating, requires information about the relationship between the 
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squeezing model predictions of area coated and actual values of areas coated in 
women. In the present study, we used values of area coated computed for the 
methylcellulose (MC) placebo gel from the Carraguard® trials as a reference.148 
2.3 Results 
2.3.1 Rheological measurements 
Viscosity values vs. shear rate for different combinations of HEC and 
Carbopol 974P are presented in Figure 2.4. Shear rates are shown from 1 - 100 
s-1 for undiluted gels (Figure 2.4A) and 1 - 1000 s-1 for gels diluted with VFS 
(Figure 2.4B). Combinations of Carbopol 974P and HEC were investigated in 
relation to any synergistic effect between the two polymers on gel viscosity. 
Similar observations for combinations of Carbopol 974P and HPMC have 
previously been reported.149  At low shear rates (~ 1 s-1) the viscosities of gels 
with both gelling agents, were approximately an order of magnitude higher than 
the sums of the viscosities for gels with the individual polymers. However, at 
higher shear rates (~100 s-1) such differences became marginal.  This result 
indicates that the shear rate dependent viscosity profile is critical, and that simply 
comparing viscosities at specific shear rates is insufficient in understanding and 
comparing rheological behavior of gels. When gels were diluted with VFS, those 
consisting of both HEC and Carbopol 974P exhibited > 50% loss in viscosity vs. 
undiluted values. The maximum impact of dilution was observed with gels 
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Figure 2.4   Results of the steady state flow experiments on undiluted gels (A) 
and gels after 20% dilution with VFS (B).  
 
2.3.2 Fitting rheological data to constitutive models 
Table 2.4 summarizes the composition-property relationship in the gels.  
In general, the consistency index decreased on dilution with VFS, whereas the 
shear thinning coefficient increased, i.e., the degree of shear thinning decreased.  
2.3.3 Stress growth and relaxation measurements  
As expected, gels with HEC alone did not demonstrate measurable 
residual stresses.150 Gels consisting of Carbopol 974P alone or in combination 
with HEC exhibited measurable residual stress. Carbopol 974P gels 
demonstrated a concentration dependent increase in measured residual stress. 
For all gels diluted with VFS (Figure 2.5B), there was a significant decrease in 
the residual stress. 
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Gel ID mundiluted mdiluted nundiluted ndiluted r2undiluted r2diluted
1 1189 743 0.30 0.30 0.99 0.99
2 6157 1288 0.08 0.29 0.96 0.71
3 2253 785 0.22 0.31 0.99 1.00
4 6587 1554 0.16 0.42 0.99 0.75
5 3117 1482 0.21 0.35 0.99 0.93
6 2488 1054 0.21 0.30 0.97 0.99
7 4.07 0.00 0.14 1.47 0.91 -
8 2720 1362 0.25 0.23 0.90 0.70
9 454 129 0.28 0.42 0.99 1.00
10 1628 675 0.28 0.32 0.99 1.00
11 2.92 0.17 0.22 0.34 0.95 0.97
12 89.2 2.40 0.47 2.48 0.98 -
13 516 535 0.35 0.40 0.98 0.97
14 2.43 0.00 0.22 1.52 0.99 -
15 669 420 0.33 0.44 0.98 0.97
16 2517 1453 0.29 0.18 0.87 0.64
17 5923 1233 0.14 0.39 0.95 0.65
18 1051 884 0.29 0.27 0.99 0.99
19 5648 1352 0.17 0.48 0.99 0.83





























































Table 2.4   Power law parameters for gels undiluted and diluted 20% with VFS. 
 
n - shear thinning index, m - consistency index , r2 - goodness of model fit and τr- residual stress 




Figure 2.5   Comparisons of the stress growth and relaxation curves for gels 
from the MDOE. Plots A and B show the stress growth and the relaxation curve 
for the undiluted and diluted gels.  
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Carbopol 974P gels, in the absence of HEC, showed ~ 50% loss in 
residual stress on dilution; in contrast, gels containing both Carbopol 974P and 
HEC showed significant but less dramatic losses in residual stress compared to 
pure Carbopol 974P gels. Gels with Carbopol 974P at its highest concentration, 
in the presence of HEC, demonstrated the highest residual stress (~ 150 Pa).  
2.3.4 Squeezing flow model 
The MC placebo gel from the Carraguard® clinical trial56, 65 has been 
previously reported to provide near complete coating of the vaginal epithelium in 
vivo, immediately after application with insignificant leakage post application.149 
For this gel we obtained an area coated of 117 cm2 at 120 s for a 3.5 mL volume. 
This value is close to the actual value of human vaginal surface area.56, 128 To 
compensate for the overestimations of area coated by the flow model, we 
renormalized all data with respect to MC placebo. Thus, Amax for both undiluted 
and diluted gels was set at 117 cm2, for a volume of administration of 3.5 mL.  
2.3.5 In vivo confirmation of the squeezing flow model  
To validate the predictions of area coated obtained from the squeezing 
flow model; model data were compared to the percentage A obtained from in vivo 
imaging studies for four over the counter (OTC) gels – K-Y Jelly®, Replens®, 
Conceptrol® and Advantage-S™. The values of A predicted by the squeezing 
flow model showed good agreement (< 25% difference) with the results from 
imaging studies reported in literature, with a consistent but small overestimation 







coated from the 
Squeezing flow 
modelc
Conceptrol® a 59 72
K-Y Jelly® b 63 76
Replens® b 68 84
Advantage-S™ a 96 104
 
2.3.6 Area coated from squeezing flow model 
Figure 2.6 summarizes the results of the squeezing flow computations on 
the gels. Upon dilution with VFS, gels with highest concentration of HEC and/or 
Carbopol 974P displayed 15-20% increase in the predicted area coated, 
whereas, at lower concentrations, there was a more pronounced effect of dilution 
(30-50%). At fixed concentrations of one gelling agent and increasing 
concentrations of the other agent, spreading of gels decreased significantly. 
These results are consistent with the trends observed in the viscosity vs. shear 
rate curves (Figure 2.4).  
2.3.7 Fitting responses to model  
Sundiluted and Sdiluted computed for the model gels were simultaneously fitted 
to linear, quadratic, cubic and higher order special cubic models. 
Table 2.5   Summary of the percentage surface area coated, obtained from the 
squeezing flow calculations and from in vivo MRI studies in women. 
 




The cubic model provided the best estimation of coefficients for both 
responses. Comparative values of model fits are summarized in Table 2.6 along 
with the regression equation generated for each response. The fits indicated that 
a significant model did exist (p < 0.05), with insignificant lack of fit (p > 0.10) and 
an adequate signal-to-noise ratio (precision > 4). Using the backward elimination 
function in the program, only statistically significant (p < 0.05) coefficients were 
included in the regression equations. In general, positive values of model 
coefficients (βi, βj, βk; Equation 2.1) indicate that the selected effect favors 




Figure 2.6   Predicted vaginal surface area covered after 120 s of constant-
volume squeezing, using the squeezing flow model. Gel volume = 3.5 mL. (A) 
Undiluted gels and (B) gels diluted 20% with VFS. Increasing size of the bubble 
and color gradations from black to gray represents increasing values of area 
coated. 1.5 w% HEC gave the highest area coated followed by 3.0 w% HEC gel. 
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Adjusted R2 Predicted R2 Model p value Lack of fit p 
value
Undiluted
V = 3.5 mL
0.9895 0.9812 < 0.0001 0.8954
Diluted
V = 3.5 mL
0.9887 0.9773 < 0.0001 0.3214
Sundiluted = -3.38 X1 + 1.64 X2 + 4.08E-04 X3 + 4.3 X1X2 + 7.0 X1X3 – 0.53 X2X3 – 13.9 
X1X2X3 + 13.6 X1X2 (X1 - X2) + 1.96 X2X3 (X2 – X3)
Sdiluted = 42.2 X1 + 6.56 X2 – 5.9E-03 X3 – 94.1 X1X2 – 81.5 X1X3 – 10.8 X2X3 + 113.7 
X1X2X3 – 31.8 X1X2 (X1 - X2) – 58.2 X1X3 (X1 – X3) – 4.4 X2X3 (X2 – X3)
 
From the linear coefficients for the pure component, it is evident that 
Carbopol 974P (X1) with a negative βi has an adverse effect on Sundiluted. This can 
be interpreted as being due to the yield stress acting to diminish spreading. The 
linear coefficient for HEC (X2) is positive and indicates that HEC favors Sundiluted. 
The effect of variation in X3 was ~ 3 orders of magnitude lower on both the 
responses, which can be considered negligible. The coefficients in the regression 
equations (Table 2.6) are large, which is due to the L-pseudo transformation that 
converts the compositions on a scale of 0 to 1. Unlike the case of Sundiluted, both 
X1 and X2 favor the optimization of the Sdiluted, and the two-component nonlinear 
blending coefficients show an antagonistic effect on Sdiluted. The surface for the 
response Sdiluted is more complex, due to the constant interplay between the 
linear and the nonlinear blending coefficients, as shown in the regression 
equation. In summary, based on the regression equations, it is evident that the 
Table 2.6   Results of the regression analysis for the responses – Sundiluted and 
Sdiluted, by fitting the responses to a cubic model. Only statistically significant 
terms included. X1, X2 and X3 is Carbopol 974P, HEC and water, respectively 




factors X1 and X2 play an important role in the optimization process. HEC (X2) has 
a favorable effect on both responses whereas Carbopol (X1) favors only the 
optimization of Sdiluted. 
2.3.8 Validation of the cubic model and RSM 
To evaluate the ability of the model and RSM to predict the score, we 
chose four checkpoints within the design space. Rheological characterization of 
these gels was performed in the same manner as on all other gels in the study. 
Table 2.7 shows the composition of the checkpoints, their predicted and 
experimental values of the score, and the percentage error in predictions.  
2.3.9 Response surface methodology (RSM) 
Response surfaces provide visual depiction of the relationship between 
composition and scores. The score is suggestive of the relative performance of 
the gels. Figure 2.7 and 2.8 shows the surface plots for the score of the gels 
under undiluted and diluted conditions. All the responses exhibited nonlinear 
relationships with composition. Figure 2.7B&D show the 2D contour plots, while 
Figure 2.7A&C are 3D surface plots depicting effects of change in composition 
on gel score. Sundiluted increases with increasing concentrations of HEC as shown 
in Figure 2.7A.  The response surface peaks at the highest concentration of HEC 
in the absence of Carbopol 974P, whereas the surface that fits Sdiluted is more 
complex. The surface exhibits curvature at the intermediate concentrations of 
HEC (2.25 – 3.0 wt%) and Carbopol 974P (1.25 wt%). However, further increase 
in Carbopol 974P concentration results in a dip in the surface (Figure 2.7C). 
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X1 - 1.6; X2 - 0.0 Sundiluted 0.3669 0.3582
Sdiluted 0.5866 0.5250
X1 - 2.0; X2 - 1.8 Sundiluted 0.1197 0.1096
Sdiluted 0.1569 0.1751
X1 - 1.0; X2 - 0.9 Sundiluted 0.1449 0.1587
Sdiluted 0.2704 0.2526
X1 - 0.0; X2 - 2.5 Sundiluted 0.5582 0.5310
Sdiluted 0.1211 0.1346
 
2.3.10 Vehicle optimization using RSM 
Individual response surfaces for the undiluted and diluted gels at 3.5 mL 
volume were generated. A multiple response optimization methodology was used 
to maximize Sundiluted and Sdiluted simultaneously, with the constraints of Carbopol 
974P (0-2.5 wt%), HEC (0-3.0 wt%) and score (0-1). Responses Sundiluted and 
Sdiluted varied in the range of 0 - 0.876 and 0 - 0.830, respectively. The response 
surface for Sdiluted exhibited a curvature at the intermediate concentrations of 
HEC (2.25 – 3.0 wt%) and Carbopol 974P (1.25 wt%) and further increase in 
Carbopol 974P concentration resulted in a dip in the surface. For multiple 
response optimizations, the software utilizes a function that converts multiple 
responses into a univariate function – ‘desirability’, which ranges from 0-1. From 
the desirability plot, 0.0 wt% Carbopol 974P and 3.0 wt% HEC was identified as 
the optimum composition for 3.5 mL volume and Amax of 117 cm2 (Figure 2.8). 
Table 2.7   Composition of the checkpoints, their predicted and experimental 
values of the scores (S) and the percentage error in the predictions. X1 and  







Figure 2.7   3D and 2D response surface plot showing the effect of concentration 
of Carbopol 974P (X1) and HEC (X2) on the responses. (A) and (B) 3D and 2D 
response surface plot of Sundiluted; (C) and (D) 3D and 2D response surface plot of 


































































































Figure 2.8   3D and 2D response surface showing the plot of desirability as a 
function of gel composition. 
 
2.4 Discussion 
The prophylactic capabilities of a vaginal microbicide depends on the 
potency of the Active Pharmaceutical Ingredients (API) and the capability of the 
vehicle to deliver it appropriately to the vaginal lumen.148 For microbicide gels, 
the latter derives directly from the time course of gel deployment within the 
lumen.  In general, an effective microbicide gel should achieve maximum coating 
of the vaginal epithelium; a coating that is retained for the desired duration of 
action.92, 95 Thus, the deployment potential of microbicide gels should be a key 
component in product design.  Only when this potential is understood, and can 
be related to gel composition during development, can rational design and 

































































Rheological behavior governs the ability of a gel to initially flow and coat 
the vaginal epithelial surfaces after insertion, as well as to resist further flow, 
facilitating retention.95, 128 The most commonly used parameter to characterize 
the rheological behavior of vaginal gels is viscosity.95 However, because majority 
of these gels are non-Newtonian, there is no single value of viscosity that 
characterizes spreading behavior.  In general, it is the shear rate dependence of 
viscosity (which requires specification of at least two parameters), and also the 
value of the yield stress (an additional parameter; should a yield stress exist) 
governing the gel spreading process.  The presence of Carbopol 974P in gels 
(but not HEC alone) gave rise to a nonzero yield stress.  We evaluated the 
dependence of gel rheological behavior across jointly varying concentrations of 
Carbopol 974P and HEC.  Consistent with results of other studies, viscosities of 
these gels increased as functions of concentration of the gelling agent.95 All gels 
exhibited shear thinning behavior, with viscosity decreasing by approximately 
one order of magnitude as shear rate increased from 1 to 100 s–1.  
When a gel is inserted into the vagina using an applicator, it is delivered 
as a bolus near the fornix. In situ, the bolus experiences a continuous squeezing 
force from the vaginal musculature, initiating spreading.56, 150 Therefore, in 
addition to the measurement of rheological properties of gels and its 
incorporation in constitutive models, in vitro methodologies have been developed 
to simulate gel flow and changes in gel properties in vivo.118, 151 Once the gel 
begins to spread, it undergoes dilution with the vaginal secretions, likely further 
enhancing the spreading.57 The rate and extent of dilution of the formulation in 
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the vagina may not be homogenous. This behavior may be due to several 
factors, including: a) the highly heterogeneous vaginal epithelium10, 57; b) 
variability between women;57 c) cyclic changes in vaginal epithelium with 
changes in menstrual cycle;10, 22, 25 and d) variability in the local dilution of the 
gels with vaginal secretions.22 In order to study the effect of dilution of gels with 
vaginal fluid, we performed rheological characterization on gels diluted with VFS 
(1:4 VFS:gel).57 This single ratio and the one time mechanical mixing do not 
mimic the kinetics of dilution in vivo, but they do provide an extreme case of 
dilution, which is relevant in understanding the potential effect of dilution on the 
deployment of gels. The degree of shear thinning decreased (i.e., n increased) 
and the consistency index (m) decreased after dilution with VFS.  That is, the 
gels became less non-Newtonian. In addition, yield stress decreased on dilution.  
Consequently, there was a significant increase in the predicted area coated for 
the diluted gels as compared to the undiluted gels (Figure 2.6). Details of the 
response to dilution with VFS differed amongst gels with varying composition, 
with a greater sensitivity to dilution when Carbopol 974P was present.   
Overall, computation of coated area and consequent computation of the 
score derived from interactions amongst the multiple rheological properties of the 
gels, whole and diluted.  This methodology points to a 3.0 wt% HEC gel as the 
optimal candidate for a vaginal microbicide gel capable of quickly spreading 
throughout the vagina across the HEC-Carbopol 974P mixture space analyzed in 
this study. However, TFV, one of the two active ingredients incorporated in the 
gel is a sodium salt. Since, Carbopol is an ionic polymer; viscosity of Carbopol 
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974P gels was significantly affected by the presence of TFV. Therefore, the gels 
optimized in the work herein are specific to the delivery of 1 wt% TFV and will 
need to be reoptimized for other drugs or gelling agents.   
To study the impact of gel volume on the score, we calculated scores for 
the 3.0 wt% HEC gel at varying volumes. Sundiluted increased as volume increased 
(up to 4.0 mL) whereas Sdiluted exhibited a maximum at 3.5 mL. Scombined, was 
calculated from the arithmetic average of Sundiluted and Sdiluted. The use of the 
arithmetic average of Sundiluted and Sdiluted is a first approximation, accounting for 
the complex process of progressive gel dilution during spreading in vivo. The 4:1 
gel dilution with vaginal fluid (gel:vaginal fluid) is an upper bound on what is 
believed to be the extent of gel dilution with vaginal fluid in vivo. The arithmetic 
average for S equally weights the spreading of undiluted and fully diluted gel, and 
effectively assumes that net gel performance (i.e. the value of S) can be 
represented as the simple average of the lower (undiluted) and upper (diluted) 
bounds to the extent of gel spreading.  Scombined showed a maximum score at 3.5 
mL (Figure 2.9). This supports our selection of 3.0 wt% HEC as the optimum 
spreading gel at an administered volume of 3.5 mL.   
Since the optimized gel lies towards the extreme corner of the tested 
design space, additional studies were performed to ensure optimization was not 
compromised or limited by the design space. In order to evaluate the effect of 
increasing concentrations of HEC, we prepared gels with increasing HEC 




Figure 2.9   Variations in the score (S) for both undiluted and gels diluted with 
VFS with (A) increasing volume of administration and (B) concentrations of HEC 
in the gel. Highest value of Scombined was achieved with 3.0 w% HEC gel at 3.5 mL 
volume. 
 
As shown in Figure 2.9, the maximum for Sundiluted was around 3.0 wt% 
HEC, and for Sdiluted it was around 4.0 wt% HEC. Since we optimized the scores 
for both undiluted and diluted gels – using the Scombined – the 3.0 wt% HEC gel 
proved to be the optimum gel followed by the 4.0 wt% HEC gel. The squeezing 
flow model has been found to predict spreading reasonably well, compared to 
data from in vivo imaging studies (Table 2.5), for four polyacrylic acid or 
cellulose-based gels. Further improvements to the model are underway57 to 
improve its accuracy and extends its applicability across different gels.  Of 
course, all such modeling should be compared and validated against imaging 
studies whenever sufficient in vivo data are available. In addition to the above 
analysis, we compared the values of the score (undiluted, diluted) for the 3.0 wt% 
HEC gel created here with values for other microbicide gels and placebos, as 
well as for commercial over-the-counter vaginal gels used for lubrication. 





































Table 2.8 summarizes these results.  In general, all undiluted gels 
exhibited spreading that did not exceed the target Amax = 117 cm2.  Upon dilution, 
spreading increased for all gels:  for some, A still did not exceed Amax, and thus S 
increased. However, for others, A exceeded Amax; for all gels evaluated here, this 
resulted in a lower score after dilution.  We note that the HEC Universal Placebo 
gel is a 2.7 wt% HEC gel,133 and it has score values (0.77, 0.90; 0.84 undiluted, 
diluted; average) very close to those of the optimal HEC gel created here (0.73, 
0.94; 0.84).  Comparisons with the other gels vary. TFV 1% microbicide gel from 
the CAPRISA 004 trial (0.92, 0.80; 0.86) and Carraguard (0.88, 0.51; 0.70) have 
good scores.  In contrast, the 6% cellulose sulfate (0.58, 0.03; 0.31) and UC781 
clinical gel (0.44, 0.00; 0.22) have low scores when diluted, because their 
significant reductions in viscosity cause them to be prone to leakage. The 
contrasts across these results exemplify the uncertainty about gel coating 
performance inherent to traditional, empirical vaginal gel design. The three 
commercial gels exhibit contrasting behavior. Two have higher scores after 
dilution:  RepHresh® (0.24, 0.85; 0.55) and K-Y Jelly® (0.59, 0.82; 0.71). The 
other gel, Replens®, exhibits the opposite trend (0.81, 0.56; 0.69).  
Our work is the first to relate gel composition – comprised of two 
commonly used gelling agents – to gel performance as predicted using a 
deterministic vaginal squeezing flow model. The methodology described herein 
offers a quick empirically derived mathematical method that can be used to 





a Optimized gel from this work; b HEC placebo gel (2.7% HEC); c Carboxymethylcellulose-
based gel; d Cellulose-based gel; e Carbopol-based gel; f Carrageenan-based gel; * Obtained 
from the CONRAD Program; ** Over the counter products 
 
Furthermore, use of the objective function establishes an analytical and 
biologically relevant method for gel evaluation that can easily be modified to 
incorporate a range of desired performance parameters. Application of this model 
could enable expedited characterization and prediction of performances of the 
next generation of microbicide gels. This approach is flexible, and by knowing the 
volume of the gel and the predicted area coated one can create objective 
predictions about gel performance in vivo prior to human trials. Our methodology 
here includes only the pre and post dilution rheological properties and 
deployment predictions. However, this DOE approach can be diversified to 
Gel Score
Undiluted Diluted Combined
3.0 wt% HEC gela 0.73 0.94 0.84
Universal placebo gelb* 0.77 0.90 0.84
6% Celluose sulfatec* 0.58 0.03 0.31






Carragaurdf* 0.88 0.51 0.70
RepHreshe** 0.24 0.85 0.55
Replense** 0.81 0.56 0.69
K-Y Jellyd** 0.59 0.82 0.71
Table 2.8   Values of score (S) for 3.0 wt % HEC gel and other commercial 
vaginal gels, clinical microbicide gels and placebos. 
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account for additional critical parameters of the formulation such as other gelling 
agents and excipients, drug release rate, drug stability, bioadhesion, toxicity, and 
dilution with other ambient vaginal fluids such as semen. Indeed, this approach 
could potentially be applied to a diverse range of vaginal delivery products used 
for artificial insemination, antifungal delivery, vaginal moisturization and hormone 
delivery. Furthermore, use of such an approach circumvents the problems 
associated with traditional methods of gel optimization and composition selection, 
which contain many subjective elements; and can lead to the reassessment of 
gel compositions to meet specific clinical applications, beyond microbicides. 
2.5 Conclusion 
This study is the first to describe the composition-property-performance 
relationship of vaginal semisolid drug delivery gels consisting of HEC and 
Carbopol 974P. The multivariate optimization approach introduced here, used in 
conjunction with rheological characterizations, fluid flow models and statistical 
tools, offers an integrated multitier approach for the optimization and selection of 
vaginal microbicide gels prior to in vivo investigations.  
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INHIBITION OF THE TRANSPORT OF HIV IN VITRO 
USING A PH-RESPONSIVE SYNTHETIC MUCIN-
LIKE POLYMER SYSTEM3 
3.1 Introduction  
Recent advances in the dissection of the early events in the acquisition of 
sexually transmitted infections (STIs), and in particular HIV, tell a story of break 
down in barrier function at the level of transport of the virus and dissemination of 
infection.152 It is believed that the doorway to the complicated, and not yet well 
understood acquisition process, is the movement of the semen-borne virus 
through the cervical mucus to the cervicovaginal epithelium.45 Therefore, 
developing materials that prevent transport of the virus from semen to the vaginal 
tissue susceptible to infection, may constitute an important mechanism in 
preventing the heterosexual transmission of HIV. In fact biopolymers present in 
                                            
 
3Adapted from Inhibition of the Transport of HIV-1 In vitro Using a pH-Responsive Synthetic 
Mucin-Like Polymer System, Biomaterials, Volume 32 (33), 2011, 8343-55, Alamelu Mahalingam, 
Julie I. Jay, Kristofer Langheinrich, Shetha Shukair, Mike McRaven, Lisa C. Rohan, Betsy C. 
Herold, Thomas J. Hope, Patrick F. Kiser.  
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the vaginal lumen are known to impede movement of viral particles and cells. 
Cervical mucus exhibits a flexible woven mesh molecular structure. The 
reversible nature of mucin crosslinks, promotes the formation of  a transient 
polymer network that impedes the diffusion of HIV, which has been observed 
primarily at acidic pH.38 Similarly, the highly viscous nature of semisolid vaginal 
formulations also interferes with viral transport.31 However, neutralization of the 
cervical mucus with semen53 and dilution of semisolid vaginal formulations with 
biological fluids (vaginal and seminal)53 compromise the barrier properties of both 
systems.153, 154  In addition, cell-associated virus within semen, which may be an 
important source of transmission,54 may be less susceptible to the effects of 
biopolymers and cervical mucus.31, 38, 54 Therefore, an effective physical barrier to 
the transmission of HIV should create a gel layer impermeable to both cell-free 
and cell-associated virions after dilution with seminal fluid of a neutral pH. 
Given the burgeoning scope of materials in drug delivery applications, 
there is significant interest in materials that mimic the properties and the behavior 
of naturally occurring systems.38, 155-158 We are interested in developing a 
synthetic mucin-like polymer system (SMP) (Figure 3.1), engineered to mimic 
certain characteristics of the cervical mucus that may be advantageous for a 
microbicide application. These include - (a) formation of a transient network at 
acidic pH (Figure 3.1-V), (b) bioadhesiveness (Figure 3.1-III) and (c) inhibition of 












Figure 3.1   Schematic demonstrating the use of the phenylboronate 
salicylhydroxamate crosslinked polymer as a microbicide drug delivery system. 
(I) The two polymer solutions, pHPMAm95-PBA5 (PBA5, blue) and pHPMAm95-
SHA5 (SHA5, yellow) on mixing form a weakly crosslinked viscoelastic fluid (b, 
green) which can be applied via an applicator (a). (II) The crosslinked polymer 
solutions form a pH-sensitive polymeric network, which should flow and coat the 
cervicovaginal epithelium at vaginal pH. (III) On a molecular scale, the gel 
network is comprised of chemical crosslinks between the polymer bound PBA 
(blue) and SHA (yellow) (d) as well as bioadhesive interactions of PBA with diols 
present (e) within cervical mucus (c) and on the epithelial surface. The 
crosslinking chemistry utilizes the reversible covalent crosslinking between 
polymer-bound PBA and SHA, creating a pH-responsive network that is transient 
and viscoelastic at vaginal pH; and is elastic and solid-like at the seminal pH. 
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However, one aspect in which the SMP differ from cervical mucus is in 
regards to the sensitivity of the phenylboronic acid (PBA) and salicylhydroxamic 
acid (SHA) complexation to pH, where the crosslinking density, and thereby the 
barrier property, increases as pH increases from vaginal pH (~ 4.0-5.5) to 
seminal pH (~7.5). Owing to the decreased network mesh size, the SMP may 
perform better than the evolved barrier function of cervical mucus. This 
represents a viable and unprecedented approach to blocking the acquisition of 
HIV.  
In engineering a semisolid system as a physical barrier to the transport of 
viral particles, it is imperative to understand and control the mechanical 
properties for ease of application, coating and retention of the system.95, 118, 153, 
159 Application and coating necessitate a comparatively low viscosity material that 
can easily flow over tissue.58, 95 However, low viscosity materials have difficulty in 
being retained in the vaginal lumen,58, 160 and therefore may not have the 
capacity to inhibit viral transport to tissue, especially if applied hours prior to 
intercourse. This biophysical property-performance tradeoff of needing both low 
and higher viscosity materials has been confirmed in optical imaging studies of 
human vaginal coating by semisolid gels.160 Our group is interested in designing 
biomaterials that respond to cues in the female reproductive tract that can be 
used for vaginal drug delivery and HIV prevention. For example, we have 
investigated temperature responsive polymeric systems as a means to create 
formulations that can be applied as a liquid ensued by in situ gelation to 
potentially improve coating and retention.164, 165 
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In this work, we have designed a biologically inspired SMP to prevent 
transport of virions in the vagina that exploits the pH change from acidic (4.0-5.5) 
to near neutral pH induced by the presence of seminal fluid.53 This pH change 
provides a physiological stimulus that could allow an environmentally responsive 
material to sense the presence of the semen and thus the potential presence of 
the infectious agent, HIV.  The goal is then to design a material that can 
modulate its properties over its deployment lifetime: from a viscoelastic, weakly 
crosslinked transient network on application, to a more elastic, densely 
crosslinked network formed on interaction with semen. This then impedes the 
transport of virions from semen to the susceptible female genital tract tissue. This 
mechanism provides a physical barrier that is capable of augmenting the efficacy 
of any antiretroviral that is also locally delivered. This pH modulation of the 
material properties can be achieved by engineering the crosslinking interactions 
of polymer chains and thereby the network properties of the material.  The 
reversible pH-dependent interaction between PBA and the diol SHA53, 161 can be 
used to create pH-sensitive transient polymer networks162, 163 that have 
properties similar to mucus but switch to a more densely crosslinked network in 
the presence of semen. 
 Boronic acids or the boronate species undergoes a well known 
condensation reaction with cis-diols to form cyclic boronate esters.164 This 
condensation reaction is reversible and is influenced by the pH, chemical 
structure of the diols and/or the boronic acid.165 The boronic acid undergoes 
conversion to the charged boronate tetrahedral conformation; a stable complex 
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that resists hydrolysis compared to its trigonal form, which is more readily 
reversible. We selected SHA as it has previously been reported that, even at 
slightly acidic pH, the complex formed between PBA-SHA exists in the 
tetrahedral boronate conformation161, 165 and yields a viscoelastic crosslinked 
network at a pH as low as three units lower than the pKa of SHA.162 
Our previous work investigated transient network gels, based on linear 
polymers composed of the water soluble, nontoxic polymer backbone poly(N-2-
hydroxypropyl)methacrylamide (pHPMAm)163 functionalized with five mole 
percent PBA  or SHA.163, 166 We investigated the structure-property relationship of 
materials created from the PBA-SHA crosslink as a function of pH163, 164 and 
composition of the system.163 Since our objective is to develop a microbicide that 
is semen-responsive, bioadhesive and safe, it is important to characterize the 
interactions between the PBA-SHA SMP and the biofluids in the vaginal milieu. 
Considering that the cervical mucus consists of high amounts of sialic acid;164 
and the seminal fluid, which is the carrier of the pathogen, is a rich source of 
fructose,167 we are particularly interested in evaluating the effect these 
endogenous diols from the vaginal milieu may have on the complexation 
between PBA and SHA, and consequently on the mechanical properties of the 
SMP (Figure 3.1-V). 
Herein, we assessed the kinetics of in situ gelation as well as the resulting 
material’s viscosity under steady state flow. Gelation kinetics and modulation of 
the viscoelastic behavior of the PBA-SHA SMP in response to the addition of 
semen and mucus were examined to determine the SMP’s potential to respond 
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to a changing vaginal milieu. Ability of the SMP to inhibit transport of 
macrophages and HIV virions across the crosslinked polymer network was 
deduced in vitro and ex vivo using a migration assay. Investigations also assayed 
the toxicity and irritation potential of the PBA-SHA SMP to human ectocervical 
tissue. 
3.2 Materials and Methods 
3.2.1 Materials  
HPMA monomer was purchased from Polysciences, Inc. (Warrington, PA). 
2,2’-azobisisobutyronitrile (AIBN) was purchased from Sigma-Aldrich, Inc. (St. 
Louis, MO) and was recrystallized from chloroform. With the exception of 
Dubelco’s Modified Eagles Media (DMEM High Glucose) purchased from 
HyClone Laboratories (Logan, UT) all the media and supplements for the 
biological assay were purchased from Invitrogen (Carlsbad, CA). Succinimidyl-7-
amino-4-methylcoumarin-3-acetate (AMCA-NHS) was purchased from Apollo 
Scientific Ltd. (Cheshire, UK). All other chemicals and reagents were purchased 
from Aldrich or Acros and were used without further purification unless otherwise 
noted. All 1H NMR spectra were acquired on a Varian Mercury 400 MHz 
spectrometer. Polymer molecular weight distributions were determined in using 
gel permeation chromatography (GPC) (HPLC 1100, Agilent Technologies) 
equipped with an aqueous column (PLaquagel-OH mixed, Polymer Labs) or an 
organic column (PLgel mixed-B, Polymer Labs), a differential refractive index 
detector (BI-DNDC, Brookhaven Instruments) and a multiangle light scattering 
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detector (BI-MwA, Brookhaven Instruments). Human Semen was purchased from 
Lee BioSolutions, Inc (St. Louis, MO).  
3.2.2 Monomer synthesis   
Methylacryloylamino-propyl-4-amido phenylboronic acid (APMAmPBA), 4-
[(2-Methyl-acryloylamino)-methyl]-salicylhydroxamic acid (MAAmSHA) and 2-
hydroxypropylmethacrylamide (HPMAm) were synthesized according to the 
previously published protocols.163, 168 
3.2.3 Polymer synthesis 
APMAmPBA or MAAmSHA was copolymerized with HPMAm at 5-95 
mol% feed ratio by free radical polymerization as previously described (Figure 
3.2).163 Briefly, polymerizations were performed in the presence of 0.7 mol% 
Azobisisobutyronitrile (AIBN) in anhydrous DMF at 65°C for 24 h under nitrogen 
atmosphere. Polymers were triturated twice in anhydrous ether. After the first 
trituration, PBA-containing polymers were deprotected by redissolving the 
polymer in methanol and acidifying with a 1:1 dilution of 1 M HCl for 30 mins at 
room temperature. Titurated polymers were then lyophilized, dissolved in 100 
mM phosphate buffer at 30 mg/mL concentration and dialyzed across a 10 KDa 
MWCO membrane using a Vivaflow 50, a tangential flow through filtration 
system. Actual molar functionalization of PBA and SHA monomers in the 
copolymers was determined in 1H NMR in D2O. 
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3.2.4 Rheological assessment of the effect of seminal fluid on 
the PBA5-SHA5 crosslinked polymer network  
The polymers were individually dissolved in buffer (100 mM acetate pH 
4.8) at 75 mg/mL concentrations. Crosslinked polymer network was formed in situ 
by simultaneous pipetting of an equal volume of the polymer solutions directly 
onto the Peltier plate of the rheometer. A steel ring 48 mm in diameter and 10 
mm in height was placed around the sample. Dynamic rheology was performed 
using methods previously described on an AR550 stress-controlled rheometer 
(TA Instruments, New Castle, DE).163 Briefly, a flat steel 20 mm diameter plate 
 
Figure 3.2   Chemical structure of the polymer bound PBA and SHA at 5 mol% 
functionalization. Both PBA5 and SHA5 were synthesized through free radical 
polymerization of APMAmPBA or MAAmSHA and mHPMA monomers in the 
presence of AIBN. Polymers were triturated twice in ether and were purified by 




geometry was used for all experiments with a total sample volume of 170 µL. Six 
holes an eighth of an inch in diameter were drilled separated by 60° around the 
perimeter of the 20 mm geometry. A time sweep was initiated for 60 mins at a 
small amplitude oscillatory stress of 5 Pa and a small angular frequency of 10 
rad/s. After approximately 25 mins, 500 µL of human semen was added into the 
trap on the top side of the steel geometry directly over the drilled holes. The 
effect of human semen on the network strength was then observed over the 
remainder of the time sweep. 
To evaluate the effect of human semen on the viscoelastic properties of 
the SMP, time sweeps were performed until the networks’ elastic modulus (G’) 
plateaued. Oscillatory frequency sweeps were then performed at a controlled 
stress of 5 Pa over a range of angular frequencies from 0.1-100 rad/s. After the 
initial time and frequency sweeps, a 5 m conditioning step allowed time for the 
human semen to be added to the sample. After addition of semen on the top side 
of the steel geometry with the drilled holes, time sweeps and oscillatory 
frequency sweeps were repeated using the parameters mentioned above. All 
experiments were done in triplicate unless otherwise noted.   
3.2.5 Rheological assessment of the effect of mucin on the 
PBA5-SHA5 crosslinked polymer network  
In general the rheological mucoadhesive interaction of materials with 
mucin has been described by calculating the rheological synergy parameter, 




G'mix = G'plateau + G'mucin + ΔG'    (3.1) 
 
where G'mix is the plateau elastic modulus of the PBA-SHA SMP in the presence 
of mucin, G'plateau is the plateau elastic modulus of the PBA-SHA SMP alone, and 
G'mucin is the elastic modulus of the mucin solution alone. The equation has been 
simplified in the literature due to negligible elastic modulus of mucin solutions169 
and therefore ΔG' was calculated from Equation 3.2. 
 
G'mix = G'plateau + ΔG'    (3.2) 
 
Polymer solutions were prepared such that the final concentration of the 
polymers in the sample was 75 mg/mL with 1% w/w porcine gastric mucin. 
Dynamic rheology was performed using a cone-and-plate geometry. 
3.2.6 Preparation of fluorescently tagged HIVBaL  
Gag Cherry labeled HIV virions were produced by transfection of 293T 
cells with proviral plasmids expressing BaL and a fluroscently labeled Gag 
protein using a previously described method.170 The cell suspension was washed 
24 h posttransfection. The supernatant solution containing the labeled virions 
was collected and concentrated by ultracentrifugation through a 30% sucrose 
cushion. The virions were then resuspended in Dubelco’s modified eagles media 
(DMEM High Glucose, 4.0 mM L-Glutamine, 4500 mg/L Glucose, and no Sodium 
Pyruvate (0.1 μm sterile filtered) with 10% fetal bovine serum (FBS) and 50 
μg/mL penicillin/streptomycin).  
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3.2.7 Tracking the fluorescently tagged HIVBaL in PBA5-SHA5 
crosslinked polymer network  
Individual polymer solutions were prepared at 82.5 mg/mL in buffers at the 
required pH to account for dilution from the virus addition. After adjusting the pH 
of the solutions, Gag-cherry labeled HIV was added and vortexed for 30 s. 
Samples were prepared by mixing equal volumes of PBA5 and SHA5 polymer 
solutions containing 10% viral stock solution at the desired pH. The crosslinked 
polymer sample was placed in a 5 mm well on a Delta T4 culture dish at 37°C 
(Bioptechs Inc.).  Five image stacks were collected using a 100x oil immersion 
objective (NA 1.4) on a DeltaVision Core microscope system with an EMCCD 
camera using SoftWorx software. Images were collected for 60 s with a 50 ms 
exposure and 85 ms time lapse. The mean squared displacement (MSD) of the 
virions was determined using an algorithm developed and kindly provided by 
John Crocker, David Grier, and Eric Weeks. Diffusion coefficients were computed 
as one-fourth of the slope of the line fitting the plot of <Δr(t)2> versus time. 
3.2.8 Fluorescent labeling of macrophages  
Fluorescent tagging was performed using a procedure provided by the 
suppliers. Briefly, a 0.05% solution of cell tracker dye (Molecular Probes, 
Invitrogen, Carlsbad, CA) was created in IMDM Serum Free Medium. The cells 
were counted using a hemocytometer and then the cells were spun down at 860 
rpm for 5 mins. The cell medium was removed and the cells were resuspended in 
the working solution of the cell tracker dye (~ 2 mL). The cells were then 
incubated for 30 mins. The cells were then spun again at 860 rpm for 5 mins. The 
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medium was removed and the cells were resuspended in complete cell culture 
medium. The cells were incubated again for 30 mins. Lastly the cells were spun 
down at 860 rpm for 5 mins and resuspended in IMDM Serum Free Medium.  
3.2.9 Z-Stack imaging to track macrophage migration in the 
PBA5-SHA5 crosslinked polymer network 
A 10 mM solution of N-Formyl-Met-Leu-Phe (FMLP) (Sigma, St. Louis, 
MO) was made in DMSO and was diluted to 1 µM in IMDM Serum Free Medium. 
In a PCR tube 30 µL of the crosslinked polymer solution at pH 4.8 was mixed 
with 10 µL of chemo-attractant solution. Using a positive displacement pipette, 15 
µL of the sample were pipetted into one of the wells on the culture dish. 
Following this, 30 µL of the sample was pipetted on top of the previous 15 µL of 
sample. The sample sat for 30 mins, to allow for diffusion of the chemo-
attractant, covered with parafilm to prevent evaporation. Imaging was done using 
an Olympus FV1000-XY inverted microscope with a 40x water objective. The 
FluoView confocal operations software was used. A black mark was made on the 
bottom of the culture dish for ease in finding the bottom of the sample. After 
focusing on the black mark, the stage was moved up 150 µm (representing the 
approximate thickness of the dish). Using the software, this location was set as 
the bottom of the sample. To set the top of the sample and the z-stack location a 









where r is the radius of the PCR tube sections (approximately 2.75 mm) and V is 
the volume of sample used. For the above volume the thickness was 
approximately 1.8 mm. The stage was moved up ~1.8 mm and was set as the 
top of the polymer sample. The z-stack step size was set to 50 µm giving 
approximately 30-40 slices per z-stack. Imaging was initiated after placing 60 µL 
of cell suspension on top of the sample layer. Z-stacks were collected every hour 
from 0 - 4 h. The z-stacks were imported into Imaris and converted into a 3D 
image. A Gaussian filter of 1 µm was used to remove digital noise. Snapshots of 
all 3D images were taken and saved as tiff stacks. 
3.2.10 In vitro safety evaluations using 3D ectocervical tissue 
model  
Safety of the individual polymer solutions (PBA5 and SHA5) were 
evaluated on VK2/E6E7 cell line171 after single exposure whereas safety of the 
PBA5-SHA5 crosslinked polymer after three repeated exposures was examined 
using VEC-100, a reconstructed human ectocervical tissue mode171. Polymer 
solutions (PBA5 and SHA5) were prepared at 150 mg/mL in keratintocyte serum-
free media (KSF) and pasteurized at 70°C for 5 mins. Equal volumes of polymer 
solution and KSF containing 2X growth factors (supplemented with 0.2 ng/mL 
epidermal growth factor (EGF), 100 μg/mL bovine pituitary extract (BPE), 2% 
pen-strep (P/S), 0.8 mM CaCl2) were mixed. The same dilution procedure was 
performed on all the samples. Cells were seeded at a density of 104 cells/100 μL 
of growth media. The cells were cultured for 24 h and were supplemented with 
additional 100 μL of growth medium containing PBA5 and SHA5. After an 
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additional 24 h of incubation, cell viability was quantified using MTS (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)- tetrazolium) 
cell proliferation assay (Promega, Madison, WI). Nonoxynol-9 (N-9, 0.0125 
mg/mL) served as toxic control with ~ 40% cell viability. pHPMA served as the 
nontoxic control.172  
Tissues were maintained as recommended by the suppliers.166 The PBA5-
SHA5 crosslinked polymer was placed in the insert on top of the VEC-100 tissue 
supported by a semiporous membrane at the bottom of the insert. pHPMA and 
N-9 were used as the nontoxic and toxic controls, respectively. After 24 h of 
incubation with the test sample, tissues were washed three times with PBS, and 
Trans Epithelial Electrical Resistance (TEER) was recorded for each tissue to 
ensure the integrity of the tissue during the study. Fresh samples were added to 
the tissue every 24 h, for 3 days and on day 3, tissues were evaluated for viability 
using MTT ((3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. 
Meanwhile, culture medium was collected every 24 h for analysis of cytokine 
levels (IL-8, IL-1α, IL-6 and TNFα).  
3.2.11 Ex vivo and in vivo safety evaluation using human 
ectocervical tissue and mouse model 
Freshly excised human cervical tissue specimens were handled as 
previously described75, 172 and were exposed to the SMP for a period of 4 h. 
Tissue culture media (DMEM) was used as the negative control. At the end of 4 
h, tissue viability was determined using MTT assay (n=3). Tissues were also 
fixed in 10% neutral-buffered formalin solution, embedded in paraffin; sections 
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were cut and stained with hematoxylin and eosin (H&E). Tissue histology was 
compared between the SMP treated tissues and the control tissues to determine 
morphological changes (n=3).  
Female BALB/c mice were used as an animal model to evaluate the in 
vivo safety of the SMP. The study consisted of six animals and two arms – the 
PBS (placebo) and SMP treated arm. On days 1 and 2, the mice were given a 
single dose (40 µL) of either the premixed PBA5-SHA5 crosslinked polymer or 
PBS. On day 3, the animals were sacrificed and the vaginal tract was dissected 
and fixed in 10% neutral-buffered formalin solution.  Tissues were embedded in 
paraffin, sectioned and stained with H&E for histological analysis.  
3.2.12 Aminomethylcoumarin Acetate (AMCA) conjugation to 
PBA polymer  
The polymer was synthesized with a mole ratio of 94.5:5:0.5 by free 
radical polymerization using HPMAm, APMAmPBA, and APMA monomers 
respectively. Initiator concentration and reaction conditions were the same as 
described previously.163, 173 Polymers were ultracentrifuged three times using 
Amicon Ultra-15 10K MWCO dialysis centrifuge tubes (Millipore) at a polymer 
concentration of 30 mg/mL. Samples were centrifuged at 3,000 rpm for 90 mins 
using 100 mM pH 7.5 PBS buffer once and using DDI water twice.  
To conjugate AMCA-NHS ester to the free amines164 on the polymer 
synthesized above, HPMA-APMAmPBA-APMA was massed to a 100 mL round 
bottom flask (115.8 mg). Anhydrous DMF (11 mL) was then added to the flask 
and the mixture was sonicated for 30 mins at 45°C to dissolve the polymer. A 
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stock of DIPEA (180 µL) was made in DMF (4.82 mL). DIPEA stock (50 µL) was 
added to the round bottom flask. While stirring, AMCA-NHS (5.6 mg) was added 
to the round bottom flask. The conjugation was performed at room temperature 
under nitrogen for 24 h. The reaction was then concentrated at 60°C and 
triturated into acetone. The polymers were ultracentrifuged seven times using an 
Amicon Ultra 10K MWCO dialysis tube to remove any unconjugated AMCA-NHS. 
Progress was determined by quantifying fluorescence in the dialysate.  
3.2.13 Assessment of the ability of the PBA-SHA SMP to inhibit 
HIVBaL transport using human cervical explants and PA-
GFP-HIV  
To determine the extent to which fluorescently labeled HIV penetrates 
intact human epithelial tissue in the presence or absence of the SMP, we utilized 
a cervical explant system.  In this system, an explant was excised from a human 
cervix after a hysterectomy (obtained with IRB approval- Northwestern University 
IRB #STU00025456). The explant was then mounted in the top chamber of a 
transwell dish; SMP was added on top of the epithelial explant and allowed to 
rest for 10 mins. DMEM containing photoactivable (PA)-GFP-Vpr labeled HIV, 
harvested from transiently transfected 293T cells, was added to the epithelial 
side of the tissue explant. PAGFP-Vpr was created by replacing the GFP with 
PA-GFP in a well characterized GFP-Vpr.174 With PAGFP-Vpr, a significant 
green signal is only achieved after photoactivation by exposure to 400-430 nm 
light (Carias et.al, manuscript in preperation). After 30 mins, 1 h or 2 h, media 
containing the virus was removed and the explant was mounted in tissue freezing 
medium (OCT) and quickly frozen at –80˚C. The OCT block was then sectioned 
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(10-12 m), mounted on a slide, fixed (except in the cases of unfixed tissue), and 
stained with propidium iodide, and was visualized in red channel, to detect nuclei. 
The sections were imaged using deconvolution microscopy. First, the 
tissue was scanned in the green channel to define any background. Then, the 
tissue was photoactivated by 413 nm light. After photoactivation, the tissue was 
scanned in the green channel again.  The appearance of any green signal was a 
consequence of the photoactivation, revealing the location of any virions. The 
tissue was then scanned to visualize AMCA-labeled polymer and PI-labeled 
nuclei. To rule out the unlikely possibility that photoactivatable signals were 
present in tissues, we also conducted a blinded analysis of tissue that had not 
been exposed to virus.  
3.2.14 Statistical Analysis 
On all rheological plots, the mean of at least three replicates is provided. 
The standard deviation has been omitted to maintain clarity of the plots. A 2-
tailed student’s t-test was used to analyze the statistical difference between the 
G'mix and G'Plateau. Due to the variation in sample size for the pH 7.6 mucin 
samples, an unpaired t-test with equal variance was used. All other statistical 
analysis used single-factor ANOVA with Bonferroni correction for multiple 
comparisons. For all the analysis, a p-value of 0.05 was used. 
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3.3 Results and Discussion  
3.3.1 Polymer characterization 
Free radical polymerization of APMAmPBA or MAAmSHA  with HPMA 
yielded polymers (Figure 3.2) with average Mw /Mn of 194/126 KDa and 212/115 
KDa for PBA5 and SHA5, respectively. The average mole percent incorporation of 
PBA and SHA in the respective polymers was determined to be 4.6% and 4.8%. 
The SMP was prepared by mixing equal volumes of PBA5 and SHA5 polymer 
solutions prepared in 100 mM pH 4.8 acetate buffer solution. 
3.3.2 Effect of semen on the viscoelasticity of the PBA5-SHA5 
crosslinked polymer network 
When developing materials for vaginal microbicide delivery, one essential  
aspect that needs to be accounted for is the dilution of the semisolid gel with 
biofluids such as seminal fluid and cervical mucus,153, 175 as well as the effect of 
sugars, ions and proteins inherently present in the vaginal milieu.154, 167 The 
presence of a high concentration of sugar in semen52 and the cervical mucus167 
could result in competitive binding between SHA and the simple and/or complex 
sugars present in the vaginal milieu, thereby resulting in altered viscoelastic 
behavior of the PBA-SHA SMP.  
Seminal fluid results in an approximately three unit change in pH,53 one 
fold dilution and a high fructose environment in the vaginal lumen.53 To assess 
the impact of these changes on the viscoelastic properties of the SMP, time 
sweeps and oscillatory frequency sweeps were collected at pH 4.8 before and 
after addition of seminal fluid. Time sweeps assess the gelation kinetics whereas 
92 
 
the oscillatory frequency sweeps provide an understanding of the overall network 
strength as well as to characterize the lifetime of the crosslinks.  
We have previously shown the pH dependent change in viscoelastic 
behavior of the PBA-SHA crosslinked polymer in the pH range 4.0 - 7.5.163, 168 
However these studies were performed by dissolving the polymers in buffers and 
adjusting the pH. Although, these results testify to the pH-responsive behavior of 
this SMP, they fail to assess the effect of competitive binding induced by the 
presence of fructose in the semen on the PBA-SHA crosslinking. The assay 
reported herein has been designed to recapitulate the in vivo situation as much 
as possible by using seminal fluid instead of buffer solutions. The rheological 
behavior, which is a bulk property of the material, is expected to be consistent 
with the dynamic nature of the crosslinks between the boronic acid and diols. At 
acidic pH, the boronic acid forms a trigonal complex with the diols, which is prone 
to hydrolysis and exhibits a very short half-life, shifting the equilibrium back to the 
uncomplexed form of the boronic acid.163 The resulting polymer network is 
therefore weakly associated through reversible transient crosslinks with high 
rates of disassociation.165 The dominance of G'' over G' at the majority of the 
frequencies is indicative of a viscous-dominant behavior with transient crosslinks 
between PBA and SHA. This molecular property of the crosslinks can be 
characterized by determining the ensemble lifetime or the relaxation time () of 
the crosslinks. The relaxation time of the crosslinks is defined as the inverse of 
the crossover frequency which can be computed from the frequency dependent 
measure of viscous and elastic moduli.161  
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At pH 4.8 the polymer network demonstrates a characteristic relaxation 
time of 0.9 s and a G'plateau of 11 Pa. The short lifetime of the crosslinks caused 
by the rapid restructuring of the polymer network in conjunction with the low 
viscosity may facilitate enhanced flow and coating of the PBA-SHA SMP at acidic 
pH. In contrast, after the addition of seminal fluid, at neutral pH the equilibrium 
between the PBA and SHA shifts predominantly to the more stable tetrahedral 
conformation  resulting in an elastic-dominant behavior of the material as shown 
by G' > G'' throughout the frequency sweep in Figure 3.3a. At neutral pH, the 
SMP demonstrate longer relaxation times ( > 60 s) and G'plateau of 1800 Pa. The 
SMP demonstrate two orders of magnitude increase in both crosslink lifetime as 
well as the overall network strength indicative of increased number of crosslinks. 
The higher crosslinking density at neutral pH should yield a smaller mesh size, 
which, if small enough, will act as an impermeable barrier to the transport to free 
and cell-associated virions from the seminal fluid to the susceptible tissue. 
Moreover, owing to the higher viscosity of these materials at neutral pH, the 
PBA-SHA SMP is expected to provide prolonged retention in the vaginal lumen.   
To assess the kinetics of increase in network strength on the addition of 
semen, time sweeps were collected on the SMP at pH 4.8. Less than 3 mins 
after the addition of seminal fluid, the elastic modulus of the crosslinked polymer 
increased to almost twice the G'plateau at pH 4.8. As seen in Figure 3.3b, a 
constant but steep increase in elastic modulus was observed until 30 mins after 
the addition of seminal fluid. Angular frequency and shear stress applied on the 




However, the shear stress experienced in vivo during intercourse is 
expected to be orders of magnitude higher than the shear stress applied in the 
above investigation. Therefore, the kinetics of mixing of the seminal fluid with the 
crosslinked polymer can be expected to be quicker merely due to increased 
shear forces. The novelty of the PBA-SHA SMP lies in its ability to transform from 
a weakly crosslinked transient network to a covalently crosslinked elastic network 
in response to seminal fluid as the stimulus.  
Figure 3.3   Oscillatory frequency sweeps for the assessment of the effect of 
semen on the network strength and relaxation time of the crosslinks. (a and b) 
Effect of semen on the network strength and relaxation time of the crosslinks at 
37°C (c) Time dependent dynamic rheology on the SMP at 37°C for the 
assessment of the gelation kinetics (d) Oscillatory frequency sweeps comparing 
the and  of the SMP at 37°C. N=3, Mean. 
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3.3.3 Assessment of the PBA5-SHA5 gelation kinetics  
Owing to the in situ gelation and the pH-responsive modulation of 
viscoelastic properties, the SMP could be administered using either a twin-screw 
applicator or as a premixed viscoelastic fluid. When administering the polymer 
solutions as a two part system, it is important to quantitatively assess the kinetics 
of network formation. We characterized the in situ gelation kinetics using 
dynamic rheology. After 60 s, which is the time taken to load the samples, the 
ratio of the elastic modulus, G', to the viscous modulus, G'', was 2.1, suggesting 
that the crosslinked polymer network had already formed. At this point, the 
polymer network had also reached 50% of its maximum elastic modulus (Figure 
3.3c). The elastic modulus reached equilibrium within 19.2 mins (1154 s) 
reaching a maximum G' of 16.8 Pa and a final ratio of G' to G'' of 2.5. These 
results suggest that the time taken for the formation of an elastic network is on 
order of seconds upon mixing of the polymer solutions. 
3.3.4 Comparison of simple and complex viscosity 
We compared the simple and complex viscosity of the PBA-SHA SMP to 
evaluate the effect of steady state and dynamic stress on the flow behavior of the 
SMP. The majority of the current semisolid microbicide systems are formulated 
with weakly associating polymer networks that exhibit shear thinning behavior 
above 0.1 s-1.176 Shear thinning behavior has the potential to improve coverage of 
vaginal tissue, but may also result in leakage,92 whereas the less common shear-
thickening systems may provide enhanced retention during and after intercourse. 
Steady state flow viscosity ߟሺߛሻሶ  was compared with complex viscosity, ߟכሺωሻ, 
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determined from dynamic oscillatory frequency sweeps. Complex viscosity 
displays Newtonian behavior at long time scales, as exhibited by the linear region 
that decreases at frequencies higher than 0.1 s-1 (Figure 3.3d). Acceptable 
superimposition  of ߟכሺωሻ with ߟሺߛሻሶ   occurs until a critical shear rate of 0.6 s-1 
indicating that the Cox-Merz rule is applicable only at the low shear rates. Above 
the critical shear, ߟሺߛሻሶ   rises sharply and similar shear thickening behavior has 
been previously observed for materials produced from boronate-diol crosslinking 
chemistry. Above 1 s-1 the flow became unstable (Figure 3.3d), a phenomenon 
exhibited by poly(vinyl alcohol))-sodium borate materials,58, 176 impeding our 
ability to quantitatively determine behavior at higher shear rates. However, it 
appears that at high shear rates the PBA-SHA SMP shear thins followed by 
ability to self-heal upon removal of the shear stress. Shear thickening behavior 
implies that an increased number of crosslinks is impacted by flow.177 It has been 
hypothesized that crosslinking between diol-boronate complexes may be 
impacted by polymer chain orientation.177, 178 An increase in the flow potentially 
allows parallel orientation of the polymer chains, which could create a favorable 
alignment for increasing association between polymer-bound PBA and SHA on 
adjacent chains. Altogether, we believe that the shear thickening behavior 




3.3.5 Effect of mucin on the viscoelastic behavior of the PBA5-
SHA5 crosslinked polymer network 
PBAs are known to bind to cis-diols of sugar residues179 found in many 
glycoproteins which may create a dynamic interaction between the PBA-SHA 
SMP and mucin that could lead to a mucoadhesive effect. Mucoadhesion of a 
vaginal formulation results in the capacity for long-term delivery and improved 
patient compliance due to noncoitally dependent application, and non-leaky 
formulations.95, 165 Dynamic rheological assessment of mucoadhesion has been 
used extensively, partly due to its simplicity.95 The rheological analysis of the 
PBA-SHA SMP in the presence of 1% (w/w) mucin does indicate that there is 
interaction, likely between PBA and mucin, that impacts the material’s 
viscoelasticity properties, including the dynamic network strength measured from 
the G'Plateau and relaxation time of the PBA-SHA crosslink. 
At pH 4.8 the oscillatory frequency sweep indicates not only an increase in 
the overall elastic modulus of the polymer network in the presence of mucin, but 
also an increase in  from 0.9 s to 2.1 s. A corresponding increase in the G'plateau 
from 16.8 Pa to 47.8 Pa was observed, yielding a positive rheological synergy 
parameter, ΔG', of 31 Pa (Figure 3.4a&b). 
The shift to longer  in the presence of mucin points to an increased 
stability of the PBA-SHA crosslink, thereby increasing the number of crosslinks 
formed at a given time resulting in the increased G'plateau. These results indicate 
that the presence of mucin results in a higher elastic modulus and increase in the 




An opposite effect is observed at pH 7.6. During the oscillatory frequency 
sweep, both G' and G'' decreased across the frequency range of 0.1-100 rad/s 
due to the presence of mucin. A shift in the relaxation time to a lower timescale 
indicates that the presence of mucin creates a more dynamic equilibrium in the 
PBA-SHA crosslink. We hypothesize that diols present in mucin may be binding 
to the PBA moieties in the crosslinked polymer, competing with the SHA moiety, 
resulting in weaker transient network. The overall G'plateau is also lower in the 
presence of mucin, with a negative rheological synergy, ΔG' of -349 Pa indicating 
 
Figure 3.4   Rheological assessment of the interactions between porcine gastric 
mucin and PBA-SHA SMP. (a) Oscillatory frequency sweeps at pH 4.8 with and 
without mucin. N=3, Mean; (b) Oscillatory frequency sweep at pH 7.6 with and 
without mucin. N=3, Mean; (c) G'Plateau at pH 4.8 with and without mucin.  N=3, 
Mean ± SD and (d) G'Plateau at pH 7.6 with and without mucin.  Study at 37°C. 
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formation of a weaker network (Figure 3.4c&d). However, the G'plateau of the 
formulation at seminal pH in the presence of mucin is still an order of magnitude 
higher when compared to the formulation at vaginal pH. A similar observation 
has previously been reported for acrylic acid polymers and mucin.170 Overall, 
these results indicate that the PBA-SHA SMP has the capacity to chemically 
interact with mucin and demonstrate mucoadhesive properties. 
3.3.6 Tracking the movement of HIV virions in the PBA-SHA 
crosslinked polymer network 
Single particle tracking using time lapse microscopy was employed for the 
quantification of the movement of Gag-cherry labeled HIV virions embedded in 
the PBA-SHA SMP as a function of pH. Rheological assessments on the PBA-
SHA crosslinked polymers reveal a pH-responsive viscoelastic behavior. In turn, 
modulations in the viscoelastic properties and the crosslink lifetime warrant 
alteration in the network mesh size, and thus the mobility of HIV virions in the 
PBA-SHA SMP. Tracking the movement of a single particle in the polymer 
network is illustrative of the local microenvironment.170, 180 Solid lines in Figure 
3.5 show the MSD of the individual virions whereas the open squares show the 
ensemble average MSD for a given location in the polymer network. At pH 4.3 
(Figure 3.5a), the linear dependence between ensemble-averaged MSD and lag 
time is a classic representation of particle diffusion in a viscoelastic fluid.181 In 
contrast, at pH ≥ 4.8 (Figure 3.5c&d), the plateaus observed in the ensemble-
averaged MSD vs. lag time is a representation of particle diffusion in an elastic 








Figure 3.5   Tracking of Gag–Cherry-labeled HIV (BaL strain) movement in PBA-
SHA SMP at 37°C as a function of pH. The mean square displacement was 
determined using IDL and the diffusion coefficients (Do) for Gag-Cherry-labeled 
virions were computed as one-fourth of the slope of ensemble-average mean 
squared displacement versus time for five image stacks with an average of 25 
virions/stack. (a-d) Representative plots of individual virion movement and the 
ensemble-average mean squared displacement of virions as a function of the lag 
time (t, s) at pH 4.3, 4.5, 4.8 and 5.5. No discernable movement of the virions 
was observed at pH above the vaginal pH (4.5-5.0), indicating that the HIV 
virions will likely be trapped in these materials. N=3, mean.120 
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The diffusion coefficients of the virions in the polymer network decreased 
by almost an order of magnitude with the increase in pH suggesting caging 
effects and impeded movement of virions in the polymer network. At pH 4.8 and 
5.5, the plateau measured is marginally above the noise level. At pH 4.8 the 
diffusion coefficient of the virions in the PBA-SHA crosslinked polymer network 
was calculated as 0.160  x 10-3 µm2/s.  Based on these results, we expect the 
HIV virions to move as little as 5 µ before the vaginal environment reacidifies. 
Once the acidic pH is restored, the innate vaginal defense mechanism presents a 
hostile environment with the capacity to attenuate HIV infection. Altogether, the 
PBA-SHA SMP exhibit the ability to impede viral transport at pH > 4.8 through 
physical entrapment. This unique functionality qualifies the use of the PBA-SHA 
SMP as a drug delivery vehicle that bears the potential to act as a physical 
barrier to the transport of virions from semen to the susceptible immune cells in 
the vaginal tissue. Moreover, the ingenuity of the material to respond to changes 
in pH would allow the crosslinked polymer to flow and coat at vaginal pH and 
when in contact with seminal fluid, form a solid-like impermeable physical barrier.  
3.3.7 Tracking the migration of macrophages in the PBA5-
SHA5 SMP 
The semen-borne infectious virions prevail as both free-virions as well as 
virions associated with T-lympocytes and macrophages in the seminal fluid.38, 54, 
181 Therefore, with the goal of attenuating the transport of both cell-free and cell-
associated viruses, migration of macrophages in the PBA-SHA SMP was 
monitored as a function of time and dilution with vaginal fluid simulant. Universal 
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placebo gel54 was used as a negative control. In the Universal placebo gel, the 
cells showed ~250 µ migration into the gel layer (Figure 3.6a). 
On dilution of Universal placebo gel, complete migration (> 1000 µ) of 
macrophages was observed (Figure 3.6b). In case of the PBA-SHA SMP, no 
discernable movement of macrophages was observed even after 4 h of 
incubation (Figure 3.6c). Similarly, postdilution the PBA-SHA SMP showed 
negligible migration of macrophages. Note that the marginal shift in the cell layer 
seen in Figure 3.6d is an artifact caused by the cell suspension settling as a 
function of time. Migration of macrophages in the polymer can be distinguished 
from settling by virtue of the stepped movement of cells as seen in Figure 
3.6a&b. Migration of the cells appeared slower and somewhat hindered in the 
undiluted Universal placebo gel; however, when subjected to dilution, complete 
migration of macrophages was observed at the end of 4 h. The figure on the right 
is a quantitative representation of the cell migration as a function of depth and 
time based on percent fluorescence intensity (Figure 3.6).  
3.3.8 Safety evaluation using reconstructed human 
ectocervical tissue  
The toxicity and irritation potential of materials indicated for 
pharmaceutical application - including those for microbicide delivery - demand 
meticulous safety assessments.152, 172 More often than not, toxicological 
investigations probe an important but specific pathway. Hence, for an integrated 
realization of the toxicity potential of the formulation, a combination of assays that 




Figure 3.6   Migration of human macrophages through SMP and the Universal 
placebo gel. (a & c) Undiluted and (b & d) on dilution with vaginal fluid simulant 
(VFS) as a function of time. Macrophages were tagged with cell tracker dye and 
the migration of the macrophages through the polymer network was monitored by 
collecting z-stacks at 1 h intervals between times 0 to 4 h. Unlike the Universal 
placebo gel, the PBA-SHA SMP demonstrated complete inhibition of 
macrophage diffusion through the crosslinked polymer network, independent of 
dilution with VFS.  
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Here we report a preliminary in vitro toxicological evaluation using a 
human vaginal cell line,75 and a detailed safety assessment using a 3D 
reconstructed ectocervical tissue model ,171 an ex vivo polarized human cervical 
tissue172 and an in vivo mouse model. MTT assay was performed to quantify cell 
proliferation and viability, while cytokine and chemokine levels were monitored to 
identify manifestation of inflammatory responses, Transepithelial electrical 
resistance (TEER) to ensure integrity of the vaginal epithelium and histological 
evaluations to monitor emergence of detrimental morphological changes.  
From the biocompatibility studies using VEC-100, tissue viability after 
three repeated exposures was determined to be 98 ± 12% as compared to the 
naive control. The TEER measurements for the tissue samples exposed to PBA-
SHA SMP were 94 ± 15, 98 ± 13 and 94 ± 8% of the no treatment control for 
days 1, 2 and 3, respectively, suggesting that the formulation caused no 
significant loss in tissue barrier properties (Figure 3.7a&b). In summary, the PBA-
SHA SMP revealed no significant loss of viability or tissue integrity after three 
repeated doses. Triton® X-100 served as the toxic control, resulting in a near 
complete loss of viability as well as tissue integrity. The discrepancy in the results 
between the Vk2/E6E7 and the tissue viability can be attributed to differences 
between the robustness of the cell monolayer and the multilayer tissue. The 3D 
reconstructed tissue models retain the complexity and therefore, offer a 
reasonable representation of the morphological characteristics of the human 







Figure 3.7   Safety evaluation of PBA-SHA SMP on reconstructed human 
ectocervical tissue model. pHPMA and Triton served as nontoxic and toxic 
controls, respectively. (a) Percentage viability of the tissue determined using 
MTT assay at the end of day 3, (b) TEER measurements graphed as percentage 
of the naïve control for days 1-3. (c-f) Pro-inflammatory cytokine IL-1α, TNFα, IL-
6 and IL-8 release for days 1-3. Samples were compared to the nontoxic control 
pHPMA, for days 1-3.Tissues treated with PBA-SHA SMP showed no major 
symptoms of toxicity or inflammatory response when compared to pHPMA 
treated tissue, N=3, Mean ± SD, single-factor ANOVA followed by Bonferroni 
correction for multiple comparisons (* p < 0.05). 
106 
 
Moreover, the tissue model allows repeated exposure to the crosslinked 
polymers in contrast to the limited assessment of polymer solutions in the cell 
cytotoxicity evaluation. Additionally, lower toxicity of the polymers in the 
crosslinked state can be attributed to the fact that polymers, when examined as 
individual solutions, possess free functional groups in contrast to the crosslinked 
polymers in which the functional groups remain conjugated. This may contribute 
to decreased toxicity. IL-1α, IL-6 and IL-8 and TNFα were chosen as biomarkers, 
as they have been found to play a critical role in predicting mucosal toxicity 
following administration of microbicides.172 As shown in Figure 3.7(c-f), when 
treated with the PBA-SHA SMP, the VEC-100 tissues showed no significant 
induction of cytokines or chemokines (single-factor ANOVA, p > 0.05) as 
compared to the pHPMA. Triton, used as the toxic control, triggered upregulation 
of IL-1α, IL-6 and IL-8, but down-regulation of TNFα. Similar results have 
previously been reported by other researchers.182 
3.3.9 Ex vivo and in vivo safety assessment 
Ancillary to the viability and cytokine analysis, which measure overall 
safety of the test product to vaginal tissue, histological examinations were 
employed to identify site-specific toxicity to the vaginal epithelium or the 
underlying submucosal tissue. Loss of basal layer and epithelial sloughing and/or 
necrosis was evaluated as indicators of toxicity.The viability of the tissues 
exposed to PBA-SHA SMP was 81±0.8%. A comparison of the histology of the 
tissue exposed to PBA-SHA SMP and DMEM reveal no evidence of significant 








Figure 3.8   Safety of the PBA-SHA SMP evaluated ex vivo in the human 
ectocervical explants and in vivo using a mouse model. Top Panel - After 
overnight culture, the explants were washed and processed for histology. Image 
shown is representative of the three repeats. The images are 5 μ sections of the 
tissues; stained with Hematoxylin and Eosin. (a) Tissue before exposure, (b) 
tissue after 4 h of exposure to DMEM (control) and (c) tissue after 4 h of 
exposure to PBA-SHA SMP. Comparison of the histology of the tissue before 
and after exposure to the PBA-SHA SMP showed no evidence of significant 
morphological changes. Bottom Panel - Two groups of three animals were 
exposed to three repeated doses of PBA-SHA SMP or PBS (placebo arm). On 
day 3, the animals were sacrificed and the vaginal tract was collected, fixed and 
stained with Hematoxylin and Eosin. The vaginal tissues demonstrated uniform 
epithelium throughout with vacuolated cells in some locations. The vacuolated 
cell localization was found to be irregular and was observed in both the PBS and 
SMP treated animals.  No sign of apoptosis was identified. 
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In conjunction to the ex vivo histopathological assessment, in vivo safety 
was evaluated using a mouse model. Vaginal tissues from the animal treated 
with PBA-SHA SMP appeared normal with intact lamina propia and submucosa. 
There were some locations in the mucosa from both the control and the PBA-
SHA SMP groups, which showed signs of vacuolated and necrotic cells (Figure 
3.8, bottom panel).  However, no evidence of specific toxicity of any other type 
was identified.  
3.3.10 Transport assay using photoactivateable-GFP-HIV  
No photoactivatable signal was detected in the uninfected control tissue, 
demonstrating specificity of the photoactivated GFP signal for PA-GFP HIV. 
Without the SMP, we were able to detect HIV penetrating the first couple of cell 
layers of the ectocervical epithelia and penetrating the endocervical epithelia, at 
various depths from the mucosal surface (Figure 3.9a&b). We noticed some 
heterogeneity in the tissue, not just between specimens but even within a single 
biopsy and as a result we scanned large areas of tissue without detecting any 
HIV particles. The addition of the SMP to the explant perturbed viral interaction 
with the epithelium. A photoactivatable GFP signal was observed in the AMCA-
labeled polymer, but not in the epithelium of the explants (Figure 3.9c&d). The 
SMP showed even spreading on the ectocervical epithelium. On the other hand, 
varying thickness of the SMP was observed on the endocervical epithelium. The 
endocervical epithelium contains mucus filled crypts which may hinder SMP-





Figure 3.9   Ex vivo evaluation of viral transport through the PBA-SHA SMP 
using human cervical tissue. Cervical tissues were inoculated with 300 µL of 
photoactivatable-GFP labeled HIV for 4 h. (a & b) Z-scan prior to photo-activation 
for background (green) deletion, (c) cervical tissue after 4 h of exposure to PA-
GFP-Vpr HIV (red) and photo-activation and (d) cervical tissue with PBA-SHA 
SMP (blue) after 4 h of exposure to PA-GFP-Vpr HIV (red) and photo-activation. 
The Z-scans reveal localization of the virions in the topmost layer of the SMP, 
suggesting that the polymer network poses an impermeable barrier to the 
transport of virions. In contrast, the Z-scan on the tissue with no SMP reveals 
penetration of the virions into the interstitial space within the columnar epithelium 




Inspired by the ability of cervical mucus to trap HIV virions at acidic pH 
and its role in transport processes in reproductive health, we designed a SMP 
that has reversible crosslinking and can impede viral transport. However, one 
way in which the SMP differ from cervical mucus is in regards to the sensitivity of 
the PBA-SHA complexation to pH, where the crosslinking density, and thereby 
the barrier property, increases as pH increases from vaginal pH to seminal pH. 
Modulation of the viscoelastic behavior of the covalently crosslinked PBA-SHA 
SMP in response to pH provides a semisolid hydrogel capable of being applied 
as a viscoelastic fluid which can interact with mucus, and thereby enhance 
spreading and retention in the vaginal lumen. Furthermore, driven by the change 
in pH caused by the presence of semen, the PBA-SHA SMP forms a crosslinked 
network that inhibits the transport of virions and cells. In summary, the pH-
responsive PBA-SHA SMP hold promise as a biologically inspired microbicide 
capable of acting as a safe physical barrier to HIV transport. 
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VAGINAL MICROBICIDE GEL FOR DELIVERY OF 
IQP-0528, A PYRIMIDINEDIONE ANALOG 
WITH DUAL MECHANISM OF  
ACTION AGAINST HIV4 
4.1 Introduction 
The need for prophylactic strategies to prevent heterosexual transmission 
of HIV was recognized more than 20 years ago.172 Since then researchers from 
various fields have actively been developing technologies to combat the rapid 
spread of HIV. These strategies include pre-exposure prophylactics9, 183 and 
microbicides184, 185 designed to topically deliver single or combination antiviral 
agents. Currently, microbicide delivery systems under development include gels, 
rings, films and suppositories. Of these systems, vaginal gels remain the 
preferred choice for the first line of microbicide product development. This can be 
attributed to the ease of vaginal gel development, the extensive work reported in 
                                            
 
4Adapted from Vaginal microbicide gel for the delivery of IQP-0528, a pyrimidinedione 
analog with a dual mechanism of action against HIV-1, Antimicrobial Agents and Chemotherapy,  
Volume 55, 2011, 1650-60, Alamelu Mahalingam, Adam P. Simmons, Shweta R. Ugaonkar, 
Karen Watson, Charlene S. Dezzutti, Lisa C. Rohan, Robert W.  Buckheit Jr. and Patrick F. Kiser. 
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the literature using this dosage form and the existence of several vaginal 
semisolid products on the market. Microbicide administration via the vaginal 
route is advantageous as it allows local, noninvasive delivery of antiviral agents 
and enhanced biodistribution of drugs facilitated by the rich underlying blood 
supply.21, 140 Furthermore, vaginal gels can be self-administered, which is critical 
in the development of woman-controlled preventive strategies such as vaginal 
microbicides.20  
An effective prevention strategy will undoubtedly require a multi-targeted 
approach that can be achieved by either combining multiple antiviral agents or by 
employing drugs that possess multiple mechanisms of inhibiting HIV 
transmission.21 Pyrimidinedione derivatives constitute a unique class of non-
nucleoside reverse transcriptase inhibitors (NNRTIs) that also inhibit HIV entry 
through an unknown mechanism thought to target a conformational epitope 
formed prior to the fusion of the viral envelope with the host cellular membrane.15 
The dual mechanisms of action, high potency, minimal toxicity to vaginal cells 
and natural flora and broad range of activity against wild-type and drug-resistant 
clinical viruses make these molecules attractive candidates for microbicide 
development. Previous work by Buckheit et al. reported a detailed exploration of 
the structure-function relationship of PYD analogs. All of the PYD derivatives 
demonstrated inhibition of both reverse transcriptase and virus entry; however, 
the effective concentration for the inhibition of cell entry and reverse transcriptase 
varied depending on the chemical modifications to the pyrimidinedione ring.186, 187 
In this work, we report a preformulation screen of nine PYDs with reverse 
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transcriptase inhibition activity in the nanomolar range and therapeutic indices ≥ 
10,000.188 
This work focuses on the development of an inexpensive vaginal gel 
formulation for the sustained delivery of PYD using GRAS (generally regarded as 
safe) ingredients - polyacrylic acid (PAA) and a cellulose derivative.97, 187, 189 In 
particular, hydroxyl ethyl cellulose (HEC) has been used in several vaginal gel 
formulations, including the universal placebo gel.190 Chemical stability of the 
active compound and mechanical stability of the gel formulation was evaluated 
under accelerated conditions for three months. The release kinetics of the active 
compound from the gel matrices were assessed using in vitro and ex vivo drug 
release studies. 
In addition to careful selection of the drug delivery vehicle and the active 
ingredient, a detailed exploration of the safety and efficacy of the end formulation 
is critical to the development of a microbicide. Particularly after the clinical 
failures of cellulose sulfate, N-9, Savvy and several other first-generation 
microbicides, in vitro safety and efficacy evaluations have become a major 
component of topical microbicide product development.72, 152, 191 These studies 
offer a cost-effective method of evaluating microbicide formulations prior to more 
complex and expensive in vivo studies.67 We evaluated the safety and efficacy of 
the PYD gel formulation using reconstructed VEC-100 tissue (MatTek Corp.) and 
human polarized ectocervical tissue. The VEC-100 tissue recapitulates only the 
morphological characteristics of the stratified squamous epithelial layer whereas 
the polarized ectocervical explants contains both the epithelium and relevant 
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immune cells.75, 173, 192, 193 In an in vitro HIV entry inhibition assay the 3.0% HEC 
gel with 0.25% IQP-0528 demonstrated an EC50 of 0.14 µg/mL of gel in culture 
media, corresponding to approximately 0.001 µM IQP-0528 and showed 
complete protection of the human polarized ectocervical tissue against HIV 
infection.  
4.2 Materials and Methods 
4.2.1 Materials 
The PYD derivatives were provided by ImQuest BioSciences, Inc. 
(Frederick, MD). HEC 250 HX PHARM was purchased from Ashland, Inc. 
(Wilmington, DE). Carbopol 974P NF was purchased from Lubrizol (Wickliffe, 
OH). Glycerin was supplied by Mallinckrodt Baker, Inc. (Phillipsburg, NJ). 
Hydrogen peroxide (ACS grade), 19-norethindrone (purity > 98%), bovine serum 
albumin, methylparaben and propylparaben were obtained from Sigma-Aldrich 
Corp. (St. Louis, MO). Acetonitrile and isopropyl alcohol (HPLC grade) were 
obtained from Fisher Scientific (Houston, TX). Lecithin and nonoxynol-9 (N-9) 
were purchased from Spectrum Chemicals (Gardena, CA). Solutol HS-15 was 
purchased from BASF (Florham Park, NJ). The 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) kit was obtained 
from Promega (Madison, WI) and all cell culture media supplies were purchased 
from Invitrogen Corp. (Carlsbad, CA). VEC-100 tissues were purchased from 
MatTek Corporation (Ashland, MA).  
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4.2.2 Selection of lead PYD analog 
We investigated the stability of nine PYD analogs to select a lead 
candidate for formulation development. The stability studies were conducted 
under various physiologically relevant conditions including pH 7.0 (neutral pH), 
pH 4.2 (vaginal pH)97 and pH 4.2 with a 0.1% hydrogen peroxide solution 
(simulates vaginal environment). All the samples were stored at 40 °C and 75% 
relative humidity to evaluate the stability of the PYD analogs under accelerated 
conditions. Stock solutions of PYD were prepared in methanol. Dilutions were 
made with 100 mM phosphate buffer (pH 7.0) containing 2% Solutol HS-15 to 
obtain a final concentration of 30 µM. Similarly, solutions were made in pH 4.2 
100 mM acetate buffer containing 2% Solutol HS-15 for the pH 4.2 conditions. 
Solutol HS-15 was added to the buffers to keep the compounds solubilized after 
dilution. Samples were collected at 0, 1, 2 and 4 weeks and analyzed using high-
performance liquid chromatography (HPLC). All samples were run on a Zorbax 
ODS 5-µm, 4.6 × 150 mm C18 column at 37 °C with a flow rate of 1.0 mL/min. A 
12 m isocratic method was run at a 65:35 water: acetonitrile ratio. PYD was 
detected at 267 nm. PYD quantification was performed on an Agilent 1200 Series 
HPLC equipped with ChemStation32 software. For each sample, the 
concentration of analyte was determined from a standard curve relating peak 
area to analyte concentration. Percentage recovery of the PYD at each time point 




4.2.3 Preparation of the gel formulation  
Appropriate amounts of the gelling agent (Carbopol 0.65%, HEC 3.0 %) 
were added to 80% 18 MΩ distilled water and stirred for 45 mins. To increase the 
buffering capacity of the gel, acetate buffer (25 mM, pH 5.2) was used instead of 
distilled water in the preparation of the HEC gel. A paste of the active compound 
(0.25%) in glycerin (3.5%) was added to the solution containing the gelling agent. 
The preservatives methylparaben (0.15%) and propylparaben (0.05%) were 
weighed and mixed with preheated glycerin (1.5%) until all solids had dissolved. 
The paste obtained was added to the solution containing the gelling agent, with 
constant stirring using an overhead stirrer equipped with a paddle-shaped 
propeller. Lastly, the pH of the gel was adjusted to 5.2 ± 0.2 and the total weight 
was adjusted to 100%. All gels were allowed to equilibrate overnight and were 
retested for pH before use.  
4.2.4 Chemical stability of the active compound in the gel 
formulation 
Upon identification of the lead PYD molecule, the drug (at a concentration 
of 0.25%) was incorporated into a gel containing 3.0% HEC gel or a gel 
containing 0.65% Carbopol 974P. Gel formulations were evaluated for stability 
under accelerated conditions, which would be predictive of the long-term stability 
of the formulation at room temperature. Aliquots of the gel formulations were 
prepared in amber vials with rubber stoppers and aluminum crimps. The vials 
were stored at 40 °C and 75% relative humidity (RH) (Caron, Marietta, OH) and 
at 50 °C in a dry convection oven (Thermo Haake, Waltham, MA). Samples were 
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collected at 0, 1, 2, 4, 8, and 12 weeks, and IQP-0528 was extracted for 
quantification using HPLC. 
IQP-0528 extraction was performed in the presence of an internal 
standard (19-norethindrone). Required amounts (100 µL) of 19-norethindrone 
stock in methanol were added to each vial containing the gel. The contents of the 
vials were transferred into 10-mL volumetric flasks and sonicated for 30 mins. 
Approximately 1 mL of the supernatant was filtered through a 0.2-µ PTFE filter 
and analyzed using HPLC. To determine the extraction efficiency of the above-
mentioned method, we created controls consisting of placebo gels spiked with 
known amounts of IQP-0528. The extraction efficiency of the method was 
determined using percent recovery of the internal control and IQP-0528 from the 
controls. Samples and controls were run in triplicate.  
4.2.5 Mechanical stability of the gel formulation 
The viscosity of the gel formulations was measured using a stress-
controlled AR 550 rheometer equipped with 20-mm 4° steel cone geometry. A 
sample of the gel (150 µL) was allowed to equilibrate for 2 mins on a Peltier plate 
at 37 °C, after which a steady-state shear was applied to the gel to obtain 
viscosity profiles. Viscosity was measured in triplicate over the range of 1-100 s-1 
to simulate physiological conditions.95 The mechanical stability of the gel 
formulations stored at 40 °C/75% RH and at 50 °C/dry atmosphere was 
evaluated at 0, 1, 2, 4, 8 and 12 weeks. Viscosity measured at each time point 
was compared to viscosity at time 0.  
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4.2.6 In vitro release study 
A continuous flow in-line Franz cell was used to perform the in vitro 
release study. The gel (200 µL) was placed on the donor compartment using a 
positive-displacement pipette. The donor and receptor compartments were 
separated by a 13-mm nylon membrane (Millipore, Billerica, MA) prewetted by 
soaking in the receptor solution for 1 hr. Three different sink conditions were 
evaluated: 2% Solutol HS-15 in 100 mM acetate buffer (pH 4.2); liposomes 
(prepared from soy lecithin)95 in acetate buffer (pH 4.2); and 50:50 isopropyl 
alcohol: phosphate buffer (pH 7.0, 100 mM). The receptor solution was circulated 
at a flow rate of 0.18 mL/m and collected at 2, 4, 6, 8 and 24 h for IQP-0528 
content analysis using HPLC (n=5).  
4.2.7  IQP-0528 uptake study 
Porcine vaginal tracts were collected immediately following sacrifice, 
placed in Kreb’s buffer and transported to the laboratory at ambient temperature 
within 1 hr.194 Small sections of the tissue were dissected using surgical scissors, 
snap-frozen and stored at -80 °C until testing. To confirm the integrity of the 
porcine vaginal tissue after a single freeze-thaw cycle, permeability studies were 
performed with the model compound caffeine. As previously reported, results 
from the permeability measurements indicated no difference between fresh and 
frozen vaginal tissue.195  The frozen tissue was thawed prior to use. To obtain 
consistent tissue thickness, the tissue samples were sliced using a Thomas-
Stadie-Riggs tissue slicer. The epithelium was separated using blunt tweezers 
and gently pulled up to generate a final tissue thickness of approximately 500 μm 
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(500 ± 200 μm). A biopsy punch was used to obtain tissues with the desired 
cross-sectional diameter.  
IQP-0528 uptake by the porcine vaginal tissue was determined using a 
continuous flow Franz cell. Gel (20 µL) was placed on the donor compartment 
using a positive-displacement pipette. Donor and receptor compartments were 
separated using a 6-mm biopsy of porcine vaginal tissue. Phosphate-buffered 
saline (PBS) was circulated continuously through the receptor compartment to 
keep the tissue hydrated. Tissue samples were collected after 2, 4 and 6 h and 
washed three times with PBS to remove any residual gel on the tissue before 
IQP-0528 content analysis.  
4.2.8  Determination of IQP-0528 content in porcine vaginal 
tissue 
Porcine vaginal tissue was placed in a 2-mL flat-bottom tube with locks. 
To create a calibration curve, 1-300 µL of a 3 mM IQP-0528 stock in methanol 
was added to blank tissue to create eight spiked samples of known 
concentrations. To precipitate proteins, 800 µL of acetonitrile and 200 µL of a 5% 
trichloroacetic acid (TCA) solution were added to each tube and incubated for 5 
mins. Finally, the samples were homogenized using the Qiagen TissueLyser for 
5 mins. Samples were centrifuged at 14,000 x g for 10 min, and the supernatant 
was filtered and analyzed for IQP-0528 content using HPLC. The extraction 
efficiency for IQP-0528 from tissue samples was determined as 92 ± 4%, with 
19-norethindrone as the internal control using the method described above for 
extraction of the drug from gels. A calibration curve was created using the 
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theoretical and experimental concentrations of IQP-0528 in the tissue sample 
after extraction. The actual concentration of IQP-0528 in the tissue was 
calculated using the calibration curve. All samples were run with n=5. 
4.2.9 IQP-0528 permeability studies using human ectocervical 
tissue  
Freshly excised human ectocervical tissue was obtained from the Tissue 
Procurement Facility at the Magee Women’s Hospital, in accordance with 
institutional review board (IRB) protocol number MWH-98-065. All tissue samples 
were from premenopausal women undergoing hysterectomy for benign 
conditions. The tissue was immersed in DMEM medium (Mediatech Cellgro, 
Fisher Scientific, Pittsburgh, PA) and used within 30 mins of retrieval. Excess 
stromal tissue from cervical tissue was removed using a Thomas-Sadie slicer 
(Thomas Scientific, Swedesboro, NJ). The thickness of the tissue was 
determined by placing the tissue between two premeasured histology slides and 
it was remeasured using calipers. 
Permeability studies were conducted using Franz cells (PermeGear, 
Nazareth, PA). Cervical tissue was placed between the donor and receptor 
compartments of the apparatus. The test compound was introduced into the 
donor compartment of the experimental apparatus. DMEM without phenol red 
(Hyclone) was used as the receptor solution. Samples were obtained from the 
receptor compartment at the predetermined time intervals of 0, 15 mins, 30 mins 
and 1-6 h. The drug permeability of the formulation across the tissue and the 
antiviral activity of the receptor solution were examined for both the Carbopol and 
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HEC formulations. Receptor solutions were split; half of each solution was used 
for quantification of the drug by HPLC and the other half was used for bioactivity 
testing.  
4.2.10 Drug uptake and permeability studies on VEC-100 
vaginal tissue  
To determine the ability of IQP-0528 to permeate and accumulate in 
human vaginal tissue, studies were performed on VEC-100 tissue, a stratified, 
well studied 3D model of human vaginal tissue. Based on the results from the in 
vitro release study and the permeability studies using human ectocervical tissue, 
the 3.0% HEC gel with higher IQP-0528 release was selected for the VEC-100 
permeability studies. The 3.0% HEC gel was applied to the tissue samples in the 
inserts and cultured as recommended by the suppliers.196 Tissue samples were 
washed three times with 100 µl of PBS, and Trans-Epithelial Electrical 
Resistance (TEER) measurements were recorded to ensure the integrity of the 
tissue during the study. Following washing, fresh gel was applied to the tissue. 
This process was repeated for 3 days to study the effect of the gel on tissue after 
three repeated exposures. Culture medium was collected every 24 h for 3 days 
for IQP-0528 quantification (n=6). Drug content in the tissue samples after 3 days 
was extracted and quantified using the same method as used with the porcine 
vaginal tissue.  
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4.2.11 In vitro safety and HIV antiviral activity 
A Vk2/E6E7 human vaginal cell line and the VEC-100 tissue model were 
used to evaluate the safety of the IQP-0528 gel formulation in vitro after a single 
exposure and three repeated exposures. Diluted gel samples were added to the 
Vk2/E6E7 cells and incubated for 24 hr. After exposure, cell viability was 
assessed using an MTS assay. N-9 and the universal placebo gel (at a 1:100 
dilution) were used as toxic and nontoxic controls, respectively.  
To evaluate the safety of the formulation in the VEC-100 tissue, gel was 
applied to the tissue samples each day for 3 days. After three repeated 
exposures, tissue samples were analyzed for viability using 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). Tissues were also 
fixed in a 10% formalin solution and processed to evaluate tissue morphology. 
Following paraffin embedding, sections were cut and stained with hematoxylin 
and eosin. Toxicity was determined based on observations of loss or damage to 
the epithelial layer. Culture medium collected every 24 h for 3 days was 
evaluated for the induction of inflammatory cytokines (IL-8, IL-1α, IL-6 and TNFα) 
using ELISA kits (R & D Systems, Minneapolis, MN). These cytokines were 
chosen as they have been reported to be consistent indicators of cumulative 
mucosal toxicity and inflammatory responses.172 All samples were evaluated in 
triplicate except for the samples undergoing cytokine analysis, which were 
evaluated with six replicates (n=6). N-(2-hydroxypropyl) methacrylamide polymer 




We also evaluated the in vitro antiviral activity of the 3.0% HEC 
formulation using a luminescence assay as described previously. The HEC 
placebo gel was used as a negative control and Chicago sky blue was used as a 
positive control. Gels were serially diluted to generate solutions that could be 
directly added to the cells. MAGI cells were seeded in a 96-well microtiter plate at 
a density of 10,000 cells/well for 24 h prior to the assay. Following the overnight 
incubation at 37°C in 5% CO2, diluted test samples were added to the cells in 
triplicate. HIV-1IIIB was diluted in the assay medium to generate the desired viral 
titer and was then added to the cells. Cells were incubated with the test sample 
for 2 h, following which the cell monolayers were washed three times and 
incubated for an additional 48 h. The inhibitory activity of the gels was evaluated 
by chemiluminescence detection with the Gal-Screen system, and toxicity was 
evaluated using the tetrazolium dye 2,3-bis-(2-methoxy-4-nitro-5-sulphenyl)-(2H)-
tetrazolium-5-carboxanilide (XTT). We also assayed the activity of the API and 
the gel formulation in the presence of 25% seminal fluid.  
In a separate assay, we preincubated the cells with the gel formulation for 
1 h, following which the virus was added to the cells and incubated for an 
additional 2 h. Additionally, to evaluate the residual activity of the formulation, 
following the preincubation of the formulation with the cells, we washed the cell 
monolayer to remove the formulation. The virus was then added and incubated 
for 2 h. Antiviral activity was assayed after an additional 48 h of incubation by 
measuring β-galactosidase activity. Antiviral and toxicity results were reported as 
50% effective concentration (EC50) and 50% toxic concentration (TC50).  
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4.2.12 Safety and antiviral activity in polarized ectocervical 
explants 
Evaluations of the safety and antiviral activity of the lead formulation, IQP-
0528, were performed as previously described.75, 197 Briefly, the explant was 
placed in a transwell. The edges around the explant were sealed with Matrigel™ 
(BD Biosciences, San Jose, CA). The explants were maintained with the luminal 
surface at the air-liquid interface. The lamina propria was immersed in culture 
medium. Cultures were maintained at 37°C in a 5% CO2 atmosphere. 
For the safety evaluation, the explants were prepared in duplicate on the 
day of surgery. To ensure an even spread of the gels and to allow them to be 
mixed with HIV for the efficacy evaluation (below), a 1:5 dilution of IQP-0528 or 
HEC placebo gels was applied to the apical side of the explants for 18 h. Control 
explants were untreated or treated with an apically-applied 1:5 dilution of 2% N-9 
gel (Gynol II; purchased over-the-counter). The following day, the explants were 
washed and safety was evaluated using an MTT [1-(4,5-dimethylthiazol-2-yl)-3,5-
diphenylformazan] assay and histology methods.75, 173 
For the evaluation of antiviral activity, a 1:5 dilution of IQP-0528 or HEC 
placebo gel was mixed with HIV-1BaL and added to the apical side of the 
explants. Eighteen hours after application, the explants were washed and fresh 
culture medium was added to the basolateral compartment. Every 3 to 4 days 
over a 3 week period, supernatant was collected and stored at -80 °C for HIV-1 
p24 gag analysis, and fresh culture medium was replenished. 
Immunohistochemistry (IHC) was performed at the study endpoint for HIV-1 
infected cells by staining for p24 gag.  
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4.2.13 Statistical Analysis 
Decreases in the drug content and viscosity of the gel were evaluated by 
comparison to levels at time 0 using a single-factor ANOVA followed by 
Bonferroni correction. Viability, TEER and cytokine levels were compared to the 
untreated controls using a single-factor ANOVA followed by Bonferroni 
correction. p-values<0.05 were considered significant.  
4.3 Results 
4.3.1 Selection of lead PYD analog 
As shown in Figure 4.1(a & b), the majority of compounds stored at pH 4.2 
and pH 7.0 and at 40°C/75% RH in the dark showed no significant degradation 
after four weeks when compared to their concentrations on day 0. However, 
recovery of IQP-0558, -0410 and -1187 was significantly reduced (single-factor 
ANOVA, p < 0.05) (Figure 4.1a) compared to day 0 concentrations. After 4 weeks 
at pH 4.2 in the presence of sunlight, all compounds with the exception of IQP-
0532 and -0528 showed significant degradation (Figure 4.1c). 
Similarly, at pH 4.2 in the presence of 0.1% H2O2, all compounds showed 
significant degradation with the exception of IQP-0528 and -0532 (Figure 4.1d). 
Owing to its higher therapeutic index and greater stability under all conditions 





















































































































































































4.3.2 Chemical and mechanical stability of IQP-0528 and the 
gel formulation 
Percent recovery of IQP-0528 at the end of 12 weeks of storage at 50 °C 
in the dark was 101.1 ± 4.8% in the HEC gel and 102.4 ± 4.1% in the Carbopol 
gel (Figure 4.2). These results indicate that there was no significant degradation 
of IQP-0528 in either the HEC or the Carbopol gel after 12 weeks when 
compared to levels on day 0 using a two-tailed Student’s t test (p > 0.05). 
Therefore, it can be concluded that the compound’s stability in the formulation 
was not impacted by the elevated temperature. As shown in Figure 4.3, the flow 
curves for IQP-0528 formulated in both HEC and Carbopol gels displayed non-
Newtonian shear-thinning behavior. The rheological data on gels stored at 
40°C/75% RH demonstrated no significant loss in viscosity after 12 weeks of 
storage. 
However, HEC gels stored under accelerated conditions (50°C) showed a 
statistically significant loss in viscosity at 1 s-1 shear rate (Figure 4.3b). This loss 
in viscosity had no statistically significant effect on the drug release profile. 
Similar loss of viscosity in HEC gels have been reported previously173 and is 
considered to be within the product specifications (<15% variation). Carbopol 
gels showed no loss in viscosity after 12 weeks under accelerated conditions 
(Figure 4.3d). Altogether, these results suggest that the Carbopol and HEC 
formulations would be mechanically stable after long-term storage. 
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4.3.3 In vitro release study 
After 24 h, approximately 90%, 45% and 35% of the IQP-0528 was 
released in 1:1 IPA:PBS, Solutol, and liposome solutions, respectively (Figure 
4.4a). A similar trend was observed with 0.65% Carbopol gels, in which 
approximately 70%, 24% and 20% of the IQP-0528 was released in 1:1 IPA: 
PBS, Solutol, and liposome solutions, respectively (data not shown). To describe 
the release kinetics of IQP-0528 from the gel formulations, the cumulative 
amount of IQP-0528 released at each time point was fitted to three mathematical 
models: Ficks’s first and second laws of diffusion and Higuchi’s equation126, 152. 
Based on the goodness of fit (r2 > 0.90), the IQP-0528 release was fitted to 
Higuchi’s equation. As described by Higuchi’s equation, the cumulative IQP-0528 
release when plotted as a function of the square root of time was linear, 
indicating diffusion-controlled release of IQP-0528. 
 
Figure 4.2   Percent IQP-0528 recovery from the 3.0% HEC and 0.65% Carbopol 





4.3.4 IQP-0528 permeability and uptake studies using porcine 
vaginal tissue  
The amount of IQP-0528 in porcine vaginal tissue samples was quantified 
after extraction in the presence of an internal standard using HPLC. As shown in 
Figure 4.4b, after 6 hr, 858 ± 78 nanomoles of IQP-0528 in the HEC gel was 
released for each gram of tissue, which corresponds to approximately 30% of the 
IQP-0528 loaded in the HEC gel. 
Figure 4.3   Steady-state flow curves of 3.0% HEC gel and 0.65% Carbopol gel. 
(a) 3.0% HEC gel with 0.25% IQP-0528 stored at 40°C/75% RH and (b) 50°C. (c) 





In contrast, with the Carbopol gel, 607 ± 160 nanomoles of IQP-0528 was 
released per gram of tissue, corresponding to approximately 20% of the IQP-
0528 loaded in the Carbopol gel. Sustained release of IQP-0528 was observed 
from both formulations until 6 h after administration. An initial lag time of 
approximately 1 h was calculated using the linear mathematical fit between the 
amount of drug released and the square root of time. 
Figure 4.4   In vitro and ex vivo release studies. (a) In vitro IQP-0528 release 
from a 3.0% HEC gel formulation under sink conditions at 37°C (n=3, Mean ± 
SD). * Indicates percent drug released at the end of 24 h; (b) IQP-0528 uptake 
study using porcine vaginal tissue (n=5, Mean ± SD); (c) Boxplot of IQP-0528 
concentration each day in the VEC-100 culture medium. (n=6). 
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4.3.5 IQP-0528 permeability studies using human ectocervical 
tissue  
In the permeability study using human ectocervical tissue, no detectable 
levels of IQP-0528 were found in any of the receptor compartment samples as 
analyzed by HPLC. However, upon bioactivity testing, the media in the receptor 
compartment showed viral inhibition, suggesting the presence of inhibitory 
concentrations of the drug at 4 h for the HEC formulation and at 6 h for the 
Carbopol formulation. These data correlate with the observation of increased 
drug release obtained using the HEC formulation in the in vitro and ex vivo 
release studies.  
Based on the in vitro release results, data on accumulation in porcine 
vaginal tissue and the results from the permeability studies on human 
ectocervical tissue, the 3.0% HEC IQP-0528 gel was chosen as the lead 
formulation for further evaluation of toxicity and antiviral activity studies in vitro 
with cell lines and ex vivo with cervical tissue. 
4.3.6 Drug uptake and permeability studies using VEC-100 
vaginal tissue 
As shown in Figure 4.4c, the concentration of IQP-0528 in growth media 
was measured as 278 ± 67 nM, 329 ± 123 nM and 360 ± 174 nM on day 1, 2 and 
3, respectively, following exposure of vaginal tissue to IQP-0528 gel. Additionally, 
the IQP-0528 that accumulated in the VEC-100 tissue after 3 days was extracted 
and the concentration was measured as 115 ± 62 µM. 
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4.3.7 In vitro safety evaluation using Vk2/E6E7 cells and VEC-
100 vaginal tissue  
As shown in Figure 4.5, the IQP-0528 gel showed no significant toxicity to 
Vk2/E6E7 cells after 24 h of exposure when compared with the untreated control, 
whereas the toxic control 0.1% N-9 caused a significant (approximately 90%) 
loss in cell viability (single-factor ANOVA).  
As shown in Figure 4.5b, tissue viability after three repeated exposure was 
determined to be 113 ± 8% compared to the nontoxic control pHPMA. The TEER 
measurements for the tissue samples exposed to the IQP-0528 3.0% HEC gel 
formulation were 112 ±  19%, 105 ± 25% and 109 ±  28% compared to the 
nontoxic control at days 1, 2 and 3, respectively, suggesting that the formulation 
caused no significant loss in tissue barrier properties (Figure 4.5c).  As shown in 
Figure 4.5d, the IQP-0528 formulation-treated tissues were morphologically 
similar to the naïve tissue. Samples treated with Triton® X-100 (1%) showed 
complete disintegration of the epithelium. These results are in agreement with 
the TEER measurements, which showed no evidence of structural damage from 
exposure to the IQP-0528 gel.  
Among the four cytokines that were evaluated, there were relatively high 
basal levels of IL-8 in naïve tissues. Similar observations have previously been 
reported in assays performed using the human vaginal Vk2/E6E7 cell line.198 
When compared to the basal cytokine levels detected in the VEC-100 naïve 
tissues, the IQP-0528 3.0% HEC gel formulation showed no significant change in 







Figure 4.5    Safety of 3.0% HEC IQP-0528 formulation in Vk2/E6E7 and 
reconstructed human vaginal tissue. (a) Vk2/E6E7 cell viability measured by 
MTS assay after 24 h of exposure (n=5, Mean ± SD). The 3.0% HEC IQP-0528 
formulation showed no significant loss in cell viability when compared to the 
untreated control. Universal placebo and N-9 at 0.1% were used as the nontoxic 
and toxic controls, respectively; (b) VEC-100 tissue viability determined using the 
MTT assay after three repeated exposures to the 3.0% HEC IQP-0528 
formulation (n=3, Mean ± SD). The formulation showed no significant loss in cell 
viability when compared to the nontoxic control (pHPMA). Triton® X-100 (1% 
solution) was used as the toxic control; (c) TEER measurements on VEC-100 
cells at days 1, 2, and 3 following treatment. No statistically significant difference 
was observed in the tissue samples exposed to the 3.0% HEC IQP-0528 
formulation when compared to the pHPMA samples (n=3; Mean ± SD); (d) 
Hematoxylin and eosin-stained sections of VEC-100 tissue after three repeated 
exposures to test samples (n=3). Single-factor ANOVA followed by Bonferroni 
correction for multiple comparisons, *p<0.05. 
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4.3.8 In vitro antiviral activity  
As shown in Figure 4.7, the HEC gels with IQP-0528 showed no 
significant toxicity to cells compared to the naïve control (single-factor ANOVA, p 
> 0.05). To evaluate the effect of the drug delivery vehicle alone, placebo gels 
were prepared using a composition similar to the IQP-0528 HEC gel formulation, 
but without the API.  
Figure 4.6   Cytokine and chemokine release after exposure to a 3.0% HEC IQP-
0528 formulation. Naïve samples were used as negative controls and 1% Triton® 
X-100-treated samples were used as positive controls. The IQP-0528 formulation 
showed no significant induction of the cytokines compared to the naive control. 
(a) IL-1α, (b) IL-6, and (c) TNFα and (d) chemokine IL-8. The positive control 1% 
Triton® X-100 resulted in a significant increase in IL-1α release at day 1 and in 
IL-6 release on day 3 when compared to the naïve samples. (Single-factor 
ANOVA followed by Bonferroni correction for multiple comparisons, *p < 0.05, 





The placebo gels did not show any antiviral activity, as indicated by the 
nearly 100% relative luminescence units (RLU) (Figure 4.7a). The 3.0% HEC gel 
with 0.25% IQP-0528 demonstrated significantly higher antiviral activity when 
compared to the HEC placebo gel (Figure 4.7b). The EC50 for the IQP-0528 
formulation was calculated using dose-response plots and was found to be 0.14 
µg/mL for the gel in the culture medium, corresponding to approximately 0.001 
 
Figure 4.7   Assessment of the antiviral activity of the 3.0% HEC gel formulation. 
(a) Gel without IQP-0528 and (b) with 0.25% IQP-0528. (c) Antiviral activity of 
when (i) formulation was added to cells for 15 m followed by addition of virus, (ii) 
formulation was preincubated with cells for 1 h followed by the addition of virus, 
(iii) formulation was added to cells for 1 h and then removed by washing, 
followed by addition of virus and incubation for an additional 2 h. (d) Comparative 
antiviral activity of the formulations (iv) in the presence of 25% seminal fluid. 
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µM IQP-0528. No significant loss in antiviral activity was observed following 
preincubation of the 3.0% HEC gel containing 0.25% IQP-0528 (Figure 4.7c). 
In the assay designed to evaluate the residual antiviral activity of the IQP-
0528 HEC gel formulation we observed a significant reduction (> 2 log scale) in 
the antiviral activity of IQP-0528 when administered alone. However, the IQP-
0528 HEC gel showed only a marginal loss in antiviral activity. Following 
simultaneous exposure to 25% seminal fluid and virus, the API showed severely 
compromised activity, whereas the IQP-0528 gel showed no significant loss in 
antiviral activity (Figure 4.7d). Taken together, these results reveal enhanced 
activity of IQP-0528 when formulated in a 3.0% HEC gel, with nanomolar antiviral 
activity that was retained following preincubation, removal of the formulation and 
in the presence of seminal fluid. Table 4.1 summarizes the antiviral activities of 
the IQP-0528 (API alone), the placebo and the IQP-0528 HEC gel formulation.  
4.3.9 Safety evaluation using a polarized ectocervical explant 
model  
To confirm the results obtained with the VEC-100 tissue, human 
ectocervical tissue was obtained after surgery and placed in culture using a 
polarized system.75, 199 The HEC IQP-0528 gel and HEC placebo gel preserved 
tissue viability similarly to control (untreated) explants, as measured by the MTT. 
The gel formulations also preserved epithelial/tissue integrity as shown by 
histology (Figure 4.8b). The results with human ectocervical tissue confirmed the 
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4.3.10 Antiviral activity using a polarized ectocervical explant 
model  
The efficacy of the HEC IQP-0528 gel was evaluated by mixing a 1:5 
dilution of the formulation with HIV-1BaL and applying this mixture to the apical 
surface of the polarized explants. After an overnight exposure, the explants were 
washed and the cultures were observed for 21 days. Unformulated IQP-0528 did 
not confer any protection in the polarized ectocervical tissue model. 
Unformulated IQP-0528 did not confer any protection in the polarized 
ectocervical tissue model.  
Table 4.1   Inhibitory activity of IQP-0528 and in the 3.0% HEC gel formulation 
 
*The test substance (API or gel formulation) was added to cells for 15 m before adding virus. 
Cells were incubated with virus and the test substance for 2 h. Following the incubation, the 
monolayer was washed and activity was assayed after an additional 48 h of incubation by 
measuring β-galactosidase activity.  
** The test substance was preincubated with cells for 1 h before adding virus.  
+ The test substance was added to cells for 1 h and then removed by washing. Virus was added 
and incubated for 2 h.  
$EC50 for IQP-0528 was back-calculated from the EC50 for the complete gel formulation, which 
consists of 0.25% IQP-0528 with the assumption that the drug was homogenously dispersed in 
the polymer matrix. 
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Figure 4.8   Evaluation of the safety and efficacy of the 3.0% HEC gel using 
ectocervical explant cultures. (a) The safety of the gels was evaluated in 
duplicate in polarized explants treated with the gels or in untreated controls. After 
overnight culture, the explants were washed and one of the duplicates was 
processed for the MTT assay and the other was processed for histology. The 
MTT assay data are based on three independent tissue samples and the (b) 
histology image is representative of one of those samples. Tissues were 
harvested after overnight exposure to the gel. (c) To evaluate the effectiveness 
of the gel, polarized ectocervical explants were treated with the gels along with 
HIV-1. After overnight culture, the explants were washed and then observed for 
21 days. Culture medium on the basolateral side was harvested to test for viral 
replication by p24 gag ELISA. The HEC gel with IQP-0528 showed a significant 
decrease in p24 levels when compared to the placebo gel and the untreated 
control, (d) Tissues were exposed to the formulation overnight, followed by 
washing and 21 days of incubation. After incubation, the tissues were stained 
using p24 monoclonal antibody. Representative tissue samples are shown. The 
red cells in the untreated control and the tissues treated with placebo gels 
indicate p24-positive cells, reflecting the presence of HIV-1 infected cells. No HIV 




However, when formulated in a 3.0 % HEC gel, IQP-0528 conferred 
protection against HIV-1 infection as indicated by a greater than 1 log reduction 
in HIV-1 p24 antigen levels by day 21 (Figure 4.8c). This significant reduction in 
HIV-1 p24 (p<0.05, single-factor ANOVA) following treatment with the gel 
formulation emphasizes the role of adequate formulation in enhancing the 
efficacy of water-insoluble and poorly permeable active pharmaceutical 
ingredients. The absence of HIV-1 infection in these samples was confirmed by 
endpoint immunohistochemistry (IHC) of the explants; the control and HEC 
placebo-treated explants harbored HIV-1 infected cells, whereas no infected cells 
were detected in the HEC IQP-0528 treated explants (Figure 4.8d). 
4.4 Discussion 
The field of rectal and vaginal microbicides is a new therapeutic area with 
several candidates in clinical trials and no registered products. Many of these 
candidates, with the exception of a 1% Tenofovir gel evaluated in the recent 
CAPRISA 004 trial, have failed to demonstrate safety or efficacy.173 Despite 
these setbacks, the field is still progressing rapidly due to the pressing need for 
prophylactic technologies and the advantages of a vaginal route of delivery for 
antiretroviral drugs.55, 66 Typically, drugs delivered through the vaginal route 
encounter an acidic environment with pH ranging from 4.0 – 5.0.21, 67 However, 
soon after intercourse, the vaginal pH increases to a neutral pH due to the 
introduction of semen. The vaginal environment also hosts several Lactobacillus 
strains that constantly generate lactic acid and hydrogen peroxide, maintaining 
an acidic pH in the vaginal cavity.20, 21 Therefore, successful development of a 
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vaginal microbicide product requires an active ingredient that can withstand both 
neutral and acidic pH in the presence of hydrogen peroxide. For this reason, we 
chose to evaluate the stability of our drug candidates at pH 4.2, pH 4.2 with 0.1% 
H2O2 and pH 7.0. Results from our stability study on the nine active PYD 
congeners suggested that substitutions at the N-1 site play a critical role in 
determining the stability of the compounds in solution. Cyclopropyl (IQP-0406, -
0407, -0408, -0528) and cyclobutyl (IQP-0530, -0532) substitutions demonstrated 
better stability compared to the 1- or 3-cyclopenten-1-yl substitutions (IQP-0558, 
-0410, -1187) at the N-1 site. Furthermore, isopropyl substitutions in the 
heterocyclic ring (IQP-0528, -1187) resulted in compounds with greater stability 
compared to drugs with ethyl substitutions (IQP-0408, -0410). As seen in Figure 
4.1, the most potent PYD congeners failed to show the desired stability profile 
and thus were eliminated from consideration for formulation development. The 
combination of the antiviral activity, the therapeutic index, and, most importantly, 
the stability of the molecules under the physiologically relevant conditions tested 
(shown in Figure 4.1) made IQP-0528 a promising candidate to be explored 
further down the formulation development pipeline.  
In addition to the stability and activity of the antiviral agent, the 
effectiveness of a vaginally-applied microbicide gel also depends on the ability of 
the gel to coat the vaginal epithelium and be retained at the target site for the 
desired duration of action.95 Formulations with high viscosity and yield stress 
would most likely result in gels that provide poor coating and, consequently, 
suboptimal release of the active ingredient, since flux is proportional to contact 
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surface area. On the other hand, low-viscosity gels often lead to excessive 
coating and leakage, resulting in poor user compliance and partial dose delivery. 
We have previously optimized semisolid vaginal gel compositions based on a 
detailed exploration of the composition, properties, and performance of vaginal 
gels.95 Our results indicated the 3.0% HEC gel, followed by the 0.65% Carbopol 
gel, as the near-ideal microbicide gel candidates at a 3.5 mL volume of 
administration because of their spreadability and coating properties.200 
To design a sustained-release formulation for vaginal microbicide delivery, 
a thorough understanding of the vaginal anatomy and the barrier properties of 
the vaginal epithelium is imperative.201 Transport across the vaginal epithelium is 
largely driven by diffusion, which is governed by the physicochemical properties 
of the active ingredient and the barrier through which the drug diffuses. The drug 
entrapped in the gel network diffuses to the boundary layer and partitions into the 
lipid and protein domains of the vaginal epithelium. The drug diffuses through the 
lipid and protein domains to repartition into the microcirculation provided by the 
local capillary network, which offers an infinite sink. This repeated diffusion-
partition process drives the diffusion of the drug into and out of the vaginal 
tissue.202 The rate at which each of these steps occurs depends on several 
factors such as the partition coefficient (Log P), solubility (melting point), polarity 
(hydrogen bond-forming functional groups), degree of ionization (pKa/pKb) and 
molecular weight of the drug. IQP-0528 has a molecular weight of 340.42 g/mole 
and is practically insoluble in water, with a cLog P = 4.1. Of all these factors, the 
one with perhaps the greatest influence on drug transport is the ability of the drug 
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to partition into host tissues.201 Typically, drugs with log P values in the range of 
2-3 show optimal permeability across the stratum cornea (SC), as well as 
moderate partitioning out of the SC. On the contrary, drugs with log P > 3 are 
expected to exhibit high partitioning into the SC but poor partitioning into the 
systemic circulation.20 It is known that lipophilic compounds have higher tissue 
residence times and therefore lower systemic exposure.203 The lipophilicity of 
IQP-0528 could similarly limit its systemic exposure when administered vaginally, 
and therefore could be advantageous for a prophylactic antiretroviral strategy 
where there is concern over generating resistant viral mutants in infected 
individuals exposed to the gel.204 
In vitro release studies are an important precursor to ex vivo or in vivo 
studies as they permit the determination of release kinetics and serve to evaluate 
the mechanism of drug release.77 In vitro release studies on gels typically employ 
synthetic membranes chosen to provide minimal resistance to drug diffusion.198 
Flux in the three sink solutions in our study varied dramatically. We believe that 
the high flux in 1:1 IPA:PBS solution can be attributed to the observation that IPA 
causes the polymer in the gel to swell, resulting in rapid depletion of drug from 
the polymer matrix. Ideally, release studies should be conducted under sink 
conditions that do not interfere with or swell the release matrix;198 therefore, 
liposomes and Solutol offered suitable sink conditions. 
Porcine vaginal tissue is a convenient alternative to human vaginal 
tissue198, 201 since human vaginal tissue is difficult to obtain in sufficient quantities 
to conduct drug transport studies with multiple replicates.  There is significant 
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similarity between the architecture of human and porcine vaginal tissue and for 
studies investigating drug-release kinetics excised porcine tissues have provided 
good correlation with human tissue studies. This is because the permeability of 
the SC has been shown to be unaltered in an nonviable tissue sample after 
removal from the body.192 IQP-0528 could not be detected in the receptor fluid 
from the ex vivo release studies using HPLC. However, the receptor fluid showed 
complete inhibition of viral replication and therefore inhibitory concentrations of 
drug. The concentration of IQP-0528 permeated across the tissue was estimated 
by comparing the extent of viral inhibition by the receptor fluid with a standard 
viral inhibition curve for IQP-0528. Using the above method for the HEC 
formulation, we estimate approximately 0.005 µM and 0.01 µM IQP-0528 to have 
permeated the ectocervical tissue after 4 h and 6 h, respectively. For the 
Carbopol formulation, we estimate approximately 0.003 µM IQP-0528 to have 
permeated the ectocervical tissue after 6 h. Following comparison of the drug 
release profiles of IQP-0528 from the HEC and the Carbopol gels, we observed 
that the HEC gel demonstrated a shorter lag time (4 h) and greater permeation 
across the tissue. However, for the IQP-0528 HEC formulation, the lag time, 
which is the time needed to attain inhibitory concentrations of drug in the basal 
compartment, was eight times longer than that of the 1% Tenofovir gel (lag time 
< 30 min). This delay can be attributed to the low permeability of IQP-0528.  
Thorough investigation of the toxicity and irritation potential of microbicide 
formulations is critical, as in the past some microbicides that have caused 
irritation to genital tissue also led to higher infection rates in women when 
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compared to placebos.172, 201 VEC-100 tissue treated with an IQP-0528 HEC gel 
formulation showed no significant induction of cytokines or chemokines (single-
factor ANOVA, p > 0.05), suggesting absence of any significant inflammatory 
response. Triton®X-100 (1% solution), which was used as the toxic control, 
induced a significant increase in the release of IL-1, IL-6 and IL-8 and a 
decrease in the levels of TNFFigure 4.6). Similar results have been reported 
previously.72 To further support these in vitro results, we evaluated the safety and 
efficacy of the 3.0% HEC gel on ectocervical tissue explants. The 3.0% HEC gel 
was chosen over the 0.65% Carbopol gel as the lead formulation based on our 
previous study that optimized gels based on their coating and retention 
properties172 and higher release of IQP-0528 from the HEC gel.  
Tissues exposed to the IQP-0528 HEC formulation showed no significant 
loss in viability or change in tissue morphology. A similar study evaluating the 
safety of a 1% Tenofovir gel showed an initial loss in TEER of the tissue, likely 
due to the hyperosmolarity of the formulation (approximately 3000 mOsm). The 
formulation developed in our study was designed to have an osmolarity of < 1000 
mOsm (~850 mOsm). As a result, although the composition of the 3.0% HEC 
IQP-0528 gel was similar to that of the Tenofovir gel, the IQP-0528 formulation 
showed no signs of loss in tissue viability or barrier functions after 4 h of 
exposure. We have observed that IQP-0528, when unformulated, does not show 
any protection in a polarized ectocervical tissue model. However, when 
formulated in a semisolid gel formulation as described in this work, IQP-0528 
showed complete protection of the tissue against HIV-1 infection. This 
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emphasizes the role of formulation in enhancing the efficacy of APIs with poor 
aqueous solubility and low tissue permeability. The formulation developed in this 
work is composed of GRAS polymers HEC and Carbopol for the delivery of IQP-
0528. These polymers are acceptable drug delivery vehicles, because of their 
cost-effectiveness, bioadhesivity and biocompatibility. The estimated cost of a 
single dose of this gel is 30 cents/dose, similar to the 1% Tenofovir gel (M. 
Schoofs and P. Wonacott, presented at the 18th International AIDS Conference 
(IAC), Vienna, Austria, 18 to 23 July 2010). Based on our in vitro and ex vivo 
evaluations, we conclude that our gels provide diffusion-controlled release of the 
active ingredient. Additionally, this formulation is expected to provide complete 
protection against infection with no significant toxicity or irritation to vaginal 
tissue. The findings of the present study indicate that the formulation developed 
in this work provides a simple, inexpensive, stable and efficacious microbicide 
gel for the prevention of heterosexual transmission of HIV-1. 
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ACTIVITY AND SAFETY OF SYNTHETIC LECTIN - 
BENZOBOROXOLE FUNCTIONALIZED 
POLYMERS FOR INHIBITION OF  
HIV-1 ENTRY5 
5.1 Introduction 
From a therapeutic perspective, each step in the HIV lifecycle provides an 
opportunity for pharmaceutical intervention. Amongst the initial steps in HIV 
infection is the binding event that occurs between the gp120 receptor on the viral 
envelope and surface proteins on the target cell. The HIV envelope is among the 
most heavily glycosylated proteins known to mankind.205, 206 The gp120 of HIVIIIB 
has 24 potential N-linked glycosylation sites, of which 13 sites contain complex-
type oligosaccharides, and the remaining 11 sites contain hybrid and/or high 
mannose-type structures.207, 208 Reports on the antiviral activity of lectin-based 
                                            
 
5Adapted from Activity and Safety of Synthetic Lectin Based on Benzoboroxole 
Functionalized Polymers for Inhibition of HIV-1 Entry, Molecular Pharmaceutics (in press), 
Alamelu Mahalingam, Anthony R. Geonnotti, Jan Balzarini, Patrick F. Kiser.  
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entry inhibitors suggest that targeting the oligomannose regions of gp120 can 
potentially produce broad spectrum entry inhibitors capable of inactivating HIV 
independent of tropism and strains. Prolonged exposure of these agents to virus-
infected cells causes deglycosylations on the viral envelope, creating virions that 
are highly susceptible to neutralization by immunogenic responses. Such 
mutated virions also lack resistance to other small molecule entry inhibitors.209-212 
Therefore,  lectin-based gp120 targeted entry inhibitors represent an interesting 
class of antiretroviral agents that potenatially can inactivate HIV in the vaginal 
lumen even before they reach susceptible CD4+ cells, preventing male-to-female 
heterosexual HIV transmission.211, 213 
All the entry inhibitors - with the exception of Maraviroc214 and Fuzeon215 - 
that have been tested in clinical trials have failed, most likely due to nonspecific 
interactions with the cell surface and/or suboptimal efficacy.216-218 Consequently, 
there are a limited number of clinical candidates that target HIV entry in 
comparison to agents that target the enzymatic machinery involved in the viral 
replication.219 Carbohydrate binding proteins (CBP), such as the nonhuman 
naturally occurring lectin protein (MBL),220 cyanovirin-N (CV-N)221 and 
griffithsin222 that bind to the high-mannose oligosaccharides found on gp120, 
demonstrate the ability to inhibit HIV infection in vitro and ex vivo, irrespective of 
the cell type, or the coreceptor tropism of the viral strain.223 However, the 
unacceptably high cost of large scale production and purification of these protein-
based lectins, added to their low-stability and plausible immunogenic 
response,224 may limit their use as a microbicide.225 
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Polyvalency - a mechanism capitalized by CBPs - pertains to 
simultaneous interactions between multiple-linked ligands and receptors with 
repeating epitopes, such as those found on the HIV envelope.226 Due to 
translational entropic advantage227 and steric stabilization, polyvalent interactions 
may enhance binding affinity of weak ligands.226, 228 Inspired by nature’s 
adaptation to harness polyvalent interactions as a mechanism to enhance weak 
binding affinity between ligand-receptor pairs,226 we aimed to develop a synthetic 
polyvalent inhibitor of the HIV entry by targeting the high-density glycosylation 
sites on the viral envelope (Figure 5.1A&B).  
Phenylboronic acids (PBA) form reversible covalent complexes with cis-
diols - a common chemical entity found on glycoproteins - e.g., mannose, 
galactose, N-acetylneuraminic acid, and fucose residues.229 The presence of end 
standing multiple mannose residues on each of the hybrid and/or complex-type 
N-linked glycans of gp120 suggests multiple binding sites for PBA-containing 
ligands. While PBA-containing polymers have demonstrated the ability to bind to 
glycosylated proteins, interactions of boronic acids with glycans have yet not 
been exploited as a mechanism to attenuate HIV entry.  This is because the  
PBA and cis-diol form hydrolytically stable complexes only when the boronic acid 
exists in its tetrahedral form, mostly prevalent at a pH value greater than the pKa 
of PBA.230 PBA without any substitutions on the aromatic ring have a pKa of 8.8 
and therefore, is found to bind strongly to diols only at alkaline pH’s.231  
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Figure 5.1   Graphical depiction of the multivalent benzoboroxole-functionalized 
polymer interacting with the gp120 complex of HIV-1. (A and B) Schematic 
illustration of the binding between the polymers (shown in panel C) and the 
gp120 through interactions between benzoboroxole groups and the gp120 and/or 
through interactions between the anionic polysulfonate polymer and the cationic 
peptide fragments in the V3 loop of the gp120. (C) Chemical structure of 
benzoboroxole and the linear water-soluble polymers containing benzoboroxole 
and 2-acrylamido-2-methyl-1-propanesulfonic synthesized using a HPMA 
polymer backbone. (D) Hypothetical scheme of the binding chemistry between 






In order to improve binding at physiological pH researchers have 
investigated various methods to facilitate the formation of stable tetrahedral 
boronate species at neutral pH by lowering the pKa,231 through dative bonds 
formed with boron,232, 233 and multivalency.234 The addition of electron-
withdrawing groups such as hydroxymethyl, fluoro and nitro to the phenyl ring of 
the PBA has been found to improve binding to diols at physiological pH 
compared to unsubstituted PBA.230, 231, 234, 235 Benzoboroxole (ortho-
hydroxymethyl phenylboronic acid; BzB; Figure 5.1c) demonstrates strong 
binding to reducing sugars like fructose and is also capable of binding to 
glycopyranosides, like galactopyranose, a nonreducing sugar structurally similar 
to those found in the terminal glycan residues on gp120 at neutral pH.236 Owing 
to the ease of synthesis, stability and improved affinity to terminal sugar residues 
at neutral pH, this work focused on investigating BzB as an gp120-targeted HIV 
entry inhibitors.   
In the past, our laboratory has shown that BzB ligands are capable of 
binding to the terminal sugar residues on the N-linked glycans of the gp120 and 
that multivalent polymers of BzB copolymerized with the water-soluble nontoxic 
2-hydroxypropyl methacrylamide (HPMAm) monomer show cross-clade antiviral 
activity at nanomolar to low micromolar concentrations.237 Based on our 
investigations to evaluate the effect of mole functionalization of BzB on antiviral 
activity of the synthetic lectins,237 we chose the 50 mol% BzB polymers for further 
assessment. However, our previous system involved problems regarding 
solubility and activity, in addition to the need for biocompatibility evaluations. We 
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hypothesized that incorporation of negatively-charged moieties would improve 
affinity to gp120 through electrostatic interactions with the positively charged V3 
loop, while improving solubility and steric availability of the reactive boronic 
moieties. This work therefore pertains to modulating the multiplicity, ligand 
density and charge of ligand presenting a polymer backbone to augment the 
entry inhibition activity of the synthetic lectins. In the current work, we investigate 
the effect of - (a) ligand density (BzB mole % incorporation), (b) molecular weight 
of the BzB50 polymers and (c) activity of the polyvalent synthetic lectins with a 
sulfonated polymer backbone to inhibit HIV entry.  Additionally, we also assayed 
the influence of fructose and the role of binding kinetics on the antiviral activity of 
the BzB50 polymers. 
5.2 Materials and Methods 
Alizarin Red S., phenylboronic acid, 2-hydroxymethyl phenylboronic acid 
and all the diols were purchased from Acros and were used as received. Water 
was double distilled with a Milli-Q filtration system. 2-Acrylamido-2-methyl- 1-
propanesulfonic acid (AMPS) and AIBN was recrystallized from chloroform 
(dissolved at 60 °C, recrystallized at -80 °C) prior to use in free radical 
polymerizations. All other chemicals and reagents were purchased from Aldrich 
(St. Louis, MO) or Acros (Morris Plains, NJ) and used without further purification 
unless otherwise noted. 
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5.2.1 Colorimetric assay to determine binding constants for 
boronic acid–diol complexes 
An ARS-based binding assay was performed as described by Wang et 
al.230, 238 Briefly, 10 µM solution of ARS dye was freshly prepared in 100 mM pH 
7.4 phosphate buffer. A 2 mM stock solution of BzB was prepared in 10 µM 
solution of ARS. The pH of both solutions was readjusted to 7.4. Using a 96-well 
plate, varying amounts of BzB solution were added to ARS solution to obtain a 
range of concentrations of BzB maintaining the concentration of ARS constantly 
at 10 µM. The plate was allowed to shake for 60 s prior to measurements. 
Fluorescence was measured at an excitation wavelength of 485 nm and 
emission at 620 nM. The experiments were carried out in triplicate. Absorbance 
spectra were collected over 300-600 nm.  
The association constant of PBA or BzB for ARS was determined by 
plotting the inverse of change in fluorescence vs. the inverse of the concentration 
of boronic acid. The quotient of the y-intercept and the slope of line were used to 
compute Ka for the boronic acid-ARS complex. To validate the assay we first 
determined the effect of varying concentrations of PBA on the absorbance and 
fluorescence intensity of ARS. ARS showed a color change, from red to yellow 
and an 80-fold increase in fluorescence intensity at pH 7.4. The association 
constant for the PBA-ARS complex was determined to be 1260 M-1, which is 
consistent with the values reported in literature.230, 238 Following this, solutions 
with varying concentrations of the diol (D-fructose, glucose, sialic acid, methyl-β-
D-galactopyranoside and methyl-α-D-mannopyranoside) were prepared in 100 
mM pH 7.4 phosphate buffers containing 10 µM ARS and 2 mM PBA or BzB. 
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Solutions containing excess of the diol were titrated against the boronic acid-ARS 
complex. As the diol replaces the ARS to form a boronic acid-diol complex, the 
concentration of free ARS in the solution increased, thereby showing a marked 
decrease in fluorescence. This shift in fluorescence was used to compute the 
association constant for the boronic acid-diol complex.238  
5.2.2 Polymer Synthesis and characterization 
BzB monomers and polymers were synthesized using methods similar to 
those described previously238. Briefly, polymers were prepared by free radical 
polymerization at 25 mol%, 50 mol% , 75 mol% and 90 mol% BzB feed ratio, in 
the presence of 5 mol% 2,2’-azobisisobutyronitrile (AIBN) (Figure 5.1). The 
reaction mixture was purged with nitrogen and degassed for 1 h in ice. Following 
this, the reaction was moved to a 65 ºC oil bath for 24 h. Polymers were 
precipitated in anhydrous ether using fractional precipitation technique. Polymers 
were centrifuged and purified using dialysis across a 10,000 MWCO membrane 
using VivaFlow dialysis system. Polymers with varying molecular weights were 
synthesized as described above, with 50 mol% feed ratio of BzB and varying 
feed ratio’s of AIBN (1  mol% - 5 mol%). Polymers with sulfonic acid were also 
synthesized using conditions described above. The degree of substitution was 
determined by 1H NMR (Mercury 400 MHz spectrometer, Varian). Molecular 
weight was determined by GPC (GPC 1100, Agilent Technologies, Santa Clara, 
CA) equipped with an organic column (PLgel mixed bed, Polymer Laboratories, 
Amherst, MA), a differential refractive index detector (BI-DNDC, Brookhaven 
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Instruments, Holtsville, NY) and a multiangle light scattering detector (BI-MwA, 
Brookhaven Instruments, Holtsville, NY). 
5.2.3 Neutralization assay to evaluate the activity of the 
synthetic lectins against clinical HIV-1 isolates 
Anti-HIV activity of the synthetic lectin polymers was evaluated using a 
single-cycle HIV-1 infectivity inhibition assay in TZM-bl cells.237 A well 
characterized R5 tropic DU156 (Clade C) virus isolated from a sexually 
transmitted virus infection and cultured in PBMC was used in the neutralization 
assay. A well characterized R5 tropic DU156 (Clade C) virus isolated from a 
sexually transmitted virus infection and cultured in PBMC was used in the 
neutralization assay. Additionally, R5 TRO (Clade C) and the pseudotyped X4 
WEAU (Clade B) viral strains were assayed to investigate cross-clade and cross-
tropism activity. Polymer solutions were prepared at 10 mg/mL in DMEM (4.5 g/ L 
D-glucose, 110 mg/mL sodium pyruvate and L-glutamine, Invitrogen, Carlsbad, 
CA), with the pH adjusted to 7.5 as necessary, and pasteurized for 5 m at 70°C. 
After pasteurization, the stock solution was diluted 1:1 with DMEM containing 2X 
nutrients (DMEM supplemented with 20% fetal bovine serum (Hyclone, Logan, 
UT), 50 mM HEPES (Gibco/Invitrogen, Carlsbad, CA) and 100 µg/mL gentamicin 
(Sigma, St. Louis, MO) under sterile conditions. Preparation was designed to 
pasteurize the polymers without proteins being present in the media. The final 
media composition after 1:1 dilution was 10% FBS, 25 mM HEPES, and 50 
µg/mL gentamicin. The assay was conducted in a 96-well plate such that the 
polymer solution at the highest concentration was added to the bottom row. From 
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the bottom row of the plate 20 μL of the test sample was added to the prior row 
with 100 μL of growth media to create a 6-fold dilution. This scheme of serial 
dilution was repeated five times to obtain a dose-response curve. Appropriate 
cell controls and virus controls were included in each plate. Following the serial 
dilutions, 50 μL of cell-free virus (200 TCID50) was added to each well, with the 
exception of the wells that served as cell control. The plate was then incubated 
for 1 h in a 37 °C, 5% CO2 incubator.  
After the preincubation, 100 μL of TZM-bl cell suspension prepared at a 
density of 1 x 105 cells/mL in growth media containing DEAE dextran (37.5 
μg/mL) were added to each well and incubated for an additional 48 h. 
Luminescence was measured after 2 m incubation with Britelite Reagent 
(PerkinElmer, Waltham, MA). Toxicity of the samples was simultaneously 
analyzed using an identical plate layout in the absence of virus. To determine 
loss in cell viability, luminescence from the sample-treated wells was compared 
to that of the cell controls. EC50 is reported as the concentration of the sample 
which reduced the relative luminescence units (RLUs) by 50% compared to the 
virus control. Dose response curves were fit to the percent neutralization data 
using GraphPad Prism software (Graph Pad, LaJolla, CA). 
In the assay evaluating the effect of preincubation time on the antiviral 
activity of the synthetic lectins, the assay was conducted using a procedure 
similar to the one above described, with the exception of the preincubation time. 
The polymer solutions were incubated for 0, 15, 30 and 60 mins with the virus 
prior to addition of TZM-bl cells. For the assay evaluating the effect of fructose, 
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30 mg/mL fructose solution was prepared in DMEM media. To the polymer 
solution, 10 μL of the fructose solution was added along with the virus to create a 
fructose concentration of 3 mg/mL. The remaining of the steps were performed 
as described above.  
5.2.4 Broad-spectrum antiviral assays and activity against 
laboratory HIV-1 strains 
The anti-HIV activity and cytotoxicity were also evaluated against the 
laboratory HIV-1 strain IIIB and HIV-2 strain ROD in human T-lymphocyte CEM 
cell cultures. Briefly, virus stocks were titrated in human T-lymphocyte CEM cells 
and expressed as the 50% cell culture infective dose (CCID50, 1 CCID50 being 
the virus dose to infect 50% of the cell cultures). CEM cells were suspended in 
culture medium at  3 x 105 cells/ml and infected with HIV at  100 CCID50. 
Immediately after viral exposure, 100 µl of the cell suspension was placed in 
each well of a flat-bottomed microtiter tray containing various concentrations of 
the test compounds. After a 4-d incubation period at 37 °C, the giant cell 
formation was microscopically determined. Compounds were tested in parallel for 
their potential cytostatic effects in uninfected CEM cell cultures.  
In a cultivation assay, 5 × 104 persistently HIV-1 infected HUT-78 cells 
(designated HUT-78/HIV-1) were mixed with 5 × 104 SupT1 cells, along with 
appropriate concentrations of the test compound. After 20 h, marked syncytium 
formation was noted in the control cell cultures, and the number of syncytia was 
determined under the microscope. The EC50 was defined as the compound 
concentration required to prevent syncytium formation by 50%. 
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The other antiviral assays were based on inhibition of virus-induced 
cytopathicity in HEL [herpes simplex virus type 1 (HSV-1), HSV-2 (G), vaccinia 
virus, and vesicular stomatitis virus], Vero (parainfluenza-3, reovirus-1, 
Coxsackie B4, and Punta Toro virus), HeLa (vesicular stomatitis virus, Coxsackie 
virus B4, and respiratory syncytial virus) and CrFK (feline corona virus (FIPV) 
and feline herpes virus) cell cultures. Confluent cell cultures in microtiter 96-well 
plates were inoculated with 100 CCID50 of virus in the presence of varying 
concentrations (5,000, 1,000, 200 nM) of the test compounds. Viral cytopathicity 
was recorded as soon as it reached completion in the control virus-infected cell 
cultures that were not treated with the test compounds. 
5.2.5 Biocompatibility evaluation in MatTek VEC-100 
reconstructed human vaginal tissue 
Triplicate solutions of BzB50-AMPS10-HPMA40 at 1 mg/mL were prepared 
in serum containing media. Polymer solutions were pasteurized at 70 °C for 5 
mins.  Media containing the polymers were applied to the apical surface of 
tissues cultured in 24-well plate inserts. Three repeated exposures to the test 
sample were performed in intervals of 24 h. After 72 h of exposure, tissue 
viability was determined using MTT assay and change in tissue morphology was 
evaluated through histological examination of the epithelium. On days 1-3, 
cytokine levels were assayed using ELISA. Levels for IL-1α, IL- 8, IL-6 and TNF-
α were measured in tissue culture supernatant by utilizing human cytokine kits 
(R&D System). Tissue integrity was monitored through measurements of 
Transepithelium Electrical Resistance (TEER). 
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5.3 Results and Discussion 
5.3.1 Comparative evaluation of the binding affinity of PBA 
and BzB  
To measure the affinity of the boronic acid ligands for reducing and 
nonreducing sugar residues, we used the ARS-based three-component 
colorimetric binding assay.238  Affinity for glucose, fructose, sialic acid, methyl-β-
D-galactopyranoside and methyl-α-D-mannopyranoside was assayed. To ensure 
the viability of the assay, the association constant of PBA-ARS was compared to 
values reported in the literature by Wang and coworkers.238 Table 5.1 
summarizes the association constants of PBA and BzB for various diols. 
Comparison between PBA and BzB affinities for simple reducing sugars revealed 
four-fold stronger affinity of BzB for fructose (~600 M-1) when compared to PBA 
(160 M-1); however, the affinity of BzB and PBA for glucose was comparable.  
Unsubstituted PBA demonstrated minimal affinity for nonreducing sugars such as 
methyl-β-D-galactopyranoside or methyl-α-D-mannopyranoside at neutral pH. In 
contrast, BzB revealed higher, but still weak, affinity (~25 M-1) for nonreducing 
complex sugars. To develop a boronic acid based synthetic entry inhibitor for 
HIV, we have exploited the ability of the BzB to bind to nonreducing sugars,236 
which are structurally similar to the terminal sugar moieties found on the high 
mannose and complex-type N-linked glycans of gp120. We have previously 
confirmed this observation also using surface plasmon resonance (SPR), in 
which BzB showed a Kd of ~180 mM for HIVBaL gp120, whereas no measurable 




Unsubstituted PBA-containing polymers have demonstrated the ability to 
bind to glycosylated proteins only at alkaline pH; whereas BzB binds to 
glycosides at neutral pH.233 This difference has been ascribed to the presence of 
oxygen from the ortho substituent that stabilizes the boronate ester towards 
hydrolysis232 and decreases the energy barrier for tetrahedral formation.239 
While the BzB shows superior binding affinity for sugar residues, when 
compared to the unsubstituted PBA, the binding is fairly weak for practical 
applications. In this regard, polyvalency has commonly been exploited to improve 
binding affinity of weak ligands. This effect is well known in natural protein-ligand 
interactions as well as for other synthetic protein mimics.226, 227 Kaur et al. 
demonstrated almost a double increase of affinity for glucose for a tweezer-like 
bis-boronic acid molecule compared to a monovalent boronic acid.234 
Incorporating ligands into polymer backbones provides a synthetically accessible 
mechanism for increasing the affinity of ligands for glycoproteins.  
Table 5.1   Association constants of phenylboronic acid and benzoboroxole 
determined using ARS assay at pH 7.4. 
Diol Association Constant (M-1) 
Phenylboronic acid Benzoboroxole 
ARS 1260 1307 
D-fructose 160 664 
N-Acetylneuraminic acid 21 160 
Glucose 6 21 
Methyl-β-D-galactopyranoside a 24 
Methyl-α-D-mannopyranoside a 21 




5.3.2 Polymer synthesis and characterization 
Table 5.2 summarizes the molecular weight of the polymers synthesized 
by free-radical polymerization, determined using size exclusion chromatography 
(Agilent Technologies, Santa Clara, CA) equipped with a PLgel mixed-B column 
(Polymer Labs, Amherst, MA), a differential refractive index detector (BI-DNDC, 
Brookhaven Instruments, Holtsville, NY) and a multiangle light scattering detector 
(BI-MwA, Brookhaven Instruments, Holstville, NY). Mole functionalization of BzB 
in the polymer was determined using 1H NMR. 
5.3.3 Effect of BzB mole functionalization (ligand density) on 
the entry inhibition activity of the synthetic lectins 
While the binding affinity of BzB for nonreducing sugars determined by the 
ARS-based colorimetric assay and for gp120 from SPR revealed weak affinity 
(Table 5.1), high molecular weight polymers with polyvalent presentation of BzB 
showed ≥ 4 log scale increase in activity (EC50 in low micromolar to nanomolar 
range). As seen in Figure 5.2, ~2 log scale increase in antiviral activity was 
observed with an increase in BzB mole functionalization from 25 mol% to 50 
mol% in the polymer (single-factor ANOVA, p < 0.001) and further increase in 
BzB functionalization from 50 mol% to 75 mol% showed only a marginal increase 
in activity (single-factor ANOVA, p = 0.01). On the contrary, an increase in ligand 
density from 75 mol% to 90 mol% showed a reduction in the ability of the 
polymers to neutralize HIV entry (single-factor ANOVA, p = 0.01), with an anti-





We believe that the increase in antiviral activity with increasing mole 
functionalization can be explained by at least two distinct mechanisms described 
by Mammen and coworkers226, 228 – polyvalency and steric stabilization. The 
combined effect of the increase in the number and density of ligands likely 
improves the probability of binding, thereby enhancing binding and antiviral 
activity through avidity and polyvalency. As a secondary mechanism, we suspect 
that, when the BzB presenting polymers bind to gp120, they escort along a large 
water-swollen polymer drape which possibly makes the viral envelope physically 
inaccessible for fusion and entry into the host cell.228, 240 If we assume that it is 
these two mechanisms that collectively determine the activity of synthetic lectins, 
the gradual increase in activity from 50 to 75 mol% and the decrease in activity 
from 75 to 90 mol% can be explained through loss in the steric stabilization effect 
of these polymers. 






BzB AMPS HPMA Mw Mn 
BzB25-HPMA75 29 - 71 103 88 1.17 
BzB75-HPMA25 70 - 30 74 50 1.48 
BzB90-HPMA10 91 - 8 98 76 1.30 
BzB50-HPMA50 48 - 52 110 91 1.21 
54 - 54 226 159 1.42 
51  51 382 285 1.34 
AMPS10-HPMA90 - - - 153 111 1.38 
BzB50-AMPS10-
HPMA40 
45 10 55 131 109 1.20 
aDegree of substitution was determined by 1H NMR and found to correlate with the feed ratios. 





Figure 5.2   Effect of BzB mole functionalization on the entry inhibition activity of 
BzB50 polymers. Results from the single-cycle HIV-1 infectivity inhibition in TZM-
bl cells against R5 DU156 (Clade B) isolated from acute STIs. (A) Dose 
response curve of BzB functionalized HPMA polymers at varying mole 
incorporation. (B) EC50 was determined by fitting a sigmoidal dose-response 
curve with variable Hill’s slope. Single-factor ANOVA followed by Bonferroni 
correction showed significant differences between groups (p<0.05). Significant 
increase in activity from 25 to 50 and 75 mol% was observed. Further increase 
from 75 to 90 mol% showed reduction in activity; EC50 of BzB90-HPMA10 was 
comparable to EC50 of BzB50-HPMA50 (N = 3, mean ± SD; *p<0.05; **p<0.01).   



































As we increase the ligand density in the polymers, the negatively charged 
borons could repel each other, thereby distorting the polymer conformation from 
an effective random coil structure to a less effective rigid elongated structure.228 
On the other hand, increasing the number of available ligands and therefore, 
points of attachment between the polymer and the gp120 could result in a 
collapsed polymer structure; compromising the ability of the polymer to sterically 
stabilize the binding surface.228 Although the relative contribution of the 
abovementioned two mechanisms towards antiviral activity is yet to be 
elucidated, it is reasonable to assume that steric stabilization plays a critical 
role228 in governing the ability of BzB-functionalized polymer to block HIV entry. 
Based on these results, further assessments were performed on 50 mol% 
functionalized BzB polymers. 
Depending on the coreceptor tropism and clades, HIV displays significant 
variations in the different areas on the viral envelope,241, 242 making it important to 
evaluate cross-clade and –tropism activity of new therapeutic agent.83, 243 For 
example, agents targeting the positively charged V3 loop of the gp120, such as 
the nonspecific sulfated polymers, show severely compromised activity against 
R5 tropic strains.244 This is because, the coreceptor tropism of the virus impacts 
the extent of the positive charge on the gp120 V3 loop, with the CXCR4 
coreceptor-tropic HIV-1 strains (X4) exhibiting more positive charges than the 
CCR5-tropic HIV-1 strains (R5). We have previously reported the antiviral activity 
of the BzB-HPMA copolymers at 25, 50 and 75 mol% BzB mole incorporation, 
against HIV strains across clades and tropism.237  
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The assays were performed using Clade B - R5 DU156 and Clade C - R5 
TRO, isolated from acute sexually transmitted infections, and the pseudotyped 
Clade B - X4 WEAU. Independent of the ligand density BzB polymers showed 
comparable antiviral activity across the clades and tropisms of HIV.237 Although, 
the HIV envelope exhibits domains of heterogeneity across viral strains, many N-
linked glycans are believed to be fairly conserved, providing a potential 
mechanism for the observed broad-spectrum activity of lectins. 
5.3.4 Effect of molecular weight of the BzB50 polymers on the 
entry inhibition activity of the synthetic lectins 
Having an understanding of how ligand density affects activity of the BzB 
functionalized polymers; we were next interested in exploring the influence of the 
molecular weight of the polymer at a fixed BzB functionalization on antiviral 
activity of the synthetic lectins. BzB functionalized polymers at 50 mol% were 
synthesized using varying concentrations of the initiator, yielding polymers with a 
range of molecular weights. As shown in Figure 5.3, EC50’s of the polymers 
decreased (thus, higher activity) from 68 nM for 132 kDa BzB50 to 12 nM for 382 
kDa BzB50 (single-factor ANOVA, p = 0.01). Owing to the increased number of 
ligands available for binding per polymer chain, increase in molecular weight of 
the polymers at a fixed percent BzB incorporation showed improved activity. 
However, the improvement in activity found with molecular weight variations was 







Figure 5.3   Effect of molecular weight on the entry inhibition activity of BzB50 
polymers. Results from the single-cycle HIV-1 infectivity inhibition in TZM-bl cells 
against R5 DU156 (Clade B) isolated from acute STIs. (A) Dose response curve 
of BzB50-HPMA50 polymers at varying molecular weights and (B) EC50 
determined by fitting a sigmoidal dose-response curve with variable Hill’s slope. 
Single-factor ANOVA followed by Bonferroni correction was used (N = 3, mean ± 
SD; *p < 0.05).  Significant increase in activity was observed with increase in MW 
of the polymer from 110 to 226 kDa and further to 382 kDa (p =0.03 and 0.01, 



































5.3.5 Antiviral activity of BzB50 polymers against viruses 
bearing glycosylated envelopes 
Entry inhibition activity of lectins originates from their ability to bind to 
glycans spiked on the viral surface. Several of the enveloped viruses bear 
carbohydrate shields on the envelope,245 which could be effectively targeted 
using lectins that nonspecifically bind to carbohydrates. Therefore, we and others 
in the field have tested the activity of plant, bacterial and/or synthetic lectins 
against lentiviruses246 (HIV-1, HIV-2, SIV, MSV), RNA viruses247 (VSV, 
Coxsackie virus B4, and respiratory syncytial virus; and parainfluenza type 3 
virus, reovirus type 1, Sindbis virus, and Punta Toro virus, Ebola, Coronaviruses, 
Influenza viruses), DNA viruses246 (herpesvirus such as cytomegalovirus) with 
glycosylated envelopes. Table 5.3 summarizes the inhibitory concentration of 
BzB50,382 kDa against the viruses we tested. 
We notably observed activity solely against HIV. Except for HIV, none of 
the other viruses were inhibited by the BzB polymers even at concentration 100-
fold higher than the EC50 for HIV. These results are in contrast with UDA that 
inhibit viruses such as HIV-1, HIV-2, RSV, Influenza, CMV, SIV and FIV. CV-N 
an extensively reviewed CBP which is derived from the cyanobacterium Nostoc 
ellipsosporum demonstrated marked inhibition of  viruses such as HIV-1,83, 248 
SIV, Ebola,247 HCV,249 Influenza A virus250 and HSV. The HIV-specific activity we 
observed with the synthetic lectins can be attributed to the fact that no other virus 
that was tested in this assay exhibited comparable extent of glycosylation sites 














HIV-1 1.1 Herpes simplex virus-1 (KOS)c > 1000
Feline Corona Virusa 1000 Herpes simplex virus-2 (G)c > 1000
Feline Herpes Virusa 5000 Herpes simplex virus-1TKc > 1000
Punta Toro virusb > 40 Vesicular stomatitis virusc,d > 1000
Parainfluenza-3 virusb > 40 Respiratory syncytial virusd > 1000
Reovirus-1b > 40 Coxsackie virus B4d > 1000
Vaccinia virusc  > 1000   
+50% Effective concentration or compound concentration producing 50%inhibition of virus-
induced cytopathic effect; aCrandell-Rees Feline Kidney cells (CRFK cells), bVero cells, cHEL 
cells, dHeLa cells 
 
Since, the interactions between a polyvalent construct such as the BzB-
based synthetic lectin and the viral envelope depends on a multitude of factors 
such as the density of glycosides on the viral surface, degree of oligomerization 
of the glycoprotein, spatial arrangement of saccharides and flexibility or both, it is 
conceivable that the synthetic lectins selectively inhibit viruses, in this particular 
case HIV and not just all types of viruses that bear a glycosylated envelope. 
5.3.6 Incorporation of sulfonic acid in the polymer backbone 
affords a synergistic increase in viral entry inhibition 
activity of BzB50 polymers   
Lead polymers from the above studies with an antiviral activity of ~ 10 nM 
(BzB75, 75kDa and BzB50, 382kDa) showed poor-aqueous solubility (< 5 mg/mL). 
Considering that the activity of the BzB polymers could be compromised in the 
presence of proteins and other components in the vaginal environment, 
improving aqueous solubility of the polymers may be required in order to deliver 
the required drug concentrations. Kataoka et al. and others have demonstrated 
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that the incorporation of amines into a PBA-containing polymer could lower the 
pKa of the boronic acid to around 7, thereby enhancing solubility.251, 252 
Incorporation of amines was also utilized by Winblade et al., who reductively 
aminated 4-formylphenylboronic acid to a poly-lysine-PEG backbone. The pKa of 
this polymer was below 6.240, 253 To address the poor aqueous solubility of the 
polymers at high benzoboroxole functionalization (≥ 50 mol%) and/or high 
molecular weight polymers (≥ 125 kDa), we have synthesized polymers with 10 
mole% 2-Acrylamido-2-methylpropane sulfonic acid (AMPS), which is an anionic 
monomer. Incorporation of AMPS into the copolymer adds charge to the 
otherwise neutral HPMA backbone, increasing the aqueous solubility of the 
polymer at neutral pHs by Nearly 100-fold. 
Since both AMPS and BzB bind to gp120, we tested both polymers 
individually, as a physical mixture and a copolymer of AMPS and BzB. The 
physical mixture of the two polymers - BzB50 and AMPS10 - did not demonstrate 
any significant increase in activity (single-factor ANOVA, p=0.21) (Figure 5.4). 
This data suggests that the presence of AMPS10 only in the polymer solution has 
no influence on the binding of BzB to gp120. In contrast, when the AMPS and 
BzB were copolymerized, the resulting polymer showed a more than two log 
scale decrease in EC50 (single-factor ANOVA, p=0.012). We believe that the 
presence of (a) simultaneous ionic and covalent interactions; (b) steric 
stabilization; and (c) entropic advantage with multiple binding events - may 
contribute to the observed synergistic improvement in antiviral activity of the 






































Figure 5.4   Effect of incorporation of sulfonic acid on the entry inhibition activity 
of BzB50 polymers. Results from the single-cycle HIV-1 infectivity inhibition in 
TZM-bl cells on (a) AMPS10-HPMA90, (b) BzB50-HPMA50, (c) physical mixture of 
AMPS10-HPMA90 and BzB50-HPMA50 and (d) copolymer BzB50-AMPS10-HPMA40 
against R5 DU156 (Clade B) isolated from acute STIs. (A) Dose response curve 
of the polymers and (B) EC50 determined by fitting a sigmoidal dose-response 
curve with variable Hill’s slope. Single-factor ANOVA followed by Bonferroni 
correction was used (N = 3, mean ± SD; p < 0.05).  AMPS10 showed an EC50 of 
2361 nM ± 60 (~350 µg/mL). Physical mixture of BzB50-HPMA50 and AMPS10-
HPMA90 showed no significant increase in antiviral activity over BzB50-HPMA50 
(p=0.21). However, copolymers of HMPBA and AMPS at 50 and 10 mol% 
functionalization, respectively, showed a dramatic increase in antiviral activity 
with EC50 of 4.0 nM ± 1.6 (~1 μg/mL) (*p = 0.012).  
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The charged sulfonated polymer backbone likely facilitates initial ionic 
interactions with the V3 loop on gp120; thereby sterically facilitating covalent 
interactions between the BzB on the polymer and the glycans on gp120. This 
implies that, irrespective of the binding affinity, the binding event would bring 
along a large polymer drape to the viral surface, thus inhibiting interactions with 
the host cell. The BzB-AMPS copolymers show activity at concentrations (~ 1 to 
4 nM) comparable to CV-N (~ 0.6 nM). BzB polymers displayed an EC50 of 50 ± 
2.6 nM in preventing syncytium formation in cultures of persistently HIV-1IIIB 
infected HUT-78 and uninfected Sup T1 cells. 
Sulfated anionic polymers have previously been evaluated as a 
microbicide that targets the V3 loop on gp120.254 We are aware of the issues 
associated with the sulfonated polymers for microbicide applications which 
include toxicity due to nonspecific binding,  tropism-specific activity244 and loss of 
antiviral activity in the presence of semen.254 In an attempt to address the above 
issues, we synthesized polymers with small amounts of AMPS copolymerized 
with the biocompatible HPMAm; most likely reducing potential toxicity. 
Furthermore, the primary mechanism of action of the synthetic lectins is through 
the ability of BzB to covalently bind to gp120, which demonstrates clade and 
tropism independent activity.237 The ionic interaction between AMPS and the V3 
loop is an auxiliary mechanism of action that augments the overall activity of the 
BzB-based synthetic lectins. In summary, incorporation of AMPS in BzB50 yields 
a polymer with enhanced aqueous-solubility and generates a heteromeric 
polyvalent presentation of ligands with superior binding to gp120. 
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5.3.7 Effect of binding kinetics on the activity of the synthetic 
lectins 
We were next interested in asking whether the activity of these polymers 
is governed by thermodynamics alone or whether binding kinetics also influences 
the entry inhibition activity of the BzB. To evaluate the effect of binding kinetics, 
the BzB-APMS copolymer samples were preincubated with the virions for 0, 15, 
30 and 60 mins. As shown in Figure 5.5, irrespective of the incubation time, the 
copolymer samples showed 50% inhibition of HIV at ~ 4.5 ± 2.0 nM (single-factor 
ANOVA, p>0.05). Unlike the α-(1-3)- and α-(1-6)-D-mannose oligomer-specific 
plant lectins, whose antiviral activity is up to 20-fold more pronounced upon a 1 h 
preincubation time with the virus,246 the BzB-based synthetic lectins show 
superior and rapid inhibition of HIV entry, irrespective of preincubation with the 
virus particles.  
5.3.8 Effect of seminal concentrations of fructose on the 
activity of the synthetic lectins 
Several antiviral agents such as sulfated polymers,254 intended to be 
delivered vaginally show compromised or complete loss of antiviral activity in the 
presence of seminal fluid. Seminal fluid is a rich source of proteins, enzymes, 
salts, immune cells and sugars.52 Of these, the presence of high concentrations 
of simple sugars such as fructose especially may raise concerns for lectin-based 
therapeutics. As seen by our results from the ARS assay, BzB show 
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Figure 5.5   Effect of incubation time and fructose on the entry inhibition activity 
of BzB50 polymers. Dose response curves of (A) BzB50-HPMA50 (382 kDa) and 
BzB50-AMPS10-HPMA40 against R5 DU156 as a function of preincubation time. 
Using single factor ANOVA, independent of the incubation time, no significant 
difference in EC50 was observed (p = 0.72 and 0.55). (B) EC50 of BzB50-HPMA50 
and BzB50-AMPS10-HPMA40 in the presence of seminal concentration of fructose. 
Both polymers showed no significant loss in antiviral activity in the presence of 
fructose. Using 2-tailed, Student’s t-test p = 0.44 and 0.53 for BzB50-HPMA50 and 
BzB50-AMPS10-HPMA40, respectively.  
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Therefore, we tested the ability of the BzB50-AMPS10-HPMA40 copolymers 
and BzB50-HPMA50 (383 kDa) to neutralize HIV entry in the presence of average 
seminal fructose concentration (3 mg/mL) of fructose. As shown in Figure 5.5d, 
activity of the synthetic lectins was fully preserved in the presence of fructose, 
suggesting that fructose from seminal fluid would not compromise the antiviral 
activity of the synthetic lectins (2-tailed student’s t-test p>0.05). 
5.3.9 Biocompatibility evaluation in MatTek VEC-100 
reconstructed human vaginal tissue 
Enabling this research for microbicide development requires careful 
determination of how interactions of BzB polymers with the epithelial cells of 
cervicovaginal tissue may impact their viability and cytokine production. Owing to 
the ability of the BzB to bind to glycoproteins and the ability of sulfonic acid to 
nonspecifically bind to positively charged surfaces; it is critical to assess the 
safety of the BzB-AMPS copolymers in vaginal tissue. The VEC-100 tissue 
purchased from MatTek Corporation for evaluating the tissue-level toxicity of 
topical microbicides.255 As can be seen in Figure 5.6, BzB-AMPS copolymers 
showed no significant loss in tissue viability when compared to the nontoxic 
control even at concentrations ~ 1000-fold the in vitro EC50, after 72 h of 
exposure. The irritation potential of test polymers were evaluated by ELISA for 
inflammatory cytokines associated with mucosal toxicity (i.e., IL-8, IL-1, IL-6, 
TNFα) using human cytokine kits (R&D System). Our investigations on 
biocompatibility revealed no significant alterations in tissue viability, cytokine 






Figure 5.6   Safety evaluation of BzB50-AMPS10-HPMA40 on reconstructed 
human ectocervical tissue after three repeated exposures. pHPMA and Triton 
served as nontoxic and toxic controls, respectively. (A) Percentage viability of the 
tissue determined using MTT assay at the end of day 3, (B) TEER 
measurements graphed as percentage of the no treatment control for days 1-3. 
(C-F) Cytokine IL-1α, TNFα, IL-6 and IL-8 release for days 1-3. Tissues treated 
with BzB50-AMPS10-HPMA40 showed no symptoms of loss in tissue viability or 
elevation in cytokine levels when compared to pHPMA treated nontoxic control. 
(Mean ± SD, single-factor ANOVA followed by Bonferroni correction; *p < 0.05). 
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In summary, these results suggest that polymers functionalized with BzB 
moieties, are likely to be nontoxic and are likely to have a high therapeutic index; 
allowing higher concentrations of the polymer to be dosed safely, thereby 
minimizing the impact of competing binding sites that may be present in the 
vaginal environment. 
5.4 Conclusion 
This work is relevant to the development of new agents capable of 
rendering the virus inactive during female-to-male heterosexual transmission. An 
ideal microbicide candidate must exhibit potency, cross-clade broad spectrum 
activity, selective inhibition of the pathogen, mass producible and biocompatible. 
While current research on CBPs suggests that they possess several of the above 
favorable properties to qualify as potential microbicide candidates, their success 
is largely impeded by the potential mitogenic properties, cost of production and 
isolation and purification in mass quantities. In this regard, our approach of 
developing synthetic lectins using the BzB moieties meet all of the above criteria 
of an ideal microbicide. The BzB can readily be incorporated into a variety of 
biocompatible polymer backbones and polymeric constructs which can be 
synthetically modified to enhance activity and specificity. Additionally, the BzB-
based synthetic lectins also present an affordable and scalable product that 
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The purpose of this final chapter is to present a summary of the motivation 
for the work, major findings and recommendation for future studies.  
6.1 Chapter 2 - Design of a Semisolid Vaginal 
Microbicide Gel by Relating Composition             
to Properties and Performance  
6.1.1 Motivation to the Work 
In the development of a semisolid microbicide gel, there has long been the 
need for a methodology that would help researchers who seek to develop new 
drug delivery vehicles (DDVs), or even improve some aspects of a current 
formulation. These tools may also prove useful in optimization exercises or 
simply in comparing multiple formulations. In this regard, research described in 
Chapter 2 of this dissertation involved the design of a semi-empirical approach to 
guide application-specific selection of a DDV, in this case for microbicide 
delivery. In doing so, a composition-property-performance relationship between 
polymer concentrations, rheological properties of the resulting gel and predicted 
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deployment characteristics of the DDV was established. This work helped identify 
tools, that when used in combination, provides insight into how composition of a 
DDV can be tailored to meet a predefined set of performance criteria.  
6.1.2 Summary of the Research 
A preclinical in vitro algorithm that allows de novo design of vaginal gels, 
by empirically relating gel composition to gel properties was developed. Gel 
performance was defined through a multivariate objective function constructed 
from gel’s mechanical properties and selected performance criteria for spreading 
within the vaginal canal. Mixture design of experiment was used to establish a 
semiempirical relationship linking composition-property and property-
performance relationships for gels with varying concentrations of 
hydroxyethylcellulose (HEC) and Carbopol 974P. This permits definition of a 
local optimum for gel composition and volume of administration, within a defined 
composition space. Rheological behavior and, consequently, the value of the 
objective function varied broadly with composition. In the composition space 
consisting of HEC (0-3% w/w) and Carbopol (0-2.5% w/w), the algorithm 
indicated a 3.0 wt% HEC gel as the near optimal composition for a 3.5 mL 
applied volume for gels, designed to spread throughout the vagina.  
6.1.3 Critical Assessment and Suggested Future Work 
The algorithm reported in this work represents the first attempt to develop 
methods that empirically relate the composition of commonly used gel excipients 
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to their performance using deterministic squeezing flow calculations. Therefore, 
the first generation squeezing flow model is simplistic.   
6.1.3.1 Consideration of intermolecular interactions. Some of the factors 
that the future generation squeezing flow models need to incorporate include 
interactions between the DDV and the vaginal epithelium. These interactions 
may depend on the surface properties of the vaginal epithelium such as 
wetability, cell turnover, variations in epithelium with menstrual cycle and 
presence of cervical mucus.256, 257 Incorporating intermolecular interactions into 
the equation for the score, could prove critical in assessing the ability of the gel to 
spread over the vaginal tissue and adhere to the surface to minimize leakage.257 
6.1.3.2 Assumption of a constant force of squeezing. The model as it 
stands, assumes a constant force of squeezing which is an idealistic 
representation of the in vivo condition.56  To address this shortcoming, tools that 
would enable measuring of the squeezing forces between the anterior and 
posterior walls of the vaginal lumen are required. Values of squeezing force 
when fed into a dynamic stress device would apply force that varies with time, 
providing a physiologically relevant measure of the area coated by the gel. 
6.1.3.3 Kinetics of dilution of the gel. A major advancement required of the 
squeezing flow model is the need for a time-dependent function that may account 
for gradual dilution of the formulation with vaginal fluid.56, 57 The approach 
employed in this study, involved physical mixing of the gel with vaginal fluid 
simulant (VFS) at 4:1 weight ratio. The dilution and physical agitation was an 
exaggeration of dilution and mixing observed in vivo. Therefore, it would be 
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necessary to develop a rheological method that, in real time, would assess the 
implication of gradual dilution of the gel with biological fluids.  
6.1.3.4 Augmenting the scoring function with factors beyond deployment 
that contribute to the overall effectiveness of a semisolid microbicide gel. This 
study evaluated the algorithm for its use in predicting deployment characteristics 
of several PAA and cellulose-based commercially available formulations. It will 
be valuable to assess the applicability of the algorithm for gels composed of 
gelling agents such as carageenan, chitosan and others. Moreover, incorporating 
terms that account for drug release and toxicity profiles of the DDV would provide 
a more complete numerical equation and a collective score that may allow 
researchers to rank order formulations during preclinical optimization process. 
Finally, to enable this research as a preclinical tool to guide selection of DDV and 
to evaluate performance of a microbicide gel, the predictions of the model would 
need to be confirmed and correlated with in vivo observations of deployment. 
6.2 Chapter 3 - Inhibition of the Transport of HIV-1       
In vitro Using a pH-Responsive Synthetic    
Mucin-Like Polymer System 
6.2.1 Motivation to the Work 
Polymeric materials based on entangled polymer networks or weak 
noncovalent interactions, offer little control over the mechanical properties and 
performance of the delivery vehicle.117 Moreover, these gels are nonresponsive 
and may be rapidly eroded in the presence of genital secretions; requiring 
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application immediately prior to intercourse.258 Advancements in the 
development of formulations capable of longer retention, along with the 
properties for acceptable application and complete distribution may require in situ 
crosslinking materials.259 Inspired by the ability of the cervicovaginal mucus to 
impede the movement of HIV-1 at acidic pH,30 we have engineered a pH-
responsive polymer system that shows improved barrier properties over the 
naturally occurring cervicovaginal mucus, such that it inhibits viral transport at 
both acidic and neutral pH. The pH-responsive synthetic mucin-like polymer 
(SMP) is constructed with phenylboronic acid (PBA) and salicylhydroxamic acid 
(SHA), each individually copolymerized with a 2-hydroxypropylmethacrylamide 
(pHPMA) polymer backbone. This research is amongst the first to apply 
contemporary capabilities for designing a platform of a bioresponsive polymer to 
the specific physiological and biomechanical requirements for a vaginal 
microbicide product, along with liberation from immediate precoital product use. 
6.2.2 Summary of Research 
At pH 4.8, the crosslinked polymers form a transient network with a 
characteristic relaxation time of 0.9 s and elastic modulus of 11 Pa. On addition 
of semen, the polymers form a densely crosslinked elastic network with a 
characteristic relaxation time greater than 60 s and elastic modulus of 1800 Pa. 
Interactions between the PBA-SHA crosslinked polymers and mucin at acidic pH 
showed a significant increase in elastic modulus and crosslink lifetime (p < 0.05). 
A transport assay revealed that migration of HIV-1 and cells was significantly 
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impeded by the polymer network at pH ≥ 4.8 with a diffusion coefficient of 0.160 x 
10-3 µm2/s for HIV-1. SMP did not induce symptoms of toxicity or irritation in 
either human vaginal explants or a mouse model. In summary the, pH-
responsive crosslinked polymer system reported in Chapter 3 of this dissertation 
holds promise as a new class of bioinspired environmentally responsive material 
that could inhibit the transport of virions from semen to the target tissue and, 
thereby, contribute to the overall activity of the microbicide drug delivery system. 
6.2.3 Critical Assessment and Suggested Future Work 
Influence of biofluids on the transport of virions through the SMP - 
Through our study on gelation kinetics, we have shown that the SMP forms a 
viscoelastic fluid almost instantaneously on mixing and on contact with semen 
forms an elastic solid. However, it is important to reassess these results in the 
presence of biological fluids such as cervical mucus and vaginal fluid. Thus far, 
we have only examined the influence of semen and simulants of mucus and 
vaginal fluid, individually on the viscoelastic properties of the SMP. Conducting 
viral tracking in samples diluted with cervical mucus, vaginal fluid and semen 
would answer important questions in regards to the ability of the SMP to inhibit 
viral transport in vivo. To further, validate SMP’s applicability as a microbicide, 
inhibition of viral transport will need to be assayed in an in vivo infectivity study, 
in the presence of the abovementioned factors, simultaneously.  
6.2.3.1 Consideration for an infectivity study in an in vivo model. For an in 
vivo study, the first step is the selection of an appropriate animal model.31, 91, 260 
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Of the various animal models such as mouse, rabbit, sheep and macaque used 
for microbicide testing, mouse or a macaque would be a suitable model for 
assaying infectivity.261, 262 However in the case of a mouse model, the variations 
in the temperature of the vaginal lumen with respect to food intake and higher pH 
in a mouse vagina when compared to human vagina need careful consideration. 
Additionally, the virus stock is usually suspended in PBS which bears lower 
buffering capacity than semen. These differences together, have the ability to 
alter the behavior of the SMP and the resulting outcome of the study.   
6.2.3.2 Influence of gelation kinetics and biodistribution on the ability of 
SMP to inhibit viral transport. Examining the effect of gelation kinetics on 
inhibiting viral transport may involve introducing the virus stock at varying time 
intervals after application of the SMP. On sacrifice, sectioning the mouse vaginal 
tract would provide a depth profile, revealing the extent of viral penetration into 
the gel and the tissue.263 These studies will also be illustrative of epithelial 
damage, if any, on exposure to the SMP.264 Future studies also need to examine 
the ability of the SMP to coat vaginal tissue and retain at the site of application. 
While our investigations reveal that the SMP can be applied as an in situ gelling 
system, effectiveness of SMP compels the need for complete coating over the 
vaginal tissue. Therefore, assessing the deployment characteristics of the SMP 
becomes imperative. Deployment of SMP can be evaluated using MRI studies in 
mouse, similar to those conducted by others in human subjects128, 265, 266 or by 
using an approach similar to the one discussed in Chapter 2 of this dissertation. 
If either of the above two studies fail to demonstrate desired performance, 
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composition of the polymers can be altered to accommodate necessary changes 
in gelation and mechanical properties of the crosslinked polymer system. In our 
lab, we have demonstrated the ability to control properties of crosslinked polymer 
systems by varying the polymer backbone, concentration of the polymers and/or 
mole functionalization in the polymers.258, 267 
6.2.3.3 SMP formulated with antiretroviral agents to provide dual level of 
protection against HIV-1 infection. Development of a microbicide delivery vehicle 
that physically inhibits viral transport, combined with agents that cause chemical 
inactivation of virus will create an effectual barrier to infectivity. Based on our 
preliminary data, we anticipate that SMP engineered with pH-responsive, 
reversible PBA-SHA crosslinks combined with BzB polymers may provide both 
chemical inhibition, through the activity of BzB as gp120 targeted entry inhibitors 
(detailed discussion in Chapter 5), and physical inhibition, through reduced 
movement of virions in the crosslinked polymer network. Studies required to 
characterize the drug delivery potential of the SMP would be parallel to those 
conducted in Chapter 4 of this dissertation. Looking forward, the PBA-SHA 
crosslinking technology can be formulated to deliver a hydrophilic drug such as 
tenofovir66, 268 or hydrophobic candidates such as IQP-0528.269  A system of this 
nature would benefit from dual mechanism of inhibition, provided by the semen-
triggered impermeability and chemical inhibition of viral multiplicity. 
6.2.3.4 Other suggested future studies. While the SMP demonstrates the 
ability to impede transport of macrophages, motility of sperms in the SMP still 
needs to be investigated.270 All the assays conducted so far employed SMP at 
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100 mM buffering capacity. Examining the effect of lower buffering capacity of 
the formulation on erosion and barrier properties of SMP would be valuable. 
Based on our observation, SMP do reheal at pH above 5.5, however the 
timescale of rehealing demands further improvement of the formulation for 
instantaneous rehealing. This characteristic is essential, as the SMP layer could 
be ruptured during intercourse which, if fails to reheal may allow free passage for 
the migration of HIV-1. The HIV-1 transport study we conducted using human 
vaginal tissue showed complete protection; however, additional studies are 
required to determine the minimum thickness of the SMP required to completely 
inhibit transport of HIV-1 over a period of 6 to 8 h.  
6.3 Chapter 4 - Vaginal microbicide gel for the 
delivery of IQP-0528, a pyrimidinedione        
analog with a dual mechanism                              
of action against HIV-1 
6.3.1 Summary of Research 
Chapter 4 discusses the work on identification of a lead pyrimidinedione 
analog based on preformulation stability evaluation, followed by development of 
a vaginal gel formulation for the delivery of the lead pyrimidinedione analog. 
Detailed in vitro and ex vivo release, safety and antiviral activity evaluation of the 
vaginal gel formulation for its application as a microbicide was conducted. With 
the increasing number of hydrophobic and poorly permeable drugs being 
evaluated as microbicide candidates, it is critical to develop a robust, 
biocompatible drug delivery system that is stable and capable of delivering the 
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molecules to vaginal tissue at a concentration high enough to prevent viral 
replication. Results in Chapter 4 reveal that although many of the PYD 
congeners exhibit potent antiviral activity with dual-mechanism of action271, their 
physicochemical properties render them nonfunctional from the perspective of 
drug delivery. The composition of the formulations used in this study, were 
selected based on the outcome from the studies conducted in Chapter 2 of this 
dissertation. Amount of glycerin in the formulation was chosen such that a 
homogenous dispersion of the solid API could be achieved, but at the same time 
maintains the osmolarity of the final formulation < 1000 mOsm to avoid toxicity to 
the tissue induced by hyperosmolarity of the formulation.270  
Chapter 4 reports the development of two vaginal gels - 3.0% 
hydroxyethyl cellulose (HEC) formulation and a 0.65% carbopol formulation, for 
the delivery of IQP-0528. Stability studies under accelerated conditions 
confirmed the chemical stability of IQP-0528 and mechanical stability of the gel 
formulation for three months. In vitro release studies revealed that diffusion-
controlled release of IQP-0528 occurred over 6 h, with an initial lag time of 
approximately 1 h. Based on the drug release profile, the 3.0% HEC gel was 
selected as the lead formulation for safety and activity evaluations. The in vitro 
and ex vivo safety evaluations showed no significant loss in cell viability or 
inflammatory response following treatment with a 3.0% HEC gel containing 
0.25% IQP-0528. In an in vitro HIV-1 entry inhibition assay, the lead formulation 
showed an EC50 of 0.14 μg/mL of gel in culture media, which corresponds to 
approximately 0.001 μM IQP-0528. The antiviral activity was further confirmed 
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using polarized cervical explants, in which the formulation showed complete 
protection against HIV-1 infection.  
IQP-0528 when unformulated did not show protection in a polarized 
ectocervical tissue model. However, when formulated in a semisolid gel 
formulation as described in Chapter 4, IQP-0528 showed protection against HIV-
1 infection as indicated by >1 log10 reduction in HIV-1 p24 antigen levels. IQP-
0528 (when unformulated) suffered from severe loss in antiviral activity in the 
presence of seminal fluid, which was circumvented when formulated in a 3.0% 
HEC gel formulation. This evidence emphasizes the role of formulation in 
retaining the efficacy of API with poor aqueous solubility and low tissue 
permeability. These results are encouraging and warrant further evaluation of 
IQP-0528 gel formulations in an in vivo model as well as the development of 
alternative formulations for the delivery of IQP-0528 as a microbicide. 
6.4 Chapter 5 - Activity and Safety of Synthetic Lectin 
Based on Benzoboroxole Functionalized 
Polymers for Inhibition of HIV-1 Entry 
6.4.1 Summary of Research 
Lectins derived from plant and microbial sources constitute a vital class of 
entry inhibitors that target the oligomannose residues on the HIV envelope 
gp120. Despite their potency and specificity, success of lectin-based entry 
inhibitors may be impeded by issues in regards to economical production, 
formulation and potential mitogenicity. Therefore, there exists a gap in the HIV 
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therapeutics pipeline that underscores the need for mass producible, synthetic, 
broad-spectrum, and biocomptabile inhibitors of HIV entry. Research in Chapter 
5, presents the development of a polymeric synthetic lectin, based on 
benzoboroxole (BzB), which exhibits weak affinity (~25 M-1) for nonreducing 
sugars, similar to those found on the HIV envelope. High molecular weight BzB-
functionalized polymers demonstrated antiviral activity that increased with an 
increase in ligand density and molecular weight of the polymer construct, 
revealing that polyvalency improves activity. Polymers showed significant 
increase in activity from 25 to 75 mol% BzB functionalization with EC50 of 15 µM 
and 15 nM, respectively. A further increase in mole functionalization to 90% 
resulted in an increase of the EC50 (59 ± 5 nM), likely due to the elongated rigid 
structure of the polymer chain compelled by electrostatic repulsion between the 
boronic acid groups. An increase in molecular weight of the polymer at 50 mol% 
BzB functionalization showed a gradual but significant increase in antiviral 
activity, with the highest activity seen with the 382 kDa polymer (EC50 of 1.1 ± 0.5 
nM in CEM cells and 11 ± 3 nM in TZM-bl cells).  
Supplementing the polymer backbone with 10 mol% sulfonic acid not only 
increased the aqueous solubility of the polymers by at least 50-fold, but also 
demonstrated a synergistic increase in anti-HIV activity (4.0 ± 1.5 nM in TZM-bl 
cells), possibly due to electrostatic interactions between the negatively charged 
polymer backbone and the positively charged V3-loop in the gp120. The 
benzoboroxole-sulfonic acid copolymers showed no decrease in activity in the 
presence of a seminal concentration of fructose (p > 0.05). Additionally, the 
189 
 
copolymers exhibit minimal, if any effect on the cellular viability, barrier 
properties, or cytokine levels in human reconstructed ectocervical tissue after 3 
days of repeated exposure and did not show pronounced activity against a 
variety of other RNA and DNA viruses. 
6.4.2 Critical Assessment and Suggested Future Work 
While Chapter 5 of this dissertation describes the examination of safety 
and efficacy of BzB-functionalized polymers as gp120 targeted HIV-1 entry 
inhibitor, further work is required to enhance the activity and affinity of the 
synthetic lectin platform for glycans on the HIV-1 viral envelope. This would 
require identification of the exact mechanism of binding between BzB polymers 
and the sugars on the viral envelope. 
6.4.2.1 Elucidate the mechanism of binding between BzB and gp120. The 
first step in attempt to develop polymers with improved activity involves 
bracketing the type of sugar moieties that are required for high affinity binding of 
BzB-functionalized polymers. These mechanistic studies may involve competitive 
binding studies, frontal affinity chromatography or X-ray crystal analysis.272 
Impact of various concentrations of mannose derivatives on the binding 
affinity of BzB polymers to gp120 can be analyzed by preincubating the polymers 
with the sugars, prior to assaying antiviral activity of the BzB polymers. Mannose 
derivatives of interest include Manα(1-2)Man, Manα(1-3)Man, Manα (1-6)Man, 
Manα(1-2)Manα(1-2)Man, and Manα(1-3)Manα(1-6)Manα(1-6)Manα(1-3)Man.273 
In attempt to clarify, the terminal residues that are required to enhance entry 
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inhibition activity of BzB polymers, gp120 consisting of N-linked glycans 
(complex, hybrid, and high-mannose types) will require a haircut using site-
specific enzymes. For example, endoglycosidase treatment of gp120 would 
digest both hybrid and high-mannose residues, whereas sialidase and β-
galactosidase, would digest hybrid and complex-type sugars leaving only the 
high-mannose sugar chains on gp120.273 Additionally, it is critical to examine if 
BzB-functionalized polymers are capable of discriminating between low and high-
density mannose residues - an important feature that may enhance gp120-
specific activity, and reduce nonspecific interactions between cellular 
glycoproteins and BzB polymers.273  
6.4.2.2 Strategies to enhance activity and specificity of BzB constructs for 
gp120. Designing BzB constructs with enhanced affinity for gp120 can be 
achieved by creating a small library of constructs with varying architectures and 
conducting a screen using surface plasmon response (SPR). Constructs with 
varying chain lengths, spacing between ligands, chain flexibility and architecture 
constructed using solid phase peptide synthesis (SPPS) would allow precisely 
controlled synthesis.234, 274-277 Similar approach employed by others showed ~50 
fold increase in affinity of the ligands over the monovalent presentation of the 
ligand.278   
An alternative approach includes a structure-guided identification of the 
lead. In this approach, on elucidating the crystal structure of the ligands, 
computer-aided tools can facilitate identification of ligands and multivalent 
constructs with high affinity for glycan on the gp120.234, 279, 280 Similar approach 
191 
 
has found application in elucidating the binding domain and affinity of several 
protein-based lectins such as cyanovirin and griffithin for gp120.279-281  
Polymer architectures studied in our lab thus far involve only linear 
architecture. It will be interesting to evaluate the effect of branched or dendritic 
architectures along with variations in chain flexibility and chain length around the 
ligand.281 Creating nanoparticles and dendritic structures decorated with multiple 
ligands for inhibition of influenza have shown promising results.282 Similar 
approach could prove useful in enhancing the activity of BzB-functionalized 
systems.  
6.4.2.3 HIV-1 specific activity of BzB. Our results from the virus screen 
indicate that the activity of BzB polymers is specific to HIV-1. Although, it is 
conceivable that the high glycosylation density on the HIV-1 envelope could be 
responsible for this aberrant result; however further experiments are necessary 
to test this hypothesis.  
6.4.2.4 Activity and safety of BzB functionalized polymers in vivo. 
Preliminary studies evaluating the effect of physiological concentrations of 
fructose showed no impact on the antiviral activity of the BzB polymers. These 
results require reassessment in an in vivo model in the presence of semen.  
6.4.2.5 Activity against cell-associated viruses. Antiviral studies need to 
evaluate if BzB polymers show uncompromised activity against cell-associated 
viruses. This is critical as semen consists of both free and cell-associated 
viruses. Assays that evaluate the inhibition of cell-cell transmission of HIV-1 use 
a culture of target cells and a chronically infected cell-line in the presence of the 
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inhibitory agent.283, 284 Inhibition of infection can be quantified by measuring cell-
associated p24 antigen levels.  
6.4.2.6 Applicability of BzB-polymers as self-therapeutic vaccine. Some 
recent studies support the hypothesis that mannose-targeted therapeutics 
against HIV-1 entry, may trigger deletion of glycosylation sites of gp120, 
exposing previously hidden epiptopes.285, 286 This in turn may make the virus 
susceptible to immunological neutralization, initiating subsequent production of 
neutralizing antibodies against HIV-1. To test if this hypothesis of self-therapeutic 
vaccine applies to the BzB-polymers, investigation would involve three steps. 
Firstly, the genetic barrier to BzB-polymers as gp120 targeted therapeutics need 
to be evaluated, followed by identification of points of mutation and its impact on 
the N-glycosylation sites of the gp120.287, 288 Finally, evaluate if point mutations in 
gp120 result in progressive increase in levels of neutralizing antibodies. Assays 
to evaluate the above hypothesis may involve dose escalating studies in a 
macaque model until the emergence of mutations in the glycosylation sequence 
is observed.288, 289 Viral isolates will need to be sequenced to identify plausible 
mutations or deletions in the conserved glycosylation amino-acid sequence.287, 
289 Monitoring the levels of neutralizing antibodies throughout the study would 
serve as a direct measure of the ability of the BzB polymers as a therapeutic 
vaccine technology. The assumption that the gp120 does not evolve through an 
alternative mechanism to escape the pressure from these agents will require 
thorough investigation.  
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